var title_f27_22_28000="Nasal fracture";
var content_f27_22_28000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Postinjury edema may mask underlying nasal bone deformity. (B) Nasal deformity becomes manifest as edema subsides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28000=[""].join("\n");
var outline_f27_22_28000=null;
var title_f27_22_28001="Olympus QuickClip2 endosc";
var content_f27_22_28001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of a bleeding gastric ulcer with endoclips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bleeding gastric ulcer following placment of Olympus QuickClip2 endoclips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M. Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28001=[""].join("\n");
var outline_f27_22_28001=null;
var title_f27_22_28002="CDC length for age girls 0 to 36 months";
var content_f27_22_28002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 585px\">",
"   <div class=\"ttl\">",
"    Length-for-age percentiles, girls, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 565px; height: 677px; background-image: url(data:image/gif;base64,R0lGODlhNQKlAtUAAP///wAAABAQEPDw8NDQ0DAwMGBgYODg4EBAQKCgoICAgMDAwCAgIIiIiERERJCQkLCwsFBQUHBwcLu7u93d3SIiIhERETMzM2ZmZszMzJmZme7u7lVVVXd3d6qqqn9/f2VlZUNDQ4eHh25ubr+/v7q6ugAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA1AqUCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3OZQHR0tPU1dbX2Nna29zd3t/g4eLj5OXm5+jp6uvs7e7saAFg8lf0X/Ze+Fz6+2H8W/+0BBTor6DBe1UGZlGYbx4WhlYgJnRIEWHFhgcxWrzYRSISj1RALuQ4RWQUk1BQOlG5MmNHly9JAhTDsknNmjbjyTwJc+ZG/41AY/4M2m8nQaNMcCbVObRkz6NEfTaVGpWq0KpQsS59ijTiQ65fp2a9SrZoV69n0YrNCVar2iIOGrRMG5KuU7tSlCrRu7ftW7d/U66ckJcp4K1rwx6ui5dnY8eJ69H0m4RvZcNEKFyIxqFBhWgXNgfwcIQakrgAAojW8JEy48V3Iwe2Wpa27dsjXy8JMGGC6gAWMiCGdoSDgyGeKVAIIBfD8b5HUDMHIKJC68dPLBvRvt11bNjfa48Vnzt85d68ATjAMJzMvwqshTR4nn7+7tNy02uwXtp7YdkTYTcXgAESaJ5Z4BXhEW++CQECe/ed8Y9xyNFHmH3QGSEdYftdZ//gfwkKJiBbH4IYYnaTjbggeg5CmCFxRmjGGYb1PXdZdPlxyF93I7aHm2InDhikkOQBOaSPKNrEIgAPIumfiLON92OU5R0ZYYmQWfmiljceOGWRVCaJpZhghilZj1eOSSSCXHpoYptrSpllmQXSqZudXlYJJ49qxikniX3mWdI0RrJp6J+FflknnoKeGaiTekL56JyKpskopYg6uqeCT2KaqZmaXkoEd3zCqCWpo3bqZ6SVNgrqq3ce2uqbkm5q6axuikqmrKx+uiivvQabKK61FgusrUKwZBqaWxK767Gwuhotrc4+W21qy14r7bbNanurr7F62y244ZJLrbhdnmv/7rDsWruuscKGCu2v6Kar66rxTsupqvTmC2m78r7rrr/lElwwwPp6anCpyNorLqpDQJwssw7X2x/FFQuML8L9AtpwrvUQGrDGHlvM8LwHj0zyvyovrDDLLTesl8Sp8QtzxxynnDC8LvPc88A34yxzztyqG/POGyNdMspFv0y00d+aHDTUS68c9dNOKz011VpfjXXWQo9rNdhNXzxpxl8DfXTYbLddttpr64z2z26TLXbaScut99t578131XT3/TfNNUvILM2IY2z2x4nbvLXdfz+equNvXiCXEA5EAyEGIs8tONd++xx35F6PTvrdpoM+eIpm2OPbdAB4tgEFFpCG/4GLpQOOt+5do967578DXzfkqhe/r+IeowYABx1g3lw0FRDmu+RwD1996KIHvzjjlOdufcSsm+r8+OrhjoEFEV+zO/WfZ/99++5jH//pwr/P+/T2h6c88+QL0SD+ADTe/Ig3QAJej371Q+D27nW/BCoweZeTHe1IcwHhOMd7GHzg8RjIvgbKD34FDOEBNTg5EpbQVK8LAH8yFwAIcQA0wgkgyKR2QqYJcIQGBCEORajDHnaQcIQ72dgad7YF0hB8yNsg95KoRBs20Ympc5dvLgcADwSEiENjIhKLaMQjTkyLWxySR6Y4hA7YyIHr61YGLAA7Fs5wbGjcoRx9mMEbzv/RgyYMIwMlskbYReOMbwQjP2i3Hyr+T4hwDGQU79jBRtbRjniEZCRzWDglELICVMSQDBdZGWyMAJMAAKX/7PGBd5jylKhMpSpXycpWuvKVrfykXEQZOxuVUn2GG4oGqHG5Qz4xkV1M4yYZ+Uge0nGYx0TmJGtohF1OI4KADCYXfxlKQ16xe3FMpiI5uUxiFtOb2QTnNgFIS02G84OQEiULAxAfZnqxkhz8pjalyc1uzhORwMTn1EQ5DQooM48zw+Y40enIf8rTnvekpjANqkwgYgaK+qznQSdKUYaes6AWHShBMapRDTk0l6cSKD3zV9GLlrSjeYRnPE9qNhkFoHn/y+lnCEQghBDg7mMj3ahKIZpQPfIUoRzNKUkzKlSddokDHAAABSpAGuRYR3nKAyNKjenTd0oMiys1KVGLKkmWchUyF0jq8ponhA1YQAPOZKcDRHPTfAYVW9JY6FSpulWFSrSu7rSqSL8KpQl8BjhkBUAHLkA+BxzHN/7MqjgjClSv2nWoWo3sXBfLV8o+VntCtMDlliM9qMplOYn9KUDlWtmefnGalzXqZC2b18A1tlkOsMAGhEAhzJEVNaDFKWN1ilXR4rWqbm0taUv7WsmudgkEiIA9YlrBUcYQAM7UAG4DENp3EreivfVidoMLXNe+NbUp3ekVDmCAuN4hiOCl/2R3h5teuv72tEuU6naBOQAFSKO8eECvcHs3X/au967G3a1qj/vd/QIYAA8QQDQQsADxxkG//x1qfw8s4JROGLMV7up74UuFBDAgGgxoMIfnAOERD3Gv7WVthCFLYMemWMUm1tYCEBANASTgxeqhImq9mi0WX9fFMfbuhi+MYQP7uLQHoHEABKCAAfDJpWTlXFw9Gz73HA7FRrYwllc84B8PucpNGEB5o2EAJ5sNqUplKgBuRwQqbznAWf6yIN/sYCHDGcfFbXEd66vgAETgABkKK22bJ+XopVW6bN3xewMq30Y7WtFc1rJ3EtBnBishua77qwUCu2b0QfWw1NUtnv+xS+erlvrUqIZ0kIkAgQ8HgAE3TgJ5zVsEzRKhQVTOrWJNW+fddC6+u86weoG8av9GWsOom3GNH6CEAUjgvvyI7Wybe0EH3PazoQ52gYudZy/fmdtHHjWxe21scHcZn7NecpOTwOcFE6CSzI3hC1UjnOhOt7rc/Ta5uy1s9+pZ3/sOd5wlrWrxOvu+gE4CpRcs4oCvocQO1zCRz33sYcu54BMPrz7aHQAEvFvhroa1uOns7fTRWuAV93fJV95vGEec4DjFh4ejUYCGH0HZS471yKXK8oH/++c9T7nLM45sgBP9PwsoAIh1fnMlM9nMLReflSd1dJVHnd87B/rVse7/c6uXhgBOV4AScB4ACUC9tFEt+NYZWnUYt53XL7f4xT82gGmYHeQIRwyU/cfGCgjHzTxfu1bfznVzw1zbXfd61oMuhFZH489IGMDM1Z1wxKB5qaSx9WBz3D+1L37khN923BWfeLh/VNWoOoByowGByCugz0+HkqDHmoEAzNY3h16r5jxfQ8sNgYUQmkDfn6vn0BPb+HNHfOkLb3gnvD4a9j3CASTQZ5GDyK/R2PT/EPtpACBW1CV8XQQrMLvaAUDzhGV7qpXffLlr/fOCN/oWFuBqBABaH+kOQAGY/gQCfPgImlV7tycPuZZtvjUn+3NtAuh9DMFoqPdowMZ+7Ud6/0JnBGJWYzpnD5jGcFQAAX2mIbJ1fnKxedY2Prp2gLXiZuuxfdmGDeU2em63fhJ4ehE4BQkWDXeHRPZFZjbXfwbQZ0o3BPHGdypUb9EgXdiGb3a2KwnoPAvoS16GfPomhe+3fKI3gUNnBWBHcz2YGkm3YJUXBQRQfWYHcRRoL8ojQeaHfqQGgShYhRXIfDCYhQJycEvGbBYoDQLQelSwAApWAB83h1PXOkOQQiu0e943fG34gIzYiDEng07ggY93dkNAf5PYh0pWAGdnhi7HeIIYh1doam74hp6IhaYXBUkGYl0IAAOwegGwik1AdmWGZzQ4iCtFhZ6Ii/EHh6Z4iv94sYMBIHZHIIllpxKyGIZxWItjIIpE0ADScDnz5gCzBX9WeHyQqFfXCC6W2HHIKASpqH8NZhJbSGbdmIxM4IzR8FmiwWmlmItJYEUbIDvqwY6fOG7MWIPYOIpfonogxodGcIPBGGn5ZwDluHwgAY+Xp2YA545I4BmCRX6xk37VmHz5iI/51ouhuAQAmYNFMI4eZ2QcR5AIBRIOOXv8s5C7mCzY8AFKFQ2E4VIWQFi3BEs0WZM2eZM4mZM6uZPlwJIxRRjYB1gAMJPV8FC4UXvVhWbUCIrWqI8XqYwVOQR2KAB4aAQL52flqBDbyAD+2EMggZREYGsouZQ75QCEYUX/z+WM0jOR8ueIM0hyuthEVzmLRjCOIZYxOEeVq7MEZllFAfBc0rZhDNmMzygEnwEfpRiXTEmRUfmWFzGONXcEUymMDkN267aXSoCO0zGEgpmSoJeNL6iYi7mQonlaO8hkSHCVkJcmx6g0UPlmDmiRoQmaL1iPX0YASseNR2CXsMgjrclNrzlnFOaZZFmattmWTrkQp1mVRDCZKfGbu0MCYDadQmac9+iYbomdXUAA0mB/R6CaBYkE3Jl31ZJ24DeaUUibRYaeiQmXW7acu6lkd/kEAxmeBSJlu4efBHg55imBLNdjFMeexCmgZHmcvGigB0oquCkN5XialBlmwBgA//YZGBuAmGz2e/ypY+eJkeqXnMNZoNZJnUsoBMvJDwuqm0/wfB23AL3lkGsGPROQe4m2oQj6mR66nhzKmBdZo1l3ot6pD6fJf0swefMJMQugXEUwQUVwPpynHqCmhLU5oDkaotnZmNYlhfB5WicaAZQ4drlpfTlaBGS3pNGEaxnaklD6oU2JozzKlu15o2zapkzpo2EoD1PZlcgVdpSoHbKID7W3ltR2HCXIeSdoXVJqm1Qqm7PJc6GXpaOyjVzqBPnHkWzZmvjgAGJFWzAEXUd4bzR6nYdHiiCqnnH6dnSahzWGp+wGjCLZYgmQmwHQqnI6oswXm9opqqMKp2yqEv+OSgTbSKlKoKKWhkwHoKICIKthynsEupiJequ46qbteHSnWgR2+IpOQKS92XULMGav9gBdKogsSXKeCaChql2kinLJmqBQ0KtDQIzPFotfKqQORHYIoKoGKaKQZqvPuqzpeqiz+q/BmTPT2pyrd5cMMY6xdz3QeU4Bm0W7CpvnGqD96q8Swa6N12c5qBDACKz3s7ANha8Oi64Aq6sSO7LqObBSuXqAmFco6zPjGKsTSosgy376aqW0mqtVarMkumzf2WcPamIWCy/1RZ7G1LA0GxK/5qxPGbEa9xQtCwDfuLIM87SYAqkxe1xFua9TuKj5yrRFF609sXB6+Y8+my7/QfsmrdiPrjmzWluzS5uzNwut/mqyUjlm3lkE3/iRN0K137GR31q0bGuuasqvE0u4dKuoXAsAJ/qzQnCDY7sXU8mcYQGZgbi24vp55Pq1FEuy5bqjRCS2XeiRV7tkj3e1KXGBd3gtRtu2iXu0nKu5BTqyadtxXeq4kiue8pmtVFB3fYasu7O6gvuwwgm3rTuD/gd9RpC3MYu6AekFkzesPwW8+ea2cUu4zaq0VgVilXuxqcsEKoqkXUB28ho40lu9iOq1Z3i42MtdsxupBEtz2zuMrhaZ3MGP6vZ2mRO401u8wYu4wstExxsAt0uMjFuXTpeBWjC0ZOZkRBRT0UBT/yWgiDNVU22ltYG0dy96cun5uul7vRbMozv4f835bPoXv2QLfZuYBQB5t3RbqGwIeMoaZAlpOxW8wcT7v/4rsgg6AErGpfjwq3+bsmC4dlvZgw0sDUn1hOwkDYiGiP6JTyZJaDC6iDncuearvorlhzlnmqrIBFrcvFeHsPIqMRBgrUSwRg3AghTQfd/3xNQUlJtGBEyqktbAv/vLwR2sv8EKv+CzpUE8BCTMACaMhdV6mcS5rb2rIQ2gxE3qqW5sZGI5SlS8voNbuIZrnPXIwws8Kqdprx2Zm3Q5V+BJVGT3YR/XAM2zRoTxwteGpp/KBIEZqJNswaCqs3a8MpJoY/94Kw3uu6qpujVf+Gq6e5yy+G6ZFg1kJXxFyKlqlYSvjAScOW/N1aE3LLIefKVVQMJSOwS268WutpoYhLqPS1HQyYlwN5jWDLF4TIfYcQC5KQHU6ooTOrtcWT0qGsod5LHmLIfoXLKlec1v+xi5jKcEzBB+KzrbCL0g5LGWfMX9bMXlBtBXXL4AoM1hOLsrOxCUqy72q8vGw9CGW8m8yA+aKRdppUKbO7xVDNFEc6Lw7KuuRpkB0c0HosBl98cABNLLF66ZWZj6WcMNPdLvaHtEwAFtJdEijdQi7XCO25V2OJ8jNrssTCuOh6Jy86pE+7FOAI9DUKHt1I7jmrTNuCP/DKiESp3O63zOEJG3Z+fSe1oExHi7WWKXnuwzxQp7vqvVTeCi8kHWYF2c1OCTLkkEF9A8RMmTiJ3Yir3YjN3Yji3Y6SEESnrYmavORwCW0BWCKd21aS2HwYnRlevH1+HWIzHK40GvdX1QX5ltFzRuD92XaAkAFaqhl2zZKw27cotIX/yzA90XpznM2fGlwC0pOu2VsHyWfwkAf3qFD13SfT2Nmx2ylJzUYPbU22vRu9HDOP0E4izXYVHcdwQRzq0emdqZxXnLEY2+eewSAUypA/DOTFDG3ZsF97zdIfGyeY1OFF3J1IveODzdpUoEvy2mCraHS4DRpuvNC0YzBzAN//ltP/uNo/1N3dWM1hgnBKIt4Hw8dq5mGR19YxATkgke3nqc3hTO2RXuz5OhxQb+vrGK0yHMolhg0xnrvH1mxmJU4sNZ2euN4rftftH6ADSHjAE8vkNworOoFFU91dyxlWXMLzal4xLu31Pe2RnpD5tMBAmgvUvQ271I17uYl3hIRBkwo/rZyLT9wYc64f9tyyfeMO8dDZKLur2MBNhdgQ76rXphmVBHRBqQysl9oYWV5oZ63m/uuinO0lQwhqz3ycjbbEr20tqam1M9avoMExsQ6DAqo06s5obe5v0L4Ba+BQsXhKxW4LrL6B6dXncqTyDdW4M6BEzKxgZY6LnNrP/q7YuJDrskjAB1RwTajNNCXsIdBanbjRLFbaTgW1YX0FZmaoK1vqNrTuXoetajfgWz+9L0EOdld+BjVueXRc/DLRL4PaGkMqZ899WyPKiO7Om3PqW57tnxnmcnisAsntqKm5veHWHuat+GB5APvngJoGSxag8/vTybam/O/MjWS+0Sa+0qjgUsXrnBuOFJkMvDrBBRO9wrpslWjVGTJwAScH/5ZZQRIda4Xdu7DuTRTQXDronNeV84HeyAA5AFDDNxrV6S52oJ+69LPe2HzrpWbo9XMGb4XOQHHunW4pGD/C+ou81zxHEMYMhB/fOffu1Cv/I9LgXcLrlbHg1Nj+H/BW7k29PdVPKr2CP141sTPB3Ds8rmWB/QP85Dqu7U327QFi8k3zviXRTjdZN/YEpcEV7tDj9aQ6+jQ/qHoZ2bYjcQdO7vk1PVkVkowQzuZJN/Co21Uk74g6LBtHz4yBkivX52oBtjJ7rvuyHGVJGX+N6xrpj5DMvjJfvQKR/UtSz3oi7E3V63C9bnR+C4HL8d0kD1303wAe8zxQy4l/vu5wv6b6r1B1TvRLC4SsTWi07pfG8T4O0pA5/Vxr38DR/0of75JJvLlVv6G0TTUwCMqF8FLOr9hRLyI6/fm99lsq/r0k3+Fb6DMA8EAMDAEAggBkKlMCAcRIyIw5JapRIK/9GmldulLhDGgGHqNXe3wwTDKFAkz+g4Nz23M+95a13v5ff/+ugE4wIJlwwPlRIVARgVHw8fn4wMlrCMFOQgBDIFByTaHhwbL8PEykqrmgYUOgMY3hoj5VT3bAtxEWd1d3vxfmkFhQF/gYO9MAMSlhI6BRb8oAIKCASdjSLKiM8UxMi49QJcjRiYVcOVQjCMj9t9e9NX2+Xn6s/u8en3jRM5AwRYc1LkCBwuC8Ro6kPgFINoi0opk+IO1wGCsM7Z4tPBgZIJFgJUyADAQQMhJd/lE9ePF0uX8fghewnTijdqBpUp5AKqnEA92NzMU2RTwCiIuiyKQfBQVx0jHYVYMP/Z4QJJk1ZTvhNqhcIFIx2EfAw50k9LmWebxqSJNi0VSmOW/IPmZQEbIwbvEImSCt7CLEf4krJFYNoRlWWXNICaIcAGABMCaBCjwYHXAOzWaqW4hAMHABQqeAAgFQBVM4cP12KrUW3b1awv/c0IwGYBvFVCwULo19MgQUSNUkkNIGkla8NvJYYKOWwACihJdoRMIbPmRBc8A+DQgbFj5ogltcaFXLh42K/RLSHq862lLsoMJEn34BnT5HkkBj56qNUrMvurU0yI7h5rAjqUKHCuOq0SmaACIyzo4LvpwCOEvPJmGs+89DLUEACJcJLNC6IgAPCMt5A4TQ/gKuyDvij/7BNMlwWKoELAqKaqygGwsEqQOtc0k9ELqQj8zhExkERtw1IuNNFD9Jjch0Ul5PKpCmUiwIuYBV7RqUUz8lNREAjsYqDErVRJ4C+nxKBOLJEAkCwyBBUE0rozHLDAMdJM+3KlDs+z88kFA23qr4mUqO22uJ45sy8vcmPASj+taEWUXPQAo43ZMGzkAHIAqjHIP0dNJMEALiDrTbJUs3BJswQtdNBYS5nSiWnc4yK3AvQTkgv4Fm21CzKz6fW+OQ6Yxo1gncz0IgYekG9UUoNscjNqaY0SSliz5TaiQ/lShtMlDvhLAmGr4BIgR+0xI9ly2NVnDp4qMfbRPNRUil1r/7UtFdA8+PV1VlkJ5nDbhZ7ho8ou1BUg3k6tSMAIXrGlAlRZ7qClv73a1ePTVwT4D+JpMfX34JIJNbhbSF5l2RaJqTmgjl2ZpW1ie68VgqD4irFigUMn7diLNSaOUUw7aBQDWmYDdtnklDNuObyTXf2330ZsylKwAU45d6dTeD56Ca5763lsggQY1w5Gfi5HbbHNyDeKh0fmwsinq+2wATGuevApNFeeGmpvC776kJ0hIuCZtz9cXGglMElbcCGwGaNmlE1pw8uo3QU1ZJz3O9UIkwKYoMA+9h79MySv8g3vgZXwoDEAKtAA3cIJNxx2lQM/UcRFHpg4aCWCp2Z41/+FWM9phor2lt4AJLgc7i+ejXZtJXxExPS79ZB9g+zlfR0SJLtooAIh/L7gx3txd7r3YaSumpDI2R1ADK0rnQZ/oUFsiajN5SeEFwVAG+5bgqbmRirReQYDk0FVACzAKjuYb3VGyM7t4geIJH2ggqZTwgawA4APJImEJTThCVGYQhWukIUtdOELYRhDGc6QhjW04Q1xmEMdxpCDSsgAaUpXINM5ADNWGKEYOHgqDw6INEcsIcn4lQjGrA8AN2If73aXO921b3L4mhheFGcEoykBG5ICRJhKYb820C087wJIcGCFwDGAjmFQsAJKgvgdDBTRDlNcAnSQd6fVOMB0ssv/wAQcsAEQtq5ZWOQi/KymRUl6YWd4wUYWdkKQFAHiGXBURF2yIT1A2AR6ouScHEWWqVOkoQFg+aHpAiAaPfLRDIQEgCFbCYBXUiqSXawi3z5jmUQCLouTDOD7zDa4r5WNclGwnxVyQoja0HFehRljI2AGmHigkpoRs8sY0uCgrwihgZHZwh4nCExxBoBHGOzlMZOJzIo5kp5brOevsiC5JSBOYGGcSx/aY4t/QK9JCDTTLxDyjW66hWgAUcAUmubLrFBteo+EpDIlek8DgukZVtLLOEwEM9sIQhnDOcApChAN8hSnEwhdZSrz4jmMCYxkvKToPAGWwXhadKc8xSk0/zsxUiUM4HfuyJopa9IGAqRmgDpBDqjicyE5BmCh5JLAK8xBzJq686Y53ahPvYpReIKVc2cIo1CFELkYpYGfeuifSph3BCulhlhHeAhyuJmO4lDjbeGgQA8ZBMXxkO+rGs2oMcdq2MReIah4eVFA5kFUIzDODLa6B72KotU7xDWrjcwDN3N2kMIsBTyQ+ZvdIhrarpZ1sYi9qDzDKtbXcuEfaEVRsAJAP95o07Nxe0UBNRuHvc5UtXEAbW8P+NJrCmEBdqQCBSwgGitw753FPOz1qjtbsmJ3tay1As2UoC6Q0qGjfbAVcqHZkOXKY2NzPNZnX6qfSDTUvQxbZRX8GP+ZCmBgnamlqU5jq93tPs661y2sPYljriVE6ni3dSu43msGzAKwbmeoHGkDOYfjBncADXUDziDwUj486CoByA5pqNtdA7eWwAVm8YthLGB6NsxRwDpIlxD2Rq5SoXLAtWm6ysRG9H4hvn5q77KGZpfPCWwDtXOE6bKXYtkqtqcBdrGMXVtlBBNummRsVBciJQ+R4owWnF1uhdN7qfCdYcPCOsBV3RY3Jc80DRgwCXRJ50HS7C1v04piln8KaO9eWcvcIpvlBsIxaP4lqisKZUXHlpugcHdECUEqLdoMnr0WgLKtmPNt0qABv2UniHEyglf6LD4q/3jFMQ70gQXNWn//ZiSatP3yf7vQVpv2uKq4TiuEKe2zIl+vuUo5c3vNgduttnii6CBsq7Eca2av+tWCK141IFefLnS5uGMrKqTNXOjzThsAmS6Ecr3wsTjveNndJrSVq+3qeBca1vUOz1v2d0lmBfSKV8qnkLUKFApPG43wNjebh82FTVPW3cv275Dpjbl3w3vL9pY3wAhgFzjCbJP+nmxwh4q24wXyo4gS8Li9e3AzqFwIe8Xwmtud4WbDNsIDlji1KV5xSXTCjErQNRUWBnLa/BapAMo4M2fbNt5eNK71vQMq2TbaMwvdC4BV8cWDHXGsZx3ng7a5F0pukI8O3GY3kbkQ6ppSsxXP/yH9QmBmWfY8mGq4yIZIwEtHzm69b53vMNd6tC3+d8HPe7N/8ZJkl7ETXPkprvosBr6LriKWZ4zXqlSoiTr8zblzndw6nzjnvd510Ad+8DknacJiA5Brimt64iWuOMTrSUgkXBFLLcfUhX15eKjboZGn+t4BT/PO++HZUya86Ul/fLM2Ng3+PF7QWzTmWQhvMLTnj6TJbl/dl2evnU2+cJIk/L5DOvSeD/750V/6ZDRWMPrW1RdRVklFnLQSvvfCADdPiMpRFb7bX8UqEQDgkI/VoE300KD40k/5yu/7FpABuUCk4KAJOC5YysUIvAZTDi375mCgGC4vpiEMqu/2uP+B5ejLAPJO/SAuAaXt5gZw/MjPAYevAIemEhDh58Lr1tolcjrwDHYFr3AsNSas4VTO08RAAnotBoEPBV0wCc/O/JTQ777uBecAZnJlCBKCC7htbR7rBM1KwYaDwRpuaH4rFSJB5SwCq4IHwNDMAFVw9JCwDd1wCZmwAbuBBofq24YKbHxPjQpCER7rTA7DxsIwzXRjDcvN+iDnIjhtEFuwCZ3wEekQCtlQEleQBSGRCgjCS5RhjGYtU3DsEOivDxnRLdAmXuohCDXLDC8iAuwjYO6haR4utLriKRyjnIxACi2xEikRBnORFwliNhomEK6NC3FDDIhRDHWs37phDH//rwoqL8KGEKrkSw2VURd/yjSgy3bQqRe5UQ4dUQYbUQl/cQmu7ZnGRn98Dz7y4S0oxhCHxS7UruaSQb0qpOnyj3Je4eXcERyrkRe1TNQ0YAMiCADKqQKW6Bu7EQ7fUAHjEOsQLyM+yj3q4OgCQPYs7MvuYaAGLhwaj7KIARUR46OcDsjghQAV0tesMee6AgMs4ILIyQJwcRf9MSafUCbBUbIgywn+IjjSoIyOMeQUjb0IAtsQcqhyYxykRxie8TTa6x4/5BTgziSfEBYFiwu24yTa6XSYwIRScg4bsiZpcvBw0if8qRWHQJPS0fD6kSShhyaXktXCzR7sQh+pYLhM/8kVvbEoC4cDqgKEwCJVCBIqvHIf87IZGXIhCS9yfEL6EKHW7gAo1iovIgX3IiEucxEkEW7dKkUav3IqZ06QuEKYHIMDTk2C5DEST9ImUzMs5+2sfIIg9mcRtC0v0NIwlSF6elHgcu4t060wsu/CcI8wT5Iq/Sy7pPIwExI5VfP8zgoOMjBi4K/wkA7iSAT0Su4IA8EyJYyURMVnggwsj1M4VzMcyVMvwXMwl/M8EVJdhOroHAY6RdEOypLdsCTyDEHpNFBYMNMMBmgiAuHtLBIxy3MtCzM9B9QwlZM1UVM9T7OZRNEnreAi3Ir9duwPK+btghN5eJNhyoQp+ECOXv/vQAWUQMdzQUWURBM0PDszRbmKChPFmapg7MLB/XgpFE1O1l7K/nxBO+dxUzpFbkayRM0TQVl0RU10SE/UQI90SUHPRYdgGi7Q2z7uI2sT0oAiQEuGO49wFfazC54nRCVQyYxwEhUURYt0RNFUPM+USI2USaeNn1jP4/5JGBxzethxSxMH2GaBGeNgQ63w0z6vTVOQQZOzEBDwl1RHIE+NikZRUNNUSd305saxcQBieJwPvTArQ31FI2fhSlWBR9+DHmMUVJbG+E40ElInAEzCtAJAMJF0Jt3Je5bgArKyUR8VUm+1TLNuUpszYii0uHrMPoHSeBqBD2+UEL50XrD/zwrOUAx2UEgbNCxlVQigS7pelR/JjYI+yMnUNEl1tVC9tUIO7RzYM1gmcA1BVV5AqS0boU4PYYCc6yKLpQpcTmI+M1DDUFsHpE6utUAXYYM6SAkaCCqcaIcM9mARNmEVdmEZtmEd9mEh1mCTyAiWiMSEoGDDrzihxI+UgANoCSWxNVfRE1c7ZiwdtAqHdSOBKmYsxFx0lMd+6zDcKCoZoUtF0gDMkhodFWR9iF+bzHZGdk3vxZYMSQOyI4S6NVJJdmmZVkUU82QrBQ/vpVd/Y43alR7XkZRw07M2FFR8bFCF1kz7kWgDIAPs7DNII2jDNcNS1SQywDLUh013tmnV/7Zu6cA1dcYOryCfzowPqPbBHm0oNAdsmyEfp/FKRDUu4PGaiPPqQLZt42TUvhVak1ZuRdZuLRdcM4ZCJ/ULyqsefxVfUK/29JRn06Uh2IgPurQjVVRpJ7dxU038xHZuJ7d2bZdhorNzyTE6wUNRAEqTZEZwk9FMWSr76oA3RTJEK5d2W9dWL5d5EeFQw5ZwoTdaQzZuYHRcY9QGB6F/3MouFOIeCg5FoSop0ypxE4VPb7d5NZd6q/d5M9d92xd+l3d+Z/AWh4BvY3Qn1wbl5oDtPFQQHgtLhaGu6JIOujTtNBV2ZZeBA8tx5ZduMbd+JbgZKoEV8ilo5nMObG/pPP8wcEcRRcjMrBriWR1Bfc/XR113ffvVdCm3guPXeWE4hieYgqsAcXIrg53xZuSzkwQh9ojU9XbRUjIBqXj0S+3PgW1OiXXWfiOYha33hWeXCyYVIIgVE0F4+YwAT2tjeLgBDClxXb8W7I4SgOAVT5n4Ep8Yip2Yfde4hqd4hm3Y5z7uQ3jXCU4hPy8hqOQhFMOmGQURCt/ioKYwZr/gL+JRiuN4adMYgt1Yhtl4jluYbrW33EL3Q9jgPXv4JtJBLjzyRKoz6wZoa0n49mRkZrH0faN4OO+1ldVYkic5kt84lnHyIbLpNiDUDtwvHHYFdB5BjHttIlHqGD9q0kihvUj/+XrbmH0b2VSZFy+Nc20n2WQBgAr5wCY67kSqlBhu0xIHWQB9g4ijchnndREM+CflGJZXeZ0JdYYzVplleZZpGD2ftpppMA3eIkq7kJkKGAchbZRftgmAeQMX9wqUBpylOZaZ2ZWjeYWh2ZHh2H3xFgD4aQvidA6IIjLr0OxaLK6IchimgZBLGSDGReBe9pHj2XmbWXZv96GdmX4rl2o7twkulYMPZVEmAWwCzFPftQhNKXlvQyTxNJ0X+XUZGqIV2qVZGqXnUKbrmAn+VovHWRnd04T34zoPwaOP0Wv1IyeUeqkXuokV2YUjGpKZmp3Ls1crWTY5uk95uAlz2avc/1UPHquAC9oZte2r8dV+V3qvW1qsiZqsyVOt9deC43OjY1OzqnQlIJM/PjB4wQQq1SbszLqsK7uF+zoK1VavydSyuZn9qJmM9DYOuLduEE+P0WCx+0CIUZKUlBcC1FKe59mz/bWoE3p53/mlYVq2hbNX61m08TcOHhJzaCyrr/AQwBjXlO5YP8QAQEajkZq2hyG3X3mslaShV1ih9c63g2pSdoZO/+1xhvEQMjqrGU1LKkXS6IaUGCCZLxutb7t+M7uzo1cMulK78Xu2rZe72zpvEw/TPhcD5Y+k1uSkAcBC60aMF0UiRo6z6Ruzj1q36dbB71u/hY6/0cq/z2G+7v9YH5QhlTe6KC7rsY9lkI2GpUCcwis8c+e7uv8au1XZtrkKw/FirR9hwNdmg3fLP3/4E+9joNy7KelIxWEVPVt8xW2byGtbsMuPxqX0n0LrOcWhw+/AsvoguW8hFBPZy2Bkt3lbnVk8wsE6qQE7pTnbye+wUtFMB6+8/ghc0RgxkOmgqdhSpJfZspl8Z4/8wGaxVb0DJOAEpZXcus1DskYqqn+7WYACnRONXfuAp8nXasFEKSal8UAcvmMczOVbzLMIGy3AdvikKgS9zM/awk07CxggCRC9u9+LsvMA8U4ReFd5uUEHszyJiJGynWVcunV918kNIAUyA4rkEa47ujH//c5JTodXvb/7Yq7jwPnkwdm7DbPAeYD474DsYoyzO7+Pna85vXBWsiW1kkI2m9TLWqmLALKWPcM7RcfvoLaOg67boG9XLtulR+lSqg6+uci53dTjeM8P6ypJgjtmx0hOCMl93d/fG00IwhrW/XIs+pL/F0bJGvLIz8TdRVmMIg0AGuG/POE33dxBjy8BwC9HI0de3NgVPs+FZhwf3mklnrRHm5s1jgWB/HKQ2SBoepgfvNuRvdsBfrH6fJhWJeUlPLChGWaY4eVPI6rn5RQ8SRhsouf8Tsun7pyFY4D9OqUXPuRhfMmL/ejNfB9gZhQMHYxifhXSPhnCex8PLbFb/4TOexQWHsZYh7rfQV7T//3be36OB73XWb4QXFSyUn2Pmf1XqPwMoK8aG8aqZSSuEOAE/2dRWHvM8T7v5TfoCZ3ffX7s+6ETLCG0KZXdf2Xtty3xfa2L/0Tr6WIue+UoGT3TP372A1/zAT/sLb/zy9r2IkAIoCAn08r0s+0uXn3xMKgCEU0cRJiMJX1vL1jkdb/Uwxz6f97vqV/vuz74zS7drcTpb4waOFJqK0wuEJq8phPo/GNRirlE/n56af8V+d7FR/3rqz/vES8JdNf74dM2uAEIIIKAgAA4IpPHgBIgCQQKhya1+gwwjFXAIQJlLKiKYSAyBTC36vWS7a6m3/9yZHz+rtvxdrZ+P+/7LUFBNTUMNiB5AAIGKjE20kGqPfoNFGAxKUAlJBEMFQy4GUAZhFImaUaF8nVeBkg0EriWqj2QKawmQTBAFYRFSm6dNg4TBwsbrxlCIR51OLAe30k3MSpuADgQUhX7de99/1EDWBIRBCRsdn7mbg0gQCkArw14BRjIxSUMCUA02hJ5RABeFC2dCArg5GjcQobzHKKB2CZQt2toAkBbE07SxmlVGlRAMmGRxIgSO7pBWWVUkYuvkpQDxUYWEYUT1dBEJ27AqAAI2s2pBwXBAUapBDwQMwgXt5Iqo510mswNSCQNMk4q2RTioEEfAFCAMkFkmg//Xc+iTat2Ldu2bt/CjSt3Lt26du/izat3L9++fv/W/Ro2wNgjV4+YXau1WtQqGQJQODISjtTGDp8m6cnJ0z2Yl1qu4SyzYZVUo//w++XnSpaHR44mVTLgSj+NlblqxZyVopzHkQEctr04iW7KShyMVZRBMknLl503SqeTMx4voNVIP028itDOdngOBSonJ62HOYk2EUJKPGPo44ojc5+PDXIAyg1jjT/8JkM9ywI0ow0UGrSHm3zH6CZdUqLVwZJBW0hXXoGtqGNHTvIEAlBtpMHWRBdfqCacgSOS2N9UW/zXTFe/GbefSc9xdBuMMwYSIQCiDRCHZmykgo9+SKh3/50c+wQUyAEEocfYeWckAVAATHlU4nu5yZgHlS6+aGKMByLIpRuc4YOjSanYtEVPsOyGhGnsqQGeTzn6QSRSwnSoxEC9PJhSlVPuSY1K8LW4H6AubQPJoKTRyKcfnEVwIzttSFfmShWm2Z2Pc1zInxvdSbHFAoOY0USdVnq5ZamGnpjoYoe65k2f0rCq6XjsiLmEdGi644qkxuW0KxtyqvaNek+6Yw8D/tjpSpLgvNpls8H8eaWLsWbJ26mp+lnJJaDUKoh3uRIRYlZB5smGmz9tt2lPBZSLhJMBiDeqq9daS++890oprZao2stsvvRcwsAA3d5ISmiftQvHmha6gv9humsswMtLVdxZEB5Lmqpqts9mTGq/0H681b/OarwGwgRzhgDAWCRMRY4G2wGsyNyxJq4u/MRWh7zYbjwyySXryfG+Q9cLNMg+U+EgymSweUQ5Ao+n63c9oTtzEzlJ0LRpTKaB8c9EK4o0v/gaXTbPHpt99tFv9LTA0lFQAo+QoZHRMsUNpykqFBu6bM+lkOIcNtg9i602VIUTLjjZiife+BZkvg3KIw7OCreFqYlIYRlNLyC1I1QzCavQhq+ddqCmi4543oOnbnqkkZtiJhTIupEdnEP20nSrctLexAIIlXtOPKr7S3zxqE+IfOnQdrU8462zrsStMbVTKyCR4n7/T+xvpBKB7g+dG/pBg0iIhMzGixNy+ui3+rz6QY+t/PrRIyE8PnJX/6isACgoxwMwV4s7Z5rPETJFMTIYQHzk6Am8Rlc0+jnPcVFiH+kqeDgIxs99BRwCPihXP/3J6lPfYkNP/naKcuiEgOejAkA6dbWGUWt/0MNgBjWYOfnVcIaLk+DXeOgoVWDvg6pA1A//toYdPYxivBCAzTRyLjYdKTxNcBMTA2jDHOrwihY8HQ19iMX5dXGHPUQC9UTosB9qhz+iecM7KNU+JCxgCK3JA96qEKTYKGEMUPCeDLPoxzF68YsXDCMgI4g2Qh6Sh9YZGAfXMcQCEQxcfEui9HK3/wfpVLFveEqPxHxBSUSCUYtbFCP8KPjAQA4Slaf04xUIQD0hphEY6omlyxDGxSOUcA9PrEIch2cnhOwqhlb8oyGJ2bFQitKYo3RE895XSsZhD3+wbBoTpFM1upnjR06zxxnfkBNAzOYL5UrFk9gjzBiiU1+gpMNZ1rlMZCZSlaQ8Jmdg4UE06u5JAMSmC0+HQl+tAVh9IIDEspasoSjwjcp8JzwXusoJ4pChk2imII8pz0MOYAgqCyI5tvW9QeBqDbP8qCPnZi6qbQ8Ve7PZzpLnzmcmc54WhehLZSpRIsY0nl/zqBnJGDDddQegTbDm915EpH56s45ZygkfNbcsbf/W9IY51WkhU3nRYs60oVjNasaU1kin2RJcKfzVPnfzvzfFDHPz0FDvXrM3PEp1qgQ0JUyv+km53tSqWuUqX6dyVgi8EpfZ3AJNhvCGKxgxK7kMCkoXEkWfiM9rdbXrXCNKU8r2saqWjStVt1rRZIgwKYtEQk/sxpksDKMn3dQIQeD6JaUS5456I4Jr9arZz+Z1sreFKl4f6lnb9jW3WQGTE6BgECQecIiUcJNQqSC8SdZOrbIZBLuU0DmEHm+znN2tcFe31+DyEANdwQAAxDuI7VY2qt6FFfU4ylHn6u8R/8QUP+w2xcb67hbWRUhtL4tZ3f62u7z1r0OVuYEKEAj/A+QFMIEDbFOK/LSe5oNCf6ep0HKYFDuDKKrmVkuOKwTgQRW7R0Ib7ODs9pbBuL3lf21alfJCoQKFIVQ7wftg33LEHBn1yYRHeDUQDrOw9s3jHr+xwk4UtA5EIrGNb+xkFKcYvVJu8lYpYAEPKAEDFpgycFf8ZDlQzqMb9LGdgGzF0w6ZjAMsxi5nW8U0hI+7OKbyd70MZRPTuaIYyA9zuOznL9fZDj3xhwcZhRMzBzCSbfLcMAx40M21wdEnvrOcKV3pzv4Z0IJ8zIwvsJw9Z5rFlw509pjw1zHTEtXmLPMjv7TEYP1Kukno5SQDEKQmCnjAo06venXdZTtj1QEc/0gCB6Dg6VBbLcrrjQ6FAxBasLZ6imKemaI9JccHyRe/SjgrUl2S6lyLetKk1jSefS1uYPPa0nku9xtEiI+AXEqa3PkMNc2HaAhZ8q4FhG1m1gMTv9H113NG97gxvewC71rFAie3wr/USOGN5p5JG6xxIsRhwZJ5mLeuJYUf3VyCpxvhBgd5w5Ot7IKHHOUpP7eHPoHPI7y3CW2zjY3YyM1bXoGWnIFukNLpQIYvHOjIVmjCB270obNb6B1VBXVW0VN8j1UYNd+U56x2AFeENAlHzdOafO7MoI8c3C5dOcuPfgeKih2nLRasABhpuSJqmFh8KOuhKT4zWrcVCVe4Jv85AD7Mopdc3SQPfNhNvvbCJ1IDFhjQEYqNEWyoXeQq1zoU3MYOJgQWvhlvAmKH9IkSz2NrmpxY/aru9YAfvOyEn/zfkaB4xlPgAlDoANLNnsgOEKgBWwYJNhxA+8gDvvYFC8ADxMQEeWteZSTs+BvOynfKtFF7zq26W+1+eu2mft1JF7y5AYB74GyZA8OmQAWw3P2TG94+W+5ABbDRgAuMXfJkbxMvImA9ibP626Q9L9voDoedAxStiZiyAMX19Vq4ad/qzd/5HYEHbNkFDBsAcMDvIeABVsNZfAVYlB9YyF4AWMAFJAZgiOAIkmAJmuAJomAKquAKsqBdZCD5Ydn/BFQAFFhAB4RgWmBJ6+VQBlgAgSiB+MVf8GXf4xDBSMGRLykFpB2ROpxCYeUdd9hDU8mcv+0bdqWf6oEd62WhFtbeMPCgDyaBBTRDBaKfS4HEciiBIcwY0SXg0EHAJkwb3E3K5sEEQSgEJexcmt2IxFQYCsFVS+mbEA5h2gWiIJJhBZ5hEziABUDeIcofTM3gIBDIDCLYFbbhILKaBGiCADAJCrHHfK1MJrVeL+mf1skRIOwc7UiWI3IfIbLh4G3h9gEfEkTigAzGsWHiI8ZiIV4iA/qUxdjaL/LC9BWhuYRVH9mOuoRHH2ydmryVAsoi4kkjFwpfF6rTqrwH2tne/zQu4C9yYv0lgdycg7TZ3byVIyCcVWLdjS/pwd6twirmYituIzX6otLV4yxiITdCIy/CYjw6yBNADdsZgR7QmzGWoxUtFhvQGqyRkT3gCq1VGCvqYzR2oz3eI+udUw5Si24YoDy1zRs62/4FY7Xgn3MtUbvoAXKtAbe1Qxz0irv0AuhJJD1eZEXKo0VaYjzeZD7OZBDy5CFGyo7hCkfpzOyYCy90G/hQnzskpCzVl0iWD0VK5VTuYlVapU7yYz/SpE9SZTUOonTIgxcUQI/BlT64kTl+WxxgGK7Jhiv0Vybkmx/Oo03u5FZyZS/2ZGb9ZFfWJD5qZQUS11lpgbs1hP/9GCQn7kYeOly4wIHf/RB02aVf/mVOuuIr5lVGYslG7uVdks4BaNQPxQZxLYShhaJ9MYFoyGSPJWUBDYJNNGNl6iBeUuZc0iVGXuNtCmFHGpNHlYPyeWYUcEPmmWOGOcJRcVhPSKESkIveSdFkciZs6qYu7iJmTsvX6aVzzuImHgCGhYJw0gHybYE4psQeFVX0eVj1NVDfQUHW0eY+uqdX9iVfxid1Cko28h92ZqVviRChDRZLsMneDFlJUkHnzcQSPaF63kPXLCV04qYhzmZ7TmeDol5e5idOxt8A8EIHVd4RCGYVxNzEheTyyV1AXds66gQTCODhxed7YmVtRmb/hT4nhNYlX0anIXmBwASRCAUgEspO1EHhfapBKjwfkDwlGrBkGcaohUqmjMInhdLncGimbCZpPEkHAYDlEfymOv7QKajkcKYDPTgkEbYa+Vyci8rnijbpgyopjC4pk77odV4lmnrXbyqAaMYEWlLCFXzcjdiSQCzoNgGQXGKfnLbomarpjE7lk2Ij6tXoMV0CUXwm27EJ/jzCh/4Yy/SRYhLjWFHHgW5mm66pZbopoTqphA7qoaKqmT6Tdk5bh05cSzBC//BTLlzPvQHAcsLcJzQqfrLpm8Ipg44qhYZqbMapsGbOfmrnEehoFZzVHXqo/+VfS1IBUZVGvhXXm+wq/2wSa7BO6URG6M85KKgShzYiKWlg6D3sJ5Z+VXownxVNHWGZWUpCq6U05Hr+6rBuK7eKq6/eK6LS2KEIU7dOFJDqa6/O1Y0eQIZC21hqngkNFbQ6UizVgZuc50tW4Vhla8EarKEKrKp+q3V6a6FuLIvGR5Xe6Cr4p8u4HCWJZt3Rklr+6WMaBK72a8iKLMka680Wa6rWrM36KkeCq5XQaZXC3IaSYxrVQcvCa7SlS2HhmhEeQc4VYNDya776687y7D4qqql2V8Z6Q29yBoYIT4WVpEvaqoVRhqY+LFqRA0Gwp9X6bM7q7NySqtyWKtXyKtxmLdZ+DhFcHY+RAzgOqP/RFubZqtokGGe1fgsA2u3epqnj0m3jQu58cm25imrkTi4cGJe8wQMtWWpEVFvEflRzTiHpcVvLeO3V8u3Iri7rWiPeVibQgiwvbYIHbWK7CM/bLoF3XmopNuW/VYibJGfH4mzmSu6+emzr9uzl4mv6mRcUkNcELF4FoKGcpq4cZGkQgaSv/GajCENBuixQqZaXXmxEMm/cGm/6Ii/HEu/HTuj8HRiBiKH3wd/cXu8buMLT/ebb8u64EifammOhHBRoHFndtu/jHjDmJrACr6/eVu1dVsVjYMNkeAtafKrrDi4/fMu2TApiiqmnHi5hfcanaF5rtJnyOjD7NjAKb63/LrZwqVhZDKbBSLAI5N6vSM1Ovj2BB1dSiD6rj/au7iimHhihpLEw7Krw+VbtDS9v8mIaqAGABAMABVsvElPB/hZFAJwBSD5h2KqBCOGh4VpPD6PLUbDl8WKwAS8wGisxv0aLFVsapyHB/HZA/Vbx7CJB5wLAKPjI/roMLyhfco1C+BIyf/QIn5KuE6txGi9yGyexI2tt5fqQsCWB9AYA9XolE0+r32bxGXAwFZysOyDl7Wie/iXjPAzQzpkvAzOy+q4wAreyK0PyC79vAmuybAyBPPRE1PotCxkXuEANKhruu7ZBUKFRarIyJKNwChfvGrNxEzNzMyuv7L7vKIyl//AwARdTwbPJDmgM1DD7H7x8BidArcZC8zLfMizHcgPT8qnaMhwra+WBiRYPAf+uK4gahB6EbvVpKdy0xMLkbTSrszIPtEAX9Bvj8SNT86DyggTgCNwwbBN0btO818UY7vg6lzjR6wUTdDJ3dCOf8xGbc0ijL401wesFAIFoQFeExCvP7e0+yt4k1A63DEh2U9Je9FnaG9PFrOp6tEH/dDofdAWhdIKN10/LcgB9n+794IKts+tmMQSIWbqyKxALUWKZLdMqQZf2GLyoLUeTNEiH9TMDtVgj9BYs9ZYhQfwitTMDnwNWMmS49SvDAwIk67mqox9zx8oWrlb/olXvMf8poIO1hqtLi3VZJzViJ/ZZrwFcW0VLH/Zcs1NXvOAGIsEF0N4NtuBmc3Zne/Zng3ZoizZgVLb5gcWVAYBm11h15ssXJoHiNeJTQ/KOKcAleK909EGyVoHclFiInS2Gtct8/a50DjU8m7UkM5wX9mASQHFbG3ayJeJaV8AYPnfWWvMmhgKd6gFVvyrqnq2QESMTgaI7S/ZHH3dCL3YFRfcRyHFBJ7Ue1GJKA0f7kTVKhJZRAkBdVwteb0GzEhZht2VBaF4RFJZQnzd6V3d5m3fWnkJ8EwglL7OCL7Q7Zajg/g9iVgcWsImslnLT9K9x5qGB1zdy+/Rha3I7W6BL3/D/Jqbsb+YM5YWYIC9tenJchhFVMop4ehv3iO84g5P4Zq42sM5BFl8Bsuj3TXjxFQ+B93LcJajBMfZbZ3TPKuS4giu2lVc5lmtrwCY4Bt9v5zY0h/byRPQmWjYNvTFCSVJsYI9Qlsv2WPN4Let483L5m094TqWDAISyi6cL+E5h23XzQM5hufzTeMO5liN4l7/5lSv6LP+4lHo5uO5Y/h7BkUeCgALAWbHlFfxCH3C10zohost5oy+4qI/6yKK45ZJ06o4CA9TzEYCk+OjTSF5Nu66tTegBmVxqEQD3nJM3qR86sKd6ew47cd+x6oiQHHUnL6xWa+51GXiKvbrGh+II/3fG+a8vOqOXOrBrOzQXe2F3tNfygsRogSYEZP1A7ETLeBJdabQG9v+6+bZne7wHu7BvuUaCbMaSk9xFtRJ07xbQ9LNH9DwQ88vN3IFju7wvOr3Xu6P3uDSH++hkcS/kMeCGIxRsOH4frXh0Dd2JyecqfMOLfLePPMOTPGOnONYG+UgPA0H8cqaP+REKsCPpLgBYB0rKoejyD49ee8rP+8Nz+4k/et7eeSCBpC/xuRJcwhNwXCD/ecL4NnC6u9IivM+HfMkDvb2PNMm/N1jHpsRIfX5b/IS1XR+Mli8DNhqYmZikzCOffNYvPNxfPcqrOkgXvTGRkwdfuPicqzzogf+rrm1Evkwasb3hxn2iX/3bI/7c33tm5vuz/CbzJb1KMYCmLGvDPjkRAEXh+3XP1z3XM/y3T6ToQ3rEewkDBbKlk9EQOCsSZGkV/HuP5gnnl6LWn3rih/7QJ6rum/PdFxIYa7GY8/D+BXIdxKHSd/61WvQQ7bPnqyhZK/7tM/7W13nI+34xuYJ3TD66+7COxLwS7DDoRQpOM7/h+7rVj3z0J/z00zm+M+qr4Hbwi73TQxuTm4R0HKg20+5LZDUQFAYAgiAgBCSVS+Yy0IRGpcrn1GqtXrXN7Nab7H61YTG2/CWfo+ltwP1WS9lxM535dqvxczsgPTByM0h6CBA4YBr/KDAcoiIyUogCDJCQKgoY9EtSPBq6RDrjsxOlI40zPe2TU11jbXW9S4WNnZ1CLbtdrQWDkngTGDowemgyMCS4G2AIiJBCOJKaLHDkZPA0Ag3d5d3OFfP+3tbsFh/fBXcUR5etXXdSbzrAiwR4Rih2W+B6to5SOJa0KFsATgKQfWqkBx45hg3bLXQ4y527MeW4RNSG8ZkbYAAKHWKSwE0CKByRQVkwUkoEgFRYGnzUaRTEhxhhUaxzrhxOW+x0Wnz3sxRNABDmARAWgNgSkQHoMTEagCQUZZikGIPpBCDCPjx1Ca1pk5XXV2JVTdwJNGiUCRfyAMCAJ6dPiUyWLeto/4/JpUxMkvZtwrIflEJSmRgzzLUr0ZuMG5td7Hgs3bpquUGhEADDEgybK850+I8BJI+GEClJeg/KojmFTzZpulTJv8TYEoIGWzm37rC9fT/OCPm3kg4OmMQNUGHCXIUNky5igHQYk2fZlvwzEoWAG9l7jQAG0PSJ4rOSywvHPXyy+cjBd6eN4sCCmwsUOFtg7l63sQJGSOpdIqrTmEgpAKOoWqQZKC5RUImmfCHvvPfWm5BC9SSssD1c4LNsDg4aSOICz5KYIIs95EqvsgIFKw0kJap6aomqBkkDq9teFOi2qGi0jTcfgbsQwx9dIausIPMDEqg5GrhgAwAu6ODJDP/gMq6nFB9L0L+kugNAtBuTEGwIMprSZzVGluCLCDess3DINpN0U0g453zTiyJLsuwyKDhwwwEn+QzggimtHIockQTwJToAUXMDAiiiKjOMpGJcAqvXYronQiLZu3JTTgvNUMM4r7jzojxLTQfUdiZRwAgIChwwiUWXmDTVJBZRrQlfAigzCYQuIQg9yjwNtdM6j0VWVDQ4VAtVPZs7J1Ff7nkGPAGhqG4tAHxxMSSVlPgVG2efpVNOYosdNlllzw3n03KNXbabkfI59DYYocAu1iyicrSJAisB1zaExjXnSFVHXVfdgxFe2E5mlRQWybGYMeaeZSj1sontDAtqEoD/vbMq4E64Irhkd6FFF2WGG1b4q5Rb1i9mVgqk+aPb5DGwiaoaTCdbnbFBU+AeC15Z5XfhNRdmmdk9mtCXk9YDRZb7qLbiSaZSYlYluP3yCewu3SRHkYUgz+SIl4Y6baTXZjvdz85W222Ha2lqYwJEg8qNWJOAtKQCsV7ipdfClcnWotFOOO6pE2e88cUlVlrxmDWYLwANkqjgjSq1dWUZTDBJqt9NLv6ZkjWWAS8JS8ceQFOzn24X9tgNltvx2p2OgnI3Ls/sDRBdhni3Di5vAD8AKrjcSFY+euOAipnImDpo1ghgsCUKw5pwNolu+nbvje4e/Mg3hJuWKYYHoHgA/zKzj9Q8uUfWA+MzD7R9zvu4WhCce0Wq0SY+ApsSXAMb7rBOU+RiWgLHF6/yMZB230Mc5Jogv/W9gQMSfCAu9vCBJFCgAh5YwgYuwIEPnMiEJ0RhClW4Qha20IUvhGEMZThDGtbQhjfEYQ51uEMe7pCD6/vgEjJggQaUEIXvG1cahpi8JTRgc4azQ+iMYQBYBUhvTcBVQN5CKyM0SHtfgqICJRfBx7VNfGMkIwRNZYUlNsEBv1OeRZLYhAZUYFAAmICfRAjHMMahYjg7QLVkRDomcC0KWCGD2ADACbINLY5itN0ZIylJM6ZRjbPDJBTqeMcGRGmIywGeHDFCv91RwP8tAfDTGvuwP8TU6zrV85f/oECmMORLCYsAxnPAeD9IVpJ8snPg4X4JzDbcjpSWmwD9ooQ7URJJapecgjEigLPqOYVW+UiEET7mF9J0oUCiW50imdnLMkJzbg08ZwYtuU5VqnOSmRwmHQA5RY7c5hk8A1PhsBgA1WRhRlvDJrf29sgFplOY8CSnOYt5Mnaaj5iUVCgvzzAtnG0McFW8nhsCmARbmiNMSWgKSfi10Ie6D50kLSkGyxlRkzYUoSdtKUtfZIQFTBFvSxAkF62JElmOo25J+Jd0TIfSgwYzfC41akIhulKkIlCpBX2bTDl6hP25agkYzRo/JYG6d9QqJpn/EEhSoRrVohq0rEQ9alPJKtaxqlWlMY3DMhIwRcRIb5tFuSIUPuqILC4SaNsyDVvf+dLBCrawZn2qW99K0LbGM7GM9YJIGLA/OCjBKB1ZAiEJGACwOSWwjBzCSA3LVMc+drSkJawvSztWgsGPoaldaxmW8QC6MqMLmp2q9XRKKT/IUnAxuWtsGzvO4YYyrbCVKnHR6FB3qhaxyJ1CSgySD71lwZWo8U8U+iojQagOIIxUrHIPi1bTnnap50XvaoVb3OdGrbKobcIzFFDbZmQBtwB4Hr4Cy4SPYm+RuNzlYsNrXPbi6bXQHTCBlyvRAq/Xue0Uw8Zohs0qXBeoGuVp/868xdnwFBC/LVHveB38YPKWt8QLNq9aW9taCA+XIrU1QH6fUBXAAWARqVskV0E2nu94l1fJhSyJRwzfFIdYyEOO6IqRCNM+aoGynKUpL27qoDMFpno34sQzkqKgkBL5xCKG63ERbGQvf1nISj4Vk52qhWnZVKtguJqMprPZAD4DGEeQSVN4O2Y+F7nP7UWxmcuM5PQy96yFBrSgJeEfjVoVDFNOQqKg4NVKAaSeXwWzgMkMZAOrWbxHDrOJXdvgUAeawVb4RwHcHB0qZJdRP95nrqhsmMLo4xKy5nSLSX1qUGv6z4rOtaET3Ws/D7vUV7hYPlwNhjdnFZ9T7daFrf+5MWKA1tTHzvSnB41tYge5253edLB9bexxd5gB/0CAZK8Ja77l9ao99VWPJzFjAO+6ydlWML7z/W1d23vN3OY3wNHwTEQDYLb+kWulcX3fHIcMRzIRyBNW5+9R6xvchyZ0gi+O8XL/2+IZ//UeyiDdQjBA3a/mX/QCd2XpdYRb20EM/z4ubIq/LqXaFjevy3wijv9a4OOW7yIUgNu6YpdjTMFwpWHSFEe9ocYz13nOPb7tjoPc51Yv9r2hjvPwesOi3Kly/7b4YVwLlVJdvkQk9Nxccmu831vXOtX3HfCoe1vubb/61A+DiSkKvdLGUEKBArhdaUeiKpnqMduB7Xb/ml/754yve8EX/3a4273rXxhAo8COWbHL45YOn81+k/CXfFojKXP09NylXvHK21zxWI/73Sef9cYT5gjolu/ffRp2aYvOu0j4Wj3wnHrLQz72kp897WGPd5+juUNTaMtbJjAfO1b9+EmQ63fcDUhNTIJL/1w3IqJCko94/uaqR/7jw51+67ff/ejfuJinlpkRAYCIAOjABdx/C5JXL6fezYQnkDT+YjndI70tYb3Vcz35Sz7lU7+8e7/iozy6U67iEKIAcJISoYITmqS+s60AGBDu84P92TCw4T6fARDUOz8JhED4Mz69Y78IjL8GZD54kQ/6oAANxKMAsJ8ZNK/M/1MKN2AJwJgiKpAmbtop3Su/FjkNFXy9B3RAGfTB1nsYBkxA2VuvDwkRDMgADNzB/duCQlC1D3wNEewtEJSesgMkBERAGFy/N2xBFoxCKaw9Crw+OIy8F2QsJnESKLE/EMk/MNSCZPucaVCCItxA8DiUveGEQQCQWXHCnnPBOJxCKiQ+OazBO8TDxQGUVJq+5LgjTKzDC0MUfkq40ds+d/OrJDxERljCJdTETKTB5aNFKJzDSbxFXJTFK1y9SpQqU5gi7eM8RATAvTPEjOIsNpyzWJxFW2xGOszDTXxGrotBXXRDPfTFGCQFnBENYjRDMwQAmiEQlQAQwrvGXMzGav8UxVp0RnakRj1EiwOzQ54ghWlZhF15DWL8sDBYhrsivSUUqAlUx3SER3lER4EcSIKURl5MyHYUxGiABDdItVcLwffqEt6zMWhAQNEaxYaMxoPsSI/8yF10yJJ8x5AUSWukHoukpJKbolP8MCL8nFfzPcACCb1IiuA6R5KERmacRpV0R6DsSZ+kRedrFk8ThdnavEb4xurKKlwbqSUMq3UcSoZcSJMUyqpcQCtsR6MMnif8t0MRQ2LUxyKsMNETqkpAwICkypMEyZH8ybbUSoPkSbckyqCsyzjSHcsBgA2onPp4O/lSSg7rPIrsPtKoNEPUC45UyLe8y7m8xMZ0zJ3/nEyrHMW9vJwS6ZOqlEy0Qh/1WQI/bLxvMoSJLMZWDMAPO0ZURMPyy8mh3Mqao8u47EzarM2ivILPNJ4OsgAQysrJnAMKUoINQJ5+g7FTbEo09ANxNMDpmEq7xMvbxEq5/M3qlE7OjM2ME84k6MIeREh/O5Ef8iDfhAtUAgAj6qH0VM/1ZM/2dM/3hM/4lM/5nCHxDCLMCQAQQU8TWrL3aCMm4ID6cyrJGsuQAcIydLdLwymrKD/GtE6UvErIXEHqpNDrlNBN+8/hLM4HnU4I2yQl0IALehIRlahneIDBPAkx1D3WrMlF3JLXjE4IpcTvjFDotE0ZrUzLVD5S+NAk/8AAEKGA++NQKRQ5JjgmDciAUwJMYcOZQzFNgzs6M8yvmbImlpiG5+xQHM3LCqXRGe3SyvRKKySFI9UA+iFRLs1SuOSlf4iAl+QY6UoIb1RFwIqOqCAAtoxRNU1TPb1QsLTRPeVTGw3TKnQxKDi4IMQsOVXOfdyLfGAVB4XN2QRUyrxRLa3Ux+zTHGUxSzVJMpAuyULEA0XNVwuDBPmwydImL8XUIV1VNA3UP81Urqy6QZVUWOWeKTJRI0jR6SnMqXqGjAIGmsHSS9XRLbVQVqVUYi1WZV1W3KxVVU1Ww5mEqCg5JYBJYpyElKDSB6gKCego4HxWZG3WSY3WWBW1rv8k1HC10DCQLDY1BoCBU9YckInMAv6gU0jN01Y9VlfV1y8FU3Xl12Sl1cgM1DAw0ewjTLJ0uDirApqxKB2r0YAdV3N1PIqtvIkV1HQlWEztgiY1BKNgNVFdxdc4uSrox4yMgL2K2H1lWX9V1oG1xI0lSpj1U61gSfdwV74bKhUFKV6F0qnwGkbAjgFKyeyM2ZoVV6M9Wmjt10mlx8xSCl3VVew7ukWQjZMbQS2RSMQsWoB12XxtWk4lV5rdOY2dULG9jE+tHpAlxUbYmITQLNuiFn7SmpX92rH1WrS1WDss14zN20jFDVxVinc9zZi0rLB7AwI4lKYYKKZVWizUW3H/xdikNdszq1xJXFclcBW9mVqRBYAok5UkBEIFYBWGs9vIldjH7UXVTcm+VUmyldWsrAKQZVO2LY1jxNp4za0BSBSbgTvWLUiZDdvhdV3Kbd3JNVa9rYJ3lSvC/dmsko3/w5lXaZRlg1ziRd6WRV3t3d67xc7ZhN1ztdUqGAZD+FwO010R3JgBqasb84XVvN7i5V7sBd7gPVvv9VvhDdinBVlfMADbJUZfaBBFRVQJA8+/pV8ETmD9zd6vDd8GK9Kh+AcJWAYIcN6pTQJHk9LPGYYjPGD9rV+mlV/8ldwQflXJJeHaFDkTzYOptV28YrUPaxBAcgMEAMd5VOAG7t4d/+bhBQbhU4hgiptfjH0CbWIGAB4qAGAJeiBBABQ8ffzdHDbh5E3hIdbhHhbYy41duQRBQ2AJ2hoqDBZBdHs1AujHG8bhH1bjNUba1F3d/vRTA+En6uKwFybjVewVNyMIKI5iNsZcK75iH75fNX1gqOkdNwAR5Bi7deWP6rlj533eizzGJ+viRf3gQRbkP7biKaZiQtZiMWIfzhBQ2a1hSnA1DL6sTVi22qoW0LvkNq7iWMbiEZ7lQm6+T0aWQxZR5FCO/fvAAXxh58XaJ6Omxk1jTKblEwZkTgbbTNZUOJaCIeIjDNjNtsSZ9/W7DwMYIDyNa9XZe+guWFZmWR7nWv/G5dOd5UDO4hzOxjdaAh08Q56jg38wANRxgyGYhF01xGFuNF751i3eZClmZ2YmV3VuVluGl04CgE+SEippP3Tz4pDB2lPULDdDgG8SXoLe2/h1ZvHd6BKGZiZIJjdYJkARFOsDFkzAYBNtW7zCrIoaBs9RYI22VeP1Y4B24+Pd1HK+S5aoJmNgNRFExNwDQMkSDJrOaWQ2aITuZOxd6jdOs5IaAMSwLYBh003AsPTVm2XYiO2YaYG+aZwmZ6dmZqaWOno8Agw+RZ79vylqim766rCWTbBW6qfW6ZD2aDe4C1K01sTIK0BijTdD6oCW64qt6aRW6nhk4LEm4qo+zXj/VVgqwoMmjOvEpmvLZuCyPuc+jgOQfQZHyefTFGO92QiHG2zGtmvMLuyL1Wx2juUgPoN3NQJEODlRfeFp2ZgErWxx5umO9mibVm10TmfGxontSGXhWwqedd5spWrAOG1zXm2+TW3e7u11XmwspkejuAcRTDiRLTlqsuTnru7p1uR0Fu/xJu9njurfwEwl8AA2+JxIuOpwPBOROMbmfQPwOO9k9m3Dltj0/m3ghq32TgIL5EzibgLdTAIHWOQNRMNTRMQv7tlDmGzopm7+xnAAD3DCjm5tU/DeeqL/RvAo2E54vgOrkC7N5TBuDt35ym/UjkSxtvALz/D97u/H204n/ypo4t6gDrrPLzxP+hTyISfyIjfyI0fyJGdP+yRPHQ/yI1rvIclQIIeekMFg512EqaitGubw8h5vGzdoDfdvxEauKXfywyZWMuhRJTDx0IuEF55anAkGOv6WGZfxL79sGgdzMQe4NU+CM0fh7oXt48GDy2Hw3bmq3HNe2y0EBWmzN4hhO99wGM9zL7/xpR2tI41n7xxu7J5niTzfk3De7mY0Q2BFPA9uS6/xzf7XSm9qpx5xNViAf1gAOOew7egIl6ymYOnyO790jg5zMDdrZ73u6n7aCW43VvNfqqWN/6P0VPf1VXd1IW7tYifep30GLR+qCu4wAaiYpOv1SZd0cf9Hb2Fn9V0c9hd82mXQh9BOceHbFZYoO1TX82kf83And3oXbvSO9VR4i5Mrwn/hJ+t99nrvcKiG9mg/6HM/665ICVZj6dB2U374aPs1+Lo2d3sv6J3u10HHBZHY7itSN1YxhGwW8HyX9oRHeT7H9FfP8CGmR2OQb2YIXWKQLHu454rf95S/eJW/94Lf+Zfvd/dChIQ7QUooZRwb95/Xd1UPdo1veWbleAxH60F496vGGSudU3xn+l9XQIZv5qeHqXTfeZzgvmV/XnQzAohF86FX+Iw/+Lsee7BXdzugZ6p1lHfn6grHW5+P+q73erl/KLJ3XLu3JpyJNBQv+RcP+xj/X3m493vprva6dvsvSLvSUJBFcBSg5vu+73mn33PI/3z1fr6S8ukhkHAgHABpYPzGj3uLd3qWB3bZB+ko7wqCE4OproIrMoppkKxAIEzXj3xgD32o51vFpnxPnwnb9YVKqI43gF+dF2HRV3jaF/zXI3xwDQW5QPaMhACcCeyna3vlH/6vN36Ex36Pn/3KD4fPXqR7hmgFfdnXD/rip//6R/+v7LkiRkMggAQKAMYwgDQAlsymcxl4SqdUZrSKrV6z3Oe2CwZ8w9wxGWs+a9XdNNv7LsfRb/fceg/bKUhkAzBhEVCRQTcXcBAgsGQQILGgWNBHQGZ3ZxmHmZk3pVnH/ynl+QnqJKpmekpaOqqK10q1F0DRZPHXcWGYKYQAkIgoEYDQR1T5CmWMWoxsLMacrPz6DCY97cwazRxKxYfEAZARsAGISd0U0KgA0KgkaYSUcFaeJb+2bI99j6/fSp/Lf/0v2yosGWpNuHJwFqxLSAj4OjAAiQCJA+JZ26eq38J8GbNp7HSRI6lyH0EKNMfFQQNw4g5a6QOzHxIi6wAIganEokhOJeHs5BkS48igAYVWIyrQToMO3yxMAFALwC1/bN49BAAMJiWdRvP0HNjVK9KhP8WOBVrV40mUUyZUQMIUkCBCVM9AEjBAwbklkvrwSlX20FmzYS+pDSx4sOG0iv+LdoyjV4kweBFhwgNceBNizZk5dwZIdjPoo6JBfXX1Rm86IwtswmQwGq3jx58Z17Y9O/RtrrxzH/YNhsDEdEgYwUyHm7by5bqZm/4NnPBuaL2dN47dJQKSAZBg++pTMXnz56UxR19cvjr59NTbW2dPWs2ARgASBFOH0/P7xNP1XMcu3X789Refe+NBd2Ax6HyHBAT6JYjeeQMK+CCEEVJYoWzqrbdWTzFdUhkBjUxUXIYBcoiheChaeCGLJp64YoEpaujiPA8M4YswAUQwYY3mzbghjDQCaeCQPv7o338xCqmHEQlERuIDPS7ZIpVVGollllcyyeWUbSCYFHxeKDL/gDDaIXGAl10CqOaWbrb55otwzslmPWLWqSIAF/yxBAdIOCBOKXsZ4Q5sdOYZJ56IJrooo0ha6WiQ83Sx5xIUXABXXWAOeVAAfDZQgTgOxGVOAJRIhIQEkRa5apIEfnknrK/KoeSjslLRKZ8ceENBBR7Y2eFPKi3RQagANIBLE0LABglMDh5qa6syQipntdY2ei22imqTEp8XeAMAB6Ryu1Yz0cT0wRLDAnApEhZc8EFM8s5Lb7323otvvvruy2+//v4LcMACD0xwwQYfjHDCAafLxLpuudtBvPWWe0xX6zaxqxOq4TfMmtuyKu2tRLo666Sx0jqrKBczEdVG5Z5W//ETKx8bwFNMCBdAOiSm6rG20YaMsoTZ/gytpECbTHTDfDZsQaAmvTwSTE90OsgSb1WggRNnDnBTH88WDfLQYYtN8shlH2k02GdP6wTVFbCLxAWFAHsSzOayMV8UjcAUntpsH62pln6LbDbh1JL9N9Ilp+3zGjsPITjiQRc+OdpjS1754R9f/vTinDOORtc895x046CXbvrnqK9+Ouuqg+X52qTDktUkkW+e+OCZ357667LP3rrvqMWeO+5e9IWEocD/rrvilDtvufCG89578S4TPz3gYsQkJfXBW1999tpfL7Tx4o/fufTnP0/3KTGl6b36gS8PvuvMo09u+ebvzv8//fuHIrVDwIRHmrPf+v43P/z55GQJbB70CrhA7PUPcy/pw2Xidz8Etg+C8mugAzeIwQzuz24xC9biliUR9oFQgbBTIfmiJ8LwTfCDL6yfATWYvjPopS854WAMv2fDDq6QhS2E4QFxmMMgCvGHHdSLOy4YwiMCUYpTnCESkxhFK14xgkusYa2aCJPWGFGLVXxgFs3oPyp2MX/6u+HdJIhGB96lRGOMIwU9uMUi+pCJa+SiC7FIRjcKcohtSF4by0jIOyYyj2xh4CJlGEj1kfCNdXOkXw7Zx0Ziko+cVGIn1fhJUHqyhJtUZKn6wJCclVKUkQylHU0JyDS+kpGapNz/JCfpxzP2og/wqyMeB/lIYHpRlrOE5C+NGcxc7pGWlNRhEuBYy2W2cpTTZKU1iynMYQJNXn+8ZjJP2QfkdFOZRBzeOPWoy2Mi8puZjCY1q4nMWHLhRqpcJTzV2U5z+pKdrsRnP/1JzVtSrJlO6JUDloCBAGqTCzvs2z4XykyCphOiEZUoMfn5ToCS8pwJ3ACmDgoADGDAmxuDpj4nKk9YsvGhFI1nSlVKTmxmU3wXEClIEzoIm7WUCpAQoz1l+s+drlOo+TwpSlfKUqR6U6OIcsBBMQBSJmDAAkw16kWJmlGM3rOqXO0qVrOqVaC6U5q24kYfojqOCnKThi91aUzZ/6rUq7bVrW+FaV1HuKnrQHUJcgspWuMK1rkOFbBwvStd0XlUw86UsJgTKMU0sddwxW1uX0VsOTeaWMsWVrN25WxEHZuyvDpSsKQNammXWtmthtWrqRVrYE9rTdCa8KeYzexYL2tR3JJQthy1qlwZ21rXMlMmXyzqbotrWuB+FrnJVaxzB4ta5a52usGtrnVhq9rrYle42dXuc2/72+5+d7zRlW5Rc7tZ8KZXvZ31rW4rikvPAvO4ozXveelrUve2t7a21a93yUvXD62Xv5fFL22pu13uKpi1CdYqb8PkOQP3Fr37pfBymVteAIsXwA8W7QclnFT5LlbE0NXwghFs3//7wnegdiNufVOcYRKr+MUwjjF7K0wSDx8YkBRwitVgkjX/HvbGIyZykYV8ZCSXWMYzRl2PbfaWPgS5xkOubQOQoNMlgEMhBB6whZP8ZTCDOMRMfi2VueuJK9fMCVv+L4Mtu+YmOAAEZbaxkptb5w3n+cQoNnGf/ZxaU8S5YSN185/VigQSmCPLHrDACBQG6UhLetKUrrSlL43pTGtaYAwTA6MtQAGJ0YvFgRk0ACqwtDvj2chN3nGDDa1qM++Zz9gVdJZR/WZaQ0GhodBpA5oG6FcLO9hnzjWrzxvmJR+71Z8b9K+dNmw9G1XNARjpBlo260PHWtrb5naXK5xsZk//ONw3pra1sQ3raC+b2OzOtrrXbedvr5jG7k53jjFcZXK3G97eHnN/5Z1vgItZx40lOJm7jXBjJ9ze+Nb1vvnt8Hq/u9sdbvh0/R1eiCtc4MpeuLY5jmyMR1zi/X4vvT0+cZCvGuUp13e8VR5Qg5P14hb/uMi9fHOc1/zjLu+5t1Puhpkx/OQwf3nO551fn4+c4m3I8suLLShU6pzoSuf50QNe9aFTvecV30m7AsABUMUNUwH4FQiHFQCyT3l7Uk96i3fe8qsHXO4D91nNDoIpC1A23UjlQFRBRQE+/CGyXkT7H0TwNqhrfdx0F/fBWf5wyOdZFHdfswMKzXOkYo0J/w0A6Zo7Hzi0P0UDiY981oEOd8XHXeZ13/q95zEBlwAABJjney79znnPPwX0Z//Dmkm/eqo3fuVF//npVY/85E++6bKn/dJr+PWw6/5Yf1Wm6AEAfOVr3OapN/3wiX9804d/+WWI/RWcv3HUTz2/3zd6973/fpKTf+vaL77ktw/r9v9c//uPP/5rzXrhJWAvYgnkQEgFeIAUZYBvhYAL1YDy9ICEFYGANYExtYAQmIAOOEQV+Hj55yYcCF4XSIHz4wki6F4g2GUoiF4qaIKaxYIJ1ILqpYK5FYO+NYNeVn9V94IbCIMZCFwxWIMEFoQ02IMaaISxNIRJWITapIRMGP+ABfaBPiiBPLhCJagpTYiBTkiFWciFI7iFSLiEYPiFFviEA+ZiYqiFaTiFLwWEYciAY0iGR7iGaEiHXqiGdliHcFaGmbBpfeiHfwiIgSiIg0iIhWiI8zJQiaiIi8iIjeiIjwiJkSiJk0iJlWiJl4iJmaiJm8iJneiJnwiKoSiKo0iKpWiKp4iKqaiKq8iKreiKrwiLsSiLs0iLtWiLt4iLuaiLu8iLveiLvwiMwSiMw0iMxWiMx+iIvIeMy8iMzeiMXEA1nkJ9TsB7yhgH1xY3XMYJFOAAWKYKatZXnNABILUB3Zh20MYG4yhVvMYGHrAFamYBa3cG5Rg3TlMp12j/jhfgNAeRamrQAUhAF1GGBPJIBuboYwBgjrWnBtT2B1RTfWTAkEswAWT3jKSQEMdCVVJQjQ8ZBxcwLnlQAfrYCuBQCMjCEwEAUty4ARuAa3wYVSLFCea4BBtQdlJRemqgkizZkH4wBznZkgUhjXHAAYWQMUzQZncwFaCyAT1mdnPgjk7DlHnwlHygkBV5BxfZAd4AeiphjkiAAaDyFiI5ByxJkHHQaOjICe5YCCzBCdbIV/24kC8JkE6nBrJ3ahywAQ0ALndwjwgJl29QKT1Gen/pj3uJkFXJBhwwUuKiLoQJkTd5lHMAKlLBkVb5BtGIAXl5UA5wAbNQjRVAAddW/5ZhkFCVyQa/5i50OQd+EgCCgJan+VcmeQduGVIZGQd2iSwOUAGqeQay2ZhtiQu98gctOQeBwGWNpo1soAGDMAvrcnk96Y0/5phgwA1P4QCCkHbJaZl1KQsAwJIdsJWfAlK8t3l3oJikwHvFYgy/BgrWiAFiKZnVZ5eXeQVseRCvSZrw6Zd58J7isJwwMZ1cQHp7R5yz+TaMuZ93EJlkmQdbFnZ8hZjbGQYXqZPhuQSySZ6jKaDg8i2kUBCFMBWtEAgBGga8dykRGpdM0FeER59aVpPLiZ9ccKIyQ6JYMKNPUKBqwJnQ9mw92ZlSQVVKGZVv4ABPoZZfyS7odgZFCv8Aaoks4uCREnqbMIGXFtoU1Zahb5ABZPej6DlZqoBTNVpISEAB/wmQAkSmkpV2e6ejUkYzramhAgoTb+M2cWCmVcMEOUoGZkWm1yamVbABrLmb6uKVktkHf0B63WCoPKmmgCKljwqpkSqpk0qplWqpl4qpmaqpm8qpneqpnwqqoSqqo0qqpWqqp4qqqTqqNdWepjkqqgqrsTqKNHmTYKAByRIHGwmoBymrveqrl4gsvAoGvjKb42maUoGiv6qsy0oxqAaTb4qSgBBla8cHgaKbf/IWoPamfcWZXmlWX1kBYbkBW6qoTWqbzIqu6SoQ9xkI41qToBeP5toEbtEwB7XwnE+BaiTpVwh5UAnxmaEZj75pKfGlrgWrrDg1kNnXeXzanRJZesMieyqRffQ6LHxAAbp6ahpAAX5yAUHGBwYLsiF7jRZgdsiir7gXr09Qrb8ZsSsRAES5mX9gsRgKUuV5LInXaCKrszsroLbJBxmAUxXQr1FWq8S6ny27rYVQsbIAlF9ZsxpAbUHWAcnKs1VrtU5wnlVwqwN1bbx5tV/Ls/monU/AquXyqmCLtmmrtmvLtm3rtm8Lt3Ert3NLt3Vrt3eLt3mrt3vLt33rt38LuIEruINLuIVruIeLuImruIvLuI3ruI8LuZEruZPbtkEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28002=[""].join("\n");
var outline_f27_22_28002=null;
var title_f27_22_28003="Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)";
var content_f27_22_28003=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15741\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?10/18/10542\">",
"         Recommended vaccine schedule for children age 0 to 6 years (United States, 2013)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/57/27538\">",
"         Patient information: Chickenpox (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/38/36450\">",
"         Patient information: Whooping cough (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/18/37156\">",
"         Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaccines-for-babies-and-children-age-0-to-6-years-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1482679102\">",
"      <span class=\"h1\">",
"       What are vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vaccines are treatments used to prevent certain serious or deadly infections that can strike at any time in life. Vaccines work by preparing the body to fight the germs that cause the infections.",
"     </p>",
"     <p>",
"      Vaccines usually come in shots, but some come in nose sprays or medicines that children swallow. Vaccines are also called &ldquo;vaccinations&rdquo; or &ldquo;immunizations.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679109\">",
"      <span class=\"h1\">",
"       Why should my child get vaccinated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Getting vaccinated can help keep your child from getting sick. If your child does get sick, being vaccinated can keep him or her from getting severely ill. Plus, being vaccinated also helps protect the people around your child from getting sick.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679116\">",
"      <span class=\"h1\">",
"       What vaccines do babies and children get?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend that babies and children get vaccines that can prevent the following infections:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hepatitis B &ndash; Hepatitis B can cause long-term liver problems or liver cancer.",
"       </li>",
"       <li>",
"        Diphtheria, tetanus, and pertussis &ndash; Vaccines to prevent these 3 different diseases are usually grouped together in one shot. Diphtheria can cause a thick covering in the back of the throat that can lead to breathing problems. Tetanus causes the muscles to work abnormally. Pertussis, also called &ldquo;whooping cough,&rdquo; can cause a severe cough.",
"       </li>",
"       <li>",
"        Polio &ndash; Polio can cause muscle weakness and pain, and lead to long-term paralysis. Paralysis is when people are unable to move their arms or legs.",
"       </li>",
"       <li>",
"        Rotavirus &ndash; Rotavirus can cause severe diarrhea. Babies and children who have severe diarrhea can lose too much water and get &ldquo;dehydrated.&rdquo;",
"       </li>",
"       <li>",
"        Haemophilus influenzae type B, called &ldquo;Hib&rdquo; &ndash; Hib can cause an infection of the skin, throat, joints, or tissues around the brain.",
"       </li>",
"       <li>",
"        Pneumococcus &ndash; Pneumococcus is a germ that can cause an infection of the lungs, ears, blood, or tissues around the brain.",
"       </li>",
"       <li>",
"        Measles, mumps, and rubella &ndash; Vaccines to prevent these 3 different diseases are grouped together in one shot. Measles can cause a rash, fever, and cough. It can lead to long-term problems with the lungs, ears, or brain. Mumps causes swelling of glands in the cheeks, and can lead to long-term problems of the brain or testes. Rubella is also called &ldquo;German measles.&rdquo; If a woman gets rubella while she is pregnant, her baby can be born with a birth defect.",
"       </li>",
"       <li>",
"        Chickenpox &ndash; Chickenpox can cause a fever, sore throat, and rash. Some children with chickenpox can get very sick and get a lung or brain infection.",
"       </li>",
"       <li>",
"        Hepatitis A &ndash; Hepatitis A does not usually cause problems in children, but can cause severe liver disease in adults. Children who get the",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?10/58/11169?source=see_link\">",
"         hepatitis A vaccine",
"        </a>",
"        help prevent the adults around them from getting the infection.",
"       </li>",
"       <li>",
"        Flu &ndash; The flu can cause fever, chills, muscle aches, cough, or sore throat.",
"       </li>",
"       <li>",
"        Meningococcus &ndash; Meningococcus is a germ that can cause an infection of the blood or tissues around the brain. Most children age 6 and younger do not need this vaccine, but some do.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679123\">",
"      <span class=\"h1\">",
"       How many vaccine doses does my child need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each vaccine is different. Some vaccines work after just one dose. But most need 2 or more doses to prevent an infection. Vaccines usually take a few weeks to start working.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679130\">",
"      <span class=\"h1\">",
"       At what ages will my child get vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different vaccines are given at different ages. Most babies get their first vaccine at birth when they get their first dose of the",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?10/38/10849?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      . After that, most healthy children follow a set vaccine schedule (",
"      <a class=\"graphic graphic_table graphicRef60399 \" href=\"UTD.htm?10/18/10542\">",
"       table 1",
"      </a>",
"      ). Even though doctors follow a set vaccine schedule, children can get certain vaccine doses at different times. For example, children can get their third dose of the polio vaccine any time from 6 to 18 months old.",
"     </p>",
"     <p>",
"      Some children will follow a different vaccine schedule. Children might be on a different schedule if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have certain medical problems",
"       </li>",
"       <li>",
"        Started getting their vaccines later than usual",
"       </li>",
"       <li>",
"        Started getting their vaccines on time, but then missed doses and fell behind schedule",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will recommend a vaccine schedule that is right for your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679137\">",
"      <span class=\"h1\">",
"       What side effects can vaccines cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, vaccines cause no side effects. When they do cause side effects, they can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness, mild swelling, or soreness where the shot was given",
"       </li>",
"       <li>",
"        A mild fever",
"       </li>",
"       <li>",
"        A mild rash",
"       </li>",
"       <li>",
"        Headache or body aches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most of these side effects happen within 1 to 2 days of getting the vaccine. But they can happen 1 to 2 weeks after the getting shot for chickenpox or the shot for&nbsp;measles, mumps, and rubella.",
"     </p>",
"     <p>",
"      Vaccines also sometimes cause more serious side effects than those listed, such as severe allergic reactions. But serious side effects are rare.",
"     </p>",
"     <p>",
"      Ask your doctor or nurse what side effects to expect each time your child gets a vaccine. If your child has a reaction or a problem after a vaccine, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679144\">",
"      <span class=\"h1\">",
"       What if my child is sick, and he or she is supposed to get a vaccine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child is sick and supposed to get a vaccine, let your doctor or nurse know. Depending on the type of vaccine and your child&rsquo;s symptoms, your doctor or nurse might give your child the vaccine or wait until your child is better.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679151\">",
"      <span class=\"h1\">",
"       What if my child has an egg allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has an egg allergy, let your doctor or nurse know. Some vaccines can have egg in them because of the way they are made. Your doctor or nurse will tell you which vaccines are safe to get.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679158\">",
"      <span class=\"h1\">",
"       Should I keep track of my child&rsquo;s vaccines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to keep a list of the vaccines that your child gets and when he or she gets them. Many schools and day cares need this information before they let a child in. You can keep your list up to date by bringing it to your check-ups.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1482679165\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=see_link\">",
"       Patient information: Chickenpox (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       Patient information: Whooping cough (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/22/28003?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15741 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28003=[""].join("\n");
var outline_f27_22_28003=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679102\">",
"      What are vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679109\">",
"      Why should my child get vaccinated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679116\">",
"      What vaccines do babies and children get?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679123\">",
"      How many vaccine doses does my child need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679130\">",
"      At what ages will my child get vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679137\">",
"      What side effects can vaccines cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679144\">",
"      What if my child is sick, and he or she is supposed to get a vaccine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679151\">",
"      What if my child has an egg allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679158\">",
"      Should I keep track of my child&rsquo;s vaccines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1482679165\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/18/10542\">",
"      Recommended vaccine schedule for children age 0 to 6 years (United States, 2013)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=related_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_22_28004="Permethrin: Drug information";
var content_f27_22_28004=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Permethrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=see_link\">",
"    see \"Permethrin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/20/23875?source=see_link\">",
"    see \"Permethrin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A200&reg; Lice [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Complete Lice Treatment System [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Creme Rinse Lice Treatment [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Creme Rinse [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Lice Control Spray [OTC];",
"     </li>",
"     <li>",
"      Rid&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kwellada-P&trade;;",
"     </li>",
"     <li>",
"      Nix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiparasitic Agent, Topical;",
"     </li>",
"     <li>",
"      Pediculocide;",
"     </li>",
"     <li>",
"      Scabicidal Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical: After hair has been washed with shampoo, rinsed with water and towel dried, apply a sufficient volume of creme rinse to saturate the hair and scalp; also apply behind the ears and at the base of the neck; leave on hair for 10 minutes before rinsing off with water; remove remaining nits. May repeat in 1 week if lice or nits still present; in areas of head lice resistance to 1% permethrin, 5% permethrin has been applied to clean, dry hair and left on overnight (8-14 hours) under a shower cap.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Scabies:",
"     </b>",
"     Topical: Apply cream from head to toe; leave on for 8-14 hours before washing off with water; may reapply in 1 week if live mites appear. Time of application was limited to 6 hours before rinsing with soap and water.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F208563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/20/23875?source=see_link\">",
"      see \"Permethrin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical: Children &gt;2 months: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Scabies:",
"     </b>",
"     Topical: Apply cream from head to toe; leave on for 8-14 hours before washing off with water; for infants, also apply on the hairline, neck, scalp, temple, and forehead; may reapply in 1 week if live mites appear. Permethrin 5% cream was shown to be safe and effective when applied to an infant &lt;1 month of age with neonatal scabies; time of application was limited to 6 hours before rinsing with soap and water.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 5% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [creme rinse formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Complete Lice Treatment System: 1% (1s) [contains isopropyl alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Creme Rinse: 1% (60 mL) [contains isopropyl alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Creme Rinse Lice Treatment: 1% (60 mL) [contains isopropyl alcohol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [for bedding, furniture and garments/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nix&reg; Lice Control Spray: 0.25% (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [for bedding, furniture and garments/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A200&reg; Lice: 0.5% (170.1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rid&reg;: 0.5% (150 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes liquid spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F208532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because scabies and lice are so contagious, use caution to avoid spreading or infecting oneself; wear gloves when applying",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream: Apply from neck to toes. Bathe to remove drug after 8-14 hours. Repeat in 7 days if lice or nits are still present. Report if condition persists or infection occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream rinse/lotion: Apply immediately after hair is shampooed, rinsed, and towel-dried. Apply enough to saturate hair and scalp (especially behind ears and on nape of neck). Leave on hair for 10 minutes before rinsing with water. Remove nits with fine-tooth comb. May repeat in 1 week if lice or nits are still present.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Single-application treatment of infestation with",
"     <i>",
"      Pediculus humanus capitis",
"     </i>",
"     (head louse) and its nits or",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     (scabies); indicated for prophylactic use during epidemics of lice",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, erythema, rash of the scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, stinging, tingling, numbness or scalp discomfort, edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrethyroid, pyrethrin, chrysanthemums, or any component of the formulation; lotion is contraindicated for use in infants &lt;2 months of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation: Treatment may temporarily exacerbate the symptoms of itching, redness, and swelling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in oral animal reproduction studies. The amount of permethrin available systemically following topical application is &le;2%. The CDC considers the use of permethrin or  pyrethrins with piperonyl butoxide the drugs of choice for the treatment of pubic lice during pregnancy (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F208537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (RID)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (141.8 g): $5.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Acticin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $29.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Elimite External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $139.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Permethrin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $76.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Permethrin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (59 mL): $8.19",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F208538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Scabs (HK, MY);",
"     </li>",
"     <li>",
"      Assy (AR);",
"     </li>",
"     <li>",
"      Destolit (PE);",
"     </li>",
"     <li>",
"      Dronol (PY);",
"     </li>",
"     <li>",
"      Gamabenceno Plus (CO, GT, HN, SV);",
"     </li>",
"     <li>",
"      Infectopedicul (DE);",
"     </li>",
"     <li>",
"      Infectoscab (CZ);",
"     </li>",
"     <li>",
"      Klinits (CN);",
"     </li>",
"     <li>",
"      Lice-omite (PK);",
"     </li>",
"     <li>",
"      Lindell (PH);",
"     </li>",
"     <li>",
"      Loxazol (CH, NL);",
"     </li>",
"     <li>",
"      Lyclear (AU, GB, IE);",
"     </li>",
"     <li>",
"      Lyclear Creme Rinse (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lyclear Dermal Cream (IL);",
"     </li>",
"     <li>",
"      Lyderm (NZ);",
"     </li>",
"     <li>",
"      Mite-X (IL);",
"     </li>",
"     <li>",
"      Nastizol EX (MX);",
"     </li>",
"     <li>",
"      Nedax Plus (BR);",
"     </li>",
"     <li>",
"      New-Nok (IL);",
"     </li>",
"     <li>",
"      Nittyfor (HU);",
"     </li>",
"     <li>",
"      Nix (BE, BG, DK, EE, FI, GR, IT, NO, PT, SE);",
"     </li>",
"     <li>",
"      Nix Cream (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Nix Creme Rinse (LU);",
"     </li>",
"     <li>",
"      Nix Dermal Cream (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Novo-Herklin 2000 (CR, DO, MX, NI, PA);",
"     </li>",
"     <li>",
"      Parapoux (FR);",
"     </li>",
"     <li>",
"      Permicren (UY);",
"     </li>",
"     <li>",
"      Permite (IN);",
"     </li>",
"     <li>",
"      Piokil Plus (VE);",
"     </li>",
"     <li>",
"      Pyrifoam (AU, NZ, PH);",
"     </li>",
"     <li>",
"      Quellada (HK);",
"     </li>",
"     <li>",
"      Quellada Head Lice Treatment (AU, NZ);",
"     </li>",
"     <li>",
"      Sarnol (EC);",
"     </li>",
"     <li>",
"      Scabimite (ID);",
"     </li>",
"     <li>",
"      Scabisan (MX);",
"     </li>",
"     <li>",
"      Zalvor (LU);",
"     </li>",
"     <li>",
"      Zehu-Ze (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium ion influx through nerve cell membrane channels in parasites resulting in delayed repolarization and thus paralysis and death of the pest",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via ester hydrolysis to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorman DC and Beasley VR, &ldquo;Neurotoxicology of Pyrethrin and the Pyrethroid Insecticides,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1991, 33(3):238-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/1713367/pubmed\" id=\"1713367\" target=\"_blank\">",
"        1713367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Head Lice,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1997, 39(992):6-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/9008683/pubmed\" id=\"9008683\" target=\"_blank\">",
"        9008683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1017):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/9442765/pubmed\" id=\"9442765\" target=\"_blank\">",
"        9442765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL and Bocchini JA Jr, &ldquo;Head Lice,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      He F, Wang S, Liu L, et al, &ldquo;Clinical Manifestations and Diagnosis of Acute Pyrethroid Poisoning,&rdquo;",
"      <i>",
"       Arch Toxicol",
"      </i>",
"      , 1989, 63(1):54-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/2742502/pubmed\" id=\"2742502\" target=\"_blank\">",
"        2742502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogan DJ, Schachner L, Tanglertsampan C, &ldquo;Diagnosis and Treatment of Childhood Scabies and Pediculosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):941-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/1870912/pubmed\" id=\"1870912\" target=\"_blank\">",
"        1870912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krowchuk DP, Tunnessen WW Jr, and Hurwitz S, &ldquo;Pediatric Dermatology Update,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(2 Pt 1):259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/1641293/pubmed\" id=\"1641293\" target=\"_blank\">",
"        1641293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quarterman MJ and Lesher JL, &ldquo;Neonatal Scabies Treated With Permethrin 5% Cream,&rdquo;",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 1994, 11(3):264-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/22/28004/abstract-text/7971563/pubmed\" id=\"7971563\" target=\"_blank\">",
"        7971563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9759 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28004=[""].join("\n");
var outline_f27_22_28004=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208544\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208545\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208576\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208547\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208563\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208548\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208529\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208517\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208532\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208531\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208574\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208535\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208521\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299857\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208525\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208526\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823809\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208550\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208537\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208538\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208520\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208534\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9759|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/6/30821?source=related_link\">",
"      Permethrin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/20/23875?source=related_link\">",
"      Permethrin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_22_28005="Diagnosis of iron deficiency in chronic kidney disease";
var content_f27_22_28005=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of iron deficiency in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28005/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28005/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28005/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28005/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28005/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28005/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/22/28005/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate iron stores are essential for achieving maximum benefit from erythropoietic-stimulating agents (ESAs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    . Decreased iron stores or decreased availability of iron are the most common reasons for resistance to the effect of these agents.",
"   </p>",
"   <p>",
"    The dialysis patient is in a state of continuous iron loss from gastrointestinal bleeding, blood drawing,",
"    <span class=\"nowrap\">",
"     and/or,",
"    </span>",
"    most important with hemodialysis, the dialysis treatment itself. Hemodialysis patients lose an average of 2 g of iron per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, iron deficiency will develop in virtually all dialysis patients receiving EPO or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    unless supplemental iron therapy is given orally or intravenously.",
"   </p>",
"   <p>",
"    An overview of the diagnosis of iron deficiency in chronic kidney disease (CKD) is presented in this topic review. Discussions related to the use of iron, erythropoietin, and darbepoetin in patients with chronic kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF IRON DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To assess iron stores and the availability of iron for erythropoiesis, the evaluation should include red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation, and serum ferritin. If iron deficiency is diagnosed, an appropriate evaluation for its cause should be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Absolute iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue in the diagnosis of iron deficiency in the patient with chronic kidney disease or end-stage renal disease is that the laboratory criteria are markedly different from those in patients with relatively normal renal function.",
"   </p>",
"   <p>",
"    Absolute iron deficiency is likely to be present in patients with end-stage renal disease when [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The percent transferrin saturation (plasma iron divided by total iron binding capacity x 100, TSAT) falls below 20 percent",
"     </li>",
"     <li>",
"      The serum ferritin concentration is less than 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      among predialysis and peritoneal dialysis patients or is less than 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      among hemodialysis patients. This difference in the serum ferritin level is based upon accumulating evidence in hemodialysis patients that the maintenance of ferritin levels above 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      is associated with decreased erythropoietin requirements. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"       \"Use of iron preparations in hemodialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, when a patient with normal renal function develops severe anemia due to iron deficiency, the serum ferritin concentration is typically below 30",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    The discrepancy between subjects with normal renal function and those with end-stage renal disease with respect to the serum ferritin concentration may in part reflect an underlying inflammatory state associated with advanced renal failure and dialysis. The accuracy of the transferrin saturation and the serum ferritin in evaluating iron deficiency among dialysis patients is shown in this table&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow biopsies to assess iron stores are rarely done in patients with chronic kidney disease or end-stage renal disease. Rather, the demonstration of enhanced erythropoiesis in response to iron supplementation, with an increase in hemoglobin level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction in epoetin or darbepoetin dose, is more commonly taken as evidence of insufficient iron stores, even in patients with iron indices that are consistent with sufficient stores(See",
"    <a class=\"local\" href=\"#H4\">",
"     'Functional iron deficiency versus inflammatory block'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    While most patients with CKD and iron indices below the parameters indicated above will have depleted bone marrow iron, significant numbers of patients with higher TSAT and ferritin levels may also have depleted bone marrow iron stores and respond to iron supplementation with increased Hb levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However most patients with percent transferrin saturation above 30 percent or serum ferritin above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    will not have a meaningful clinical response to further iron supplementation. Indications for iron supplementation among CKD patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link&amp;anchor=H6#H6\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\", section on 'Initiation of iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Functional iron deficiency versus inflammatory block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to absolute iron deficiency, it is now recognized that dialysis patients may have functional iron deficiency. This is characterized by the presence of adequate iron stores as defined by conventional criteria, but an inability to sufficiently mobilize this iron from the liver and other storage sites to adequately support erythropoiesis with the administration of erythrocyte stimulating agents (ESA). Among such patients, the serum ferritin level is either normal or elevated (sometimes markedly), but the transferrin saturation typically is about 20 percent or less. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is clinically important to distinguish functional iron deficiency, which usually responds to iron therapy, from inflammatory iron block, which may not or may respond less briskly. Inflammatory iron block occurs among patients with refractory anemia due largely to an underlying inflammatory state [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, both functional deficiency and inflammatory block are associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transferrin saturation &le;20 percent",
"     </li>",
"     <li>",
"      Elevated ferritin level (typically &gt;100 to 200",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The response to ESA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenteral iron may help distinguish between these two possibilities:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Response to ESA",
"    </span>",
"    &nbsp;&mdash;&nbsp;With increasing doses of ESA, ferritin levels may decrease (and Hb levels increase) in patients with functional deficiency but not with inflammatory iron block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Response to iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory block is most likely present if the weekly administration of intravenous iron (50 to 125 mg) for up to 8 to 10 doses fails to result in increased erythropoiesis and the patient has hyporesponsiveness to ESA therapy; instead, this course of iron therapy typically results in a progressive increase in ferritin concentration. Among patients with inflammatory block, further intravenous iron should not be given until the inflammatory condition has resolved. This is thought to be particularly important in patients with active, ongoing infections.",
"   </p>",
"   <p>",
"    By comparison, among patients with functional iron deficiency, additional intravenous iron in association with a concomitant increase in ESA dose can be effective in increasing Hgb levels, at least over the short-term. This was best shown in the DRIVE study, in which 134 patients with anemia (hemoglobin levels less than 11",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    elevated ferritin levels (500 to 1200",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    low transferrin saturation levels (&le;25 percent), and high erythropoietin requirements (&ge;225 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week or &ge;22,500 international units per week) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    (125 mg with eight consecutive dialysis sessions) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/8\">",
"     8",
"    </a>",
"    ]. Erythropoietin doses were increased in all patients by 25 percent at the beginning of the study. At six weeks, hemoglobin levels had increased significantly more in the active therapy group (1.6 versus 1.1",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p>",
"    In a post-hoc analysis of this study, none of the iron parameters typically used in clinical practice, including percent transferrin saturation, ferritin, and reticulocyte hemoglobin content, were found to be particularly sensitive or specific for predicting a response to iron supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this study shows that the combination of a 25 percent increase in EPO dose and supplemental intravenous iron was associated with a greater erythropoietic response compared with an increase in EPO dose alone over six weeks, the differences in response are of unclear clinical significance. There is concern that some patients who received both intravenous iron and the increase in EPO dose were more likely to have larger, more rapid increases in Hgb level, possibly resulting in adverse effects. Clinical outcomes beyond an increase in Hgb level were not assessed and the long-term safety of this approach is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial evaluation of iron indices is necessary for the early detection of iron deficiency on dialysis once therapy with EPO or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    is initiated. Serum ferritin levels and the percent transferrin saturation should be measured at baseline and then periodically thereafter. The 2012 KDIGO guidelines suggest evaluating iron status at least every three months during ESA treatment and more frequently when increasing the ESA dose or monitoring the response to IV iron, or when there is blood loss or other circumstances (eg, hospitalization) when iron stores may be depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with adequate iron stores who are on maintenance oral or intravenous iron, monitoring every three months is probably adequate, especially after the first few months when iron stores are most likely to become depleted. By comparison, monitoring every one to two months is recommended in patients just starting ESA therapy or in whom the dose has been increased, in those with marginal iron status, or in those with declining serum ferritin or TSAT levels.",
"   </p>",
"   <p>",
"    A reduction in serum ferritin can be expected during the first few months after the initiation of an ESA as iron is mobilized from iron stores and used for red cell production. Causes of iron deficiency not related to use of an ESA or dialysis-related losses must be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Alternative measures of iron status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the difficulties in accurately diagnosing iron deficiency in some patients with end-stage renal disease, additional parameters have been examined for possible utility. These include the percentage of hypochromic cells and the reticulocyte hemoglobin content [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. As an example, 157 hemodialysis patients were randomly assigned to iron management based upon serum ferritin and transferrin saturation, or reticulocyte hemoglobin content [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28005/abstract/15\">",
"     15",
"    </a>",
"    ]. Iron was administered if reticulocyte hemoglobin content was less than 29 pg or either serum ferritin was less than 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or transferrin saturation was less than 20 percent. No difference was seen at six months in hemoglobin level or the required dose of erythropoietin.",
"   </p>",
"   <p>",
"    The proper role for these alternative measures of iron status, which are not widely available in the United States, in the dialysis patient is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H14#H14\">",
"     \"Automated hematology instrumentation\", section on 'Automated counting of reticulocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To assess iron stores, the evaluation of patients with kidney disease and anemia must include red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation, serum ferritin, and testing for blood in stool. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis of iron deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absolute iron deficiency is likely to be present in patients with end-stage renal disease when:",
"      <br/>",
"      <br/>",
"      - The percent transferrin saturation (plasma iron divided by total iron binding capacity x 100) falls below 20 percent.",
"      <br/>",
"      <br/>",
"      AND",
"      <br/>",
"      <br/>",
"      - The serum ferritin concentration is less than 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      among predialysis and peritoneal dialysis patients or is less than 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      among hemodialysis patients.",
"      <br/>",
"      <br/>",
"      However, not all patients with percent transferrin saturation or ferritin levels below these limits will respond to supplemental iron and percent transferrin saturation or ferritin levels above these lower limits do not necessarily indicate that further iron supplementation would be without an erythropoietic stimulating effect. Most patients with percent transferrin saturation above 30 percent or serum ferritin above 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      will not have a meaningful clinical response to further iron supplementation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Absolute iron deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional iron deficiency is characterized by the presence of adequate iron stores, but an inability to sufficiently mobilize this iron to adequately support erythropoiesis with the administration of erythropoietic-stimulating agents (ESAs). The serum ferritin level is either normal or markedly elevated, but the transferrin saturation typically falls to about 20 percent or below. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Functional iron deficiency versus inflammatory block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional iron deficiency, which usually responds somewhat to iron therapy, must be distinguished from inflammatory iron block, which usually does not. Inflammatory iron block occurs among patients with refractory anemia due largely to an underlying inflammatory state. Both functional deficiency and inflammatory block are associated with transferrin saturation &le;20 percent and elevated ferritin level (between 100 to 800",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or even higher). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Functional iron deficiency versus inflammatory block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response to an ESA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parenteral iron may help distinguish between functional iron deficiency and inflammatory block. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Response to ESA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Response to iron'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring serum ferritin levels and the percent transferrin saturation every three months is probably adequate in patients with adequate iron stores who are on maintenance oral or intravenous iron, especially after the first few months when iron stores are most likely to become depleted. By comparison, monitoring every one to two months is recommended in patients just starting ESA therapy or in whom the dose has been increased, in those with marginal iron status, or in those patients with declining serum ferritin or TSAT levels. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring indices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/1\">",
"      Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/2\">",
"      Fern&aacute;ndez-Rodr&iacute;guez AM, Guindeo-Casas&uacute;s MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999; 34:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/3\">",
"      Nissenson AR. Achieving target hematocrit in dialysis patients: new concepts in iron management. Am J Kidney Dis 1997; 30:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/4\">",
"      Rocha LA, Barreto DV, Barreto FC, et al. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/5\">",
"      Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 55:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/6\">",
"      Stancu S, B&acirc;rsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010; 5:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/7\">",
"      Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/8\">",
"      Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/9\">",
"      Singh AK, Coyne DW, Shapiro W, et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/10\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/11\">",
"      Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 1998; 13:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/12\">",
"      Sunder-Plassmann G, H&ouml;rl WH. Laboratory diagnosis of anaemia in dialysis patients: use of common laboratory tests. Curr Opin Nephrol Hypertens 1997; 6:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/13\">",
"      Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/14\">",
"      Bovy C, Tsobo C, Crapanzano L, et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999; 56:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28005/abstract/15\">",
"      Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60:2406.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1951 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28005=[""].join("\n");
var outline_f27_22_28005=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Absolute iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Functional iron deficiency versus inflammatory block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Response to ESA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Response to iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring indices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Alternative measures of iron status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_22_28006="Treatment of hypopituitarism";
var content_f27_22_28006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypopituitarism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28006/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28006/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28006/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28006/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28006/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28006/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/22/28006/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with hypopituitarism is the sum of the treatments of each of the individual pituitary hormonal deficiencies detected when a patient with a pituitary or hypothalamic disease is tested. The treatments of corticotropin (ACTH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) deficiencies are in many ways the same as the treatments of primary deficiencies of the respective target glands, but in other ways they differ. Both the similarities and differences will be highlighted below. Treatment of growth hormone (GH) deficiency is unique to hypopituitarism.",
"   </p>",
"   <p>",
"    The specifics of therapy for hypopituitarism will be reviewed here. The causes, clinical manifestations, and diagnosis of hypopituitarism, as well as growth hormone deficiency in adults and the management of individual hormone deficiencies, are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151093437\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One reason to optimize treatment is that in a retrospective study of 344 patients who had hypopituitarism after pituitary surgery, the long-term mortality was about double that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of the excess mortality was due to cerebrovascular disease. The relationship between the hypopituitarism and the excess mortality remains unknown, and we do not know if even optimal treatment will improve mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTH DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary consequence of lack of ACTH is cortisol deficiency. As a result, treatment consists of the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or other glucocorticoid in an amount and timing to mimic the normal pattern of cortisol secretion. Because there is no test to assess the adequacy of the replacement, the optimal replacement glucocorticoid and the optimal doses are not known. Most authorities recommend replacement with hydrocortisone because that is the hormone the adrenal glands make normally, but others prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for their longer durations of action.",
"   </p>",
"   <p>",
"    Most authorities recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    doses of 15 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] because those doses are similar to daily production rates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who are more severely deficient or weigh more tend to need doses at the upper end of this range and vice versa. Some patients, however, need even larger doses to avoid severely symptomatic adrenal insufficiency, and others can get by on smaller amounts.",
"   </p>",
"   <p>",
"    Although dividing the total daily dose into two or even three doses (with the largest dose on arising in the morning) makes sense physiologically, many patients cannot remember to take doses in the middle of the day. For them, taking the entire dose in the morning is preferable to missing doses. Most patients feel well while taking the entire dose on arising.",
"   </p>",
"   <p>",
"    Whatever the preparation and dose, the patient should be instructed in the need for larger doses in times of illness and other stresses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An inadequate dose may result in persistence (or recurrence) of the symptoms of cortisol deficiency, while an excessive dose can lead to symptoms of cortisol excess and to bone loss. Small deviations from the optimal dose are usually not detected clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151093685\">",
"    <span class=\"h2\">",
"     Assessment of dose adequacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike replacement of other pituitary-dependent hormones, no tests exist to assess objectively the adequacy of the replacement of cortisol, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma ACTH measurements cannot be used because the values are low or normal before treatment.",
"     </li>",
"     <li>",
"      Serum cortisol values vary from patient to patient and in relation to the timing of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      dose. This was illustrated in a study of 46 patients with adrenal insufficiency, 23 of whom had a secondary cause, stably treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"       cortisone acetate",
"      </a>",
"      . Clinical status was assessed by a questionnaire and serum cortisol concentrations were measured for up to eight hours after a single 25 mg dose [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/5\">",
"       5",
"      </a>",
"      ]. In the 33 patients considered clinically &ldquo;well-replaced,&rdquo; the serum cortisol concentrations not only fluctuated from a mean maximum of approximately 21",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      at two hours after the dose to 7",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      six hours after the dose, but varied among individuals from &lt;14 to &gt;28",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      at two hours and from virtually undetectable to &gt;14",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      at six hours.",
"     </li>",
"     <li>",
"      Salivary cortisol values also fluctuate widely and do not correlate with plasma values after oral administration. In a study of 27 patients with adrenal insufficiency, 18 of whom had a secondary cause and who were stably treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      , plasma and salivary cortisol were measured for eight hours after a single 20 mg dose [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/6\">",
"       6",
"      </a>",
"      ]. The plasma concentration fluctuated widely among patients, as shown by a fivefold variation in area under the curve. The correlation between plasma and salivary cortisol was poor.",
"     </li>",
"     <li>",
"      Urinary cortisol values are also unreliable for the assessment of adequacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8249423\">",
"    <span class=\"h2\">",
"     Subjective health status",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a possible consequence of the lack of objective measurements of the adequacy of the replacement dose of glucocorticoid, patients with adrenal insufficiency have impaired self-reported health status by standard questionnaires. This was illustrated in a study of 210 patients with adrenal insufficiency, 78 of whom had a secondary cause. Scores on validated self-assessment questionnaires (SF-36, Geissen Complaint List, and Hospital Anxiety and Depression Scale) were significantly impaired compared with age- and gender-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with secondary insufficiency were slightly more impaired than those with primary adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151093699\">",
"    <span class=\"h2\">",
"     Unmasking diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unusual side effect of glucocorticoid replacement is the unmasking of underlying central diabetes insipidus, leading to marked polyuria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/8\">",
"     8",
"    </a>",
"    ]. Correction of cortisol deficiency can increase the blood pressure and renal blood flow and, in patients with partial diabetes insipidus, reduce the secretion of vasopressin. All of these effects increase urine output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6691?source=see_link\">",
"     \"Urine output in diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151093706\">",
"    <span class=\"h2\">",
"     Need for mineralocorticoid coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the situation in primary adrenal insufficiency, mineralocorticoid replacement is rarely necessary in hypopituitarism. Angiotensin II and potassium, not ACTH, are the major regulators of aldosterone secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151093813\">",
"    <span class=\"h2\">",
"     Adrenal androgen replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with secondary adrenal insufficiency, exogenous dehydroepiandrosterone (DHEA) replacement appears to have a modest beneficial effect on psychological well-being. However, the available data are from women with panhypopituitarism, who have combined adrenal and ovarian androgen deficiency. No data are available in women with isolated ACTH deficiency, a very rare disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link&amp;anchor=H3#H3\">",
"     \"Dehydroepiandrosterone and its sulfate\", section on 'Use in adrenal insufficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Androgen replacement (DHEA)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TSH DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH deficiency results in thyroxine (T4) deficiency and is treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     Levothyroxine",
"    </a>",
"    . The factors that influence dosing are similar to those of primary hypothyroidism. However, treatment of secondary hypothyroidism differs in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T4 should",
"      <strong>",
"       not",
"      </strong>",
"      be administered until adrenal function, including ACTH reserve, has been evaluated and either found to be normal or treated. In a patient with coexisting hypothyroidism and hypoadrenalism, treatment of the hypothyroidism alone may increase the clearance of the little cortisol that is produced, thereby increasing the severity of the cortisol deficiency.",
"     </li>",
"     <li>",
"      Measurement of serum TSH cannot be used as a guide to the adequacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       Levothyroxine",
"      </a>",
"      replacement therapy. We suggest starting with a weight-based T4 dose of 1.6",
"      <span class=\"nowrap\">",
"       mcg/kg.",
"      </span>",
"      The dose should be adjusted according to the serum T4 or free T4 values, aiming to maintain them in the middle of the normal range. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link&amp;anchor=H13#H13\">",
"       \"Central hypothyroidism\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LH AND FSH DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of LH and FSH deficiency depends upon gender and whether or not fertility is desired.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement is indicated in men who have secondary hypogonadism and who are not interested in fertility. The choice of treatment does not differ from that in men with primary hypogonadism, but serum LH measurements cannot be used to monitor the adequacy of therapy. This can be achieved by measurements of serum testosterone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H11#H11\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men with secondary hypogonadism who wish to become fertile can be treated with gonadotropins if they have pituitary disease or with either gonadotropins or gonadotropin-releasing hormone (GnRH) if they have hypothalamic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link\">",
"     \"Induction of fertility in men with secondary hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hypogonadism due to pituitary disease, who are not interested in fertility, should be treated with estrogen-progestin replacement therapy. The goal of treatment is",
"    <strong>",
"     not",
"    </strong>",
"    the same as in postmenopausal women, in whom the goal is to give estrogen and progestin only if necessary to relieve hot flushes. Instead, the goal of treatment of women of premenopausal age is similar to that of replacement of thyroxine and cortisol, ie, to replace the missing hormones as physiologically as possible.",
"   </p>",
"   <p>",
"    Toward this end, we suggest treatment with estradiol (the estrogen the human ovaries secrete) transdermally, so estradiol is absorbed into the systemic circulation (as when it is secreted by the ovaries). Women with an intact uterus must also take a progestin to avoid the risk of endometrial hyperplasia or carcinoma. We also recommend that estradiol be administered cyclically with progesterone or a progestin. Some clinicians suggest a traditional regimen of estradiol on days 1 through 25 of each month and progesterone on days 16 through 25 of each month. The goals are to achieve both a normal late-follicular serum estradiol concentration and menses the patient considers normal. Another regimen is to give transdermal estradiol continuously throughout the month, with progestin added days 1 to 10 of the calendar month. This regimen is similar to that used for treatment of premature ovarian failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .) For women who develop cyclic mood changes (premenstrual syndrome) on either of these regimens, a continuous daily regimen of both estrogen and a lower dose of progestin is usually better tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=see_link\">",
"     \"Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with secondary hypogonadism who wish to become fertile should be offered ovulation induction. Women with GnRH deficiency are candidates for either gonadotropin therapy or pulsatile GnRH, while those with gonadotropin deficiency due to pituitary disease are candidates only for gonadotropin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link&amp;anchor=H16#H16\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151093784\">",
"    <span class=\"h3\">",
"     Androgen replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum androgen concentrations in women with hypopituitarism, particularly those with both gonadotropin and ACTH deficiency, are significantly lower than those in normal control women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/9\">",
"     9",
"    </a>",
"    ]. Adrenal androgen replacement is discussed above. The role of exogenous testosterone therapy in these women is unclear, but is not recommended.",
"   </p>",
"   <p>",
"    The effect of exogenous testosterone therapy in women with androgen deficiency due to hypopituitarism was addressed in a study of 51 such patients taking exogenous estrogen orally. Testosterone replacement was administered transdermally at doses of 150 to 300",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    for one year, resulting in serum free testosterone concentrations in the normal range and increased mean bone mineral density of the hip and radius, but not the spine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/10\">",
"     10",
"    </a>",
"    ]. Other effects included an increase in fat-free mass and thigh muscle area, and improvements in some aspects of mood, sexual function, and quality of life, as assessed by questionnaires. One-third of the women receiving testosterone developed acne but no patients developed hirsutism or other hyperandrogenic side effects. Androgen therapy in women is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H21#H21\">",
"     \"Sexual dysfunction in women: Management\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GROWTH HORMONE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of several",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    preparations (Humatrope&reg;, Nutropin&reg;, Serostim&reg;, and Genotropin&reg;) for treating adults with growth hormone deficiency allows clinicians to prescribe this treatment. Patients with GH deficiency acquired as an adult must, to be reimbursed by insurance companies in the United States, meet at least two criteria for therapy: a low IGF-1 concentration or a poor GH response to at least two standard stimuli, and hypopituitarism due to pituitary or hypothalamic damage. The criteria are different in children in whom GH is required for normal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients who develop GH deficiency in adulthood have unfavorable serum lipid profiles, increased body fat, decreased muscle mass, decreased bone mineral density, and a diminished sense of well-being. There is substantial evidence that growth hormone treatment in these patients increases muscle mass and reduces body fat. The evidence for improvement in bone mineral density is good for men but not for women. The evidence concerning improvements in the sense of well-being, muscle strength, and serum lipids is conflicting. Thus, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    as routine treatment for all patients with adult-onset growth hormone deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROLACTIN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only known presentation of prolactin deficiency is the inability to lactate after delivery, for which there is currently no available treatment. Recombinant human prolactin, although not commercially available, has been used experimentally in an open-label pilot study of five women with prolactin deficiency due to Sheehan syndrome or other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28006/abstract/11\">",
"     11",
"    </a>",
"    ]. Prolactin deficiency was defined as baseline or peak serum prolactin levels below the normal range for their postpartum date and production of less than 8 mL of milk per day. Subcutaneous administration of r-hPRL every 12 hours for 28 days increased mean milk production from 3.4 &plusmn; 1.6 mL to 66.1 &plusmn; 8.3 mL per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/10/38050?source=see_link\">",
"       \"Patient information: Panhypopituitarism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with hypopituitarism is the sum of the treatments of each of the individual pituitary hormonal deficiencies detected when a patient with a pituitary or hypothalamic disease is tested. The treatments of corticotropin (ACTH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) deficiencies are in many ways the same as the treatments of primary deficiencies of the respective target glands, but in other ways they differ.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of ACTH primarily causes cortisol deficiency. Treatment consists of the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      or other glucocorticoid in an amount and timing to mimic the normal pattern of cortisol secretion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'ACTH deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TSH deficiency, which results in thyroxine (T4) deficiency, is treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       Levothyroxine",
"      </a>",
"      . T4 should",
"      <strong>",
"       not",
"      </strong>",
"      be administered until adrenal function, including ACTH reserve, has been evaluated and either found to be normal or treated. Measurement of serum TSH cannot be used as a guide to the adequacy of Levothyroxine replacement therapy. We suggest starting with a weight-based T4 dose of 1.6",
"      <span class=\"nowrap\">",
"       mcg/kg.",
"      </span>",
"      The dose should be adjusted according to the serum T4 or free T4 values, aiming to maintain them in the middle part of the normal range. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'TSH deficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link&amp;anchor=H13#H13\">",
"       \"Central hypothyroidism\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In men with gonadotropin deficiency, testosterone replacement is indicated when fertility is not desired. Men with secondary hypogonadism who wish to become fertile may be treated with gonadotropins if they have pituitary disease or with either gonadotropins or gonadotropin-releasing hormone (GnRH) if they have hypothalamic GnRH deficiency. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Men'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with gonadotropin deficiency, treatment depends upon the patient's goals. Estradiol and progestin replacements are indicated in women who are not pursuing fertility, while gonadotropin or pulsatile GnRH therapy may be used when ovulation induction and fertility are the goal. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of androgen therapy in women with hypopituitarism is unclear. (See",
"      <a class=\"local\" href=\"#H151093813\">",
"       'Adrenal androgen replacement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H151093784\">",
"       'Androgen replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/1\">",
"      B&uuml;low B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997; 46:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/2\">",
"      Arafah BM. Medical management of hypopituitarism in patients with pituitary adenomas. Pituitary 2002; 5:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/3\">",
"      Grossman AB. Clinical Review#: The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010; 95:4855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/4\">",
"      Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991; 72:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/5\">",
"      Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 2006; 64:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/6\">",
"      Thomson AH, Devers MC, Wallace AM, et al. Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2007; 66:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/7\">",
"      Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92:3912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/8\">",
"      Martin MM. Coexisting anterior pituitary and neurohypophyseal insufficiency. A syndrome with diagnostic implication. Arch Intern Med 1969; 123:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/9\">",
"      Miller KK, Sesmilo G, Schiller A, et al. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/10\">",
"      Miller KK, Biller BM, Beauregard C, et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006; 91:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28006/abstract/11\">",
"      Powe CE, Allen M, Puopolo KM, et al. Recombinant human prolactin for the treatment of lactation insufficiency. Clin Endocrinol (Oxf) 2010; 73:645.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6640 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28006=[""].join("\n");
var outline_f27_22_28006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H151093437\">",
"      IMPORTANCE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTH DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151093685\">",
"      Assessment of dose adequacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8249423\">",
"      Subjective health status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151093699\">",
"      Unmasking diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151093706\">",
"      Need for mineralocorticoid coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151093813\">",
"      Adrenal androgen replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TSH DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LH AND FSH DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H151093784\">",
"      - Androgen replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GROWTH HORMONE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROLACTIN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=related_link\">",
"      Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=related_link\">",
"      Induction of fertility in men with secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/10/38050?source=related_link\">",
"      Patient information: Panhypopituitarism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6691?source=related_link\">",
"      Urine output in diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_22_28007="Etiology of hypercalcemia";
var content_f27_22_28007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of hypercalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28007/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28007/contributors\">",
"     Elizabeth Shane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28007/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28007/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/22/28007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a relatively common clinical problem. It results when the entry of calcium into the circulation exceeds the excretion of calcium into the urine or deposition in bone. This occurs when there is accelerated bone resorption, excessive gastrointestinal absorption, or decreased renal excretion of calcium. In some disorders, however, more than one mechanism may be involved. As examples, hypervitaminosis D increases both intestinal calcium absorption and bone resorption, and primary hyperparathyroidism increases bone resorption, tubular calcium reabsorption, and renal synthesis of calcitriol (1,25-dihydroxyvitamin D, the most active metabolite of vitamin D), and intestinal calcium absorption.",
"   </p>",
"   <p>",
"    Among all causes of hypercalcemia, primary hyperparathyroidism and malignancy are the most common, accounting for greater than 90 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic card will review the etiology of hypercalcemia. The clinical manifestations, diagnostic approach, and treatment are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BONE RESORPTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia in primary hyperparathyroidism is due to parathyroid hormone-mediated activation of osteoclasts leading to increased bone resorption. In addition, intestinal calcium absorption is elevated. Primary hyperparathyroidism is most often due to a parathyroid adenoma. Patients typically have only small elevations in serum calcium concentrations (less than 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 2.75",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and many have mostly high-normal values with intermittent hypercalcemia. Thus, when one suspects primary hyperparathyroidism, as with high-normal serum calcium values in a patient with calcium nephrolithiasis, it may be necessary to obtain a series of serum calcium measurements to detect hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary and tertiary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe chronic kidney disease and secondary hyperparathyroidism usually have low or normal serum calcium concentrations, but with prolonged disease, may develop hypercalcemia. The rise in plasma calcium most often occurs in patients with adynamic bone disease and markedly reduced bone turnover. In such patients, hypercalcemia is due to a marked reduction in the bone uptake of calcium after a calcium load, as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    to treat hyperphosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Adynamic bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other patients with advanced renal failure, hypercalcemia is due to progression from appropriate parathyroid hyperplasia to autonomous overproduction of PTH, a disorder called tertiary hyperparathyroidism.",
"   </p>",
"   <p>",
"    If the patient with end-stage renal disease undergoes renal transplantation, the parathyroid gland hyperplasia subsides over a period of months to years. In some patients, hypercalcemia may develop after renal transplantation, because correction of the renal failure normalizes phosphate balance and increases calcitriol production, thereby raising serum calcium concentrations transiently until the parathyroid hyperplasia subsides. In some cases, parathyroid hyperplasia may not resolve completely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link&amp;anchor=H2#H2\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\", section on 'Persistent hyperparathyroidism and hypercalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia occurs in patients with many tumors, both solid tumors and leukemias. Values above 13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.25",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are less commonly seen in primary hyperparathyroidism and, in the absence of another apparent cause, are more likely due to malignancy.",
"   </p>",
"   <p>",
"    The mechanism of increased bone resorption with malignancy depends upon the cancer. In patients with bone metastases, direct induction of local osteolysis by the tumor cells is common. Cytokines such as tumor necrosis factor and interleukin-1 appear to play an important role by stimulating the differentiation of osteoclast precursors into mature osteoclasts.",
"   </p>",
"   <p>",
"    In patients with multiple myeloma, hypercalcemia is similarly due to the release of osteoclast activating factors such as lymphotoxin, interleukin-6, hepatocyte growth factor, and receptor activator of nuclear factor kappa B ligand (RANK ligand). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link&amp;anchor=H593827#H593827\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Osteoclasts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common cause of hypercalcemia in patients with nonmetastatic solid tumors is secretion of PTHrP. In contrast, hypercalcemia is caused by PTH-independent extrarenal production of calcitriol from calcidiol by activated mononuclear cells (particularly macrophages) in patients with lymphoma. Although rare, a few patients with ectopic non-parathyroid cancers that secreted PTH, not PTH-related protein, have been reported.",
"   </p>",
"   <p>",
"    Hypercalcemia of malignancy is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thyrotoxicosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild hypercalcemia occurs in up to 15 to 20 percent of thyrotoxic patients, due to a thyroid hormone mediated increase in bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It typically resolves following correction of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. If the hypercalcemia persists after the restoration of euthyroidism, serum PTH should be measured to assess for concomitant hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other less common causes of hypercalcemia due to increased bone resorption include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immobilization [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paget disease of bone, primarily if the patient is at bed rest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The administration of estrogen or an antiestrogen (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ) to patients with breast cancer and extensive skeletal metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypervitaminosis A (in which there is prolonged ingestion of more than 50,000 International Units per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/10,11\">",
"       10,11",
"      </a>",
"      ] or the administration of retinoic acid to patients with certain tumors, as either cis-retinoic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/12\">",
"       12",
"      </a>",
"      ] or all-trans retinoic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Retinoic acid causes a dose-dependent increase in bone resorption, resulting in an overall incidence of hypercalcemia of approximately 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/12\">",
"       12",
"      </a>",
"      ]. All-trans retinoic acid inhibits cell growth in part by downregulation of interleukin-6 receptors; the subsequent rise in serum interleukin-6 concentrations may be responsible for increased bone resorption and hypercalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link\">",
"       \"Differentiation (retinoic acid) syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CALCIUM ABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium is absorbed in the small intestine via both active and passive transport. The former is more important physiologically and is stimulated by vitamin D metabolites. On the other hand, when calcium intake is greater than 1 to 2 grams daily, or more, substantial amounts of calcium are absorbed passively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increased calcium intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high calcium intake alone is rarely a cause of hypercalcemia, because the initial elevation in serum calcium concentration inhibits both the release of parathyroid hormone (PTH) and in turn the synthesis of calcitriol. In patients who also have reduced urinary excretion, however, increased intake can cause hypercalcemia. This combination of high calcium intake and low urine calcium excretion occurs in two clinical situations: chronic kidney disease and the milk-alkali syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure alone, although associated with decreased calcium excretion, does not lead to hypercalcemia because of the calcium-lowering effects of concurrent hyperphosphatemia and decreased calcitriol synthesis. However, hypercalcemia is not unusual in patients who are given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    to bind dietary phosphate, particularly if they have adynamic bone disease or are also treated with calcitriol (or another form of vitamin D) in an attempt to reverse both hypocalcemia and secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\", section on 'Approach to hypercalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Milk alkali syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of renal failure, hypercalcemia can be induced by a high intake of milk or more commonly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    , leading to hypercalcemia, metabolic alkalosis, and renal insufficiency (the milk-alkali syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The metabolic alkalosis augments the hypercalcemia by directly stimulating calcium reabsorption in the distal tubule, thereby diminishing calcium excretion. A calcium-induced decline in renal function, due to renal vasoconstriction and, with chronic hypercalcemia, structural injury, can also contribute to the inability to excrete the excess calcium. Renal function usually returns to baseline after cessation of milk or calcium carbonate intake, but irreversible injury can occur in patients who have prolonged hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=see_link\">",
"     \"The milk-alkali syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The milk-alkali syndrome typically occurs in the setting of excess",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    supplementation to treat osteoporosis or dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. One study found that the milk-alkali syndrome accounted for two percent of hospitalized patients with hypercalcemia between 1985 and 1989, as compared with 12 percent between 1990 and 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/15\">",
"     15",
"    </a>",
"    ]. In another study, milk-alkali syndrome accounted for 8.8 percent of hypercalcemia cases between 1998 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypervitaminosis D",
"    </span>",
"    &nbsp;&mdash;&nbsp;High serum concentrations of either 25-hydroxyvitamin D (calcidiol) or 1,25-dihydroxyvitamin D (calcitriol) can cause hypercalcemia by increasing calcium absorption and bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal transport of calcium is primarily regulated by 1,25-dihydroxyvitamin D, which is more potent than 25-hydroxyvitamin D (25OHD). However, hypercalcemia does occur in patients with markedly elevated serum 25OHD concentrations, for example, those who ingest high doses of either vitamin D (which is converted to calcidiol in the liver), calcidiol itself, or use topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    , a vitamin D analog used in the treatment of some dermatologic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In some patients with hypervitaminosis D, the excess intake was unknown to the patients because milk was inadvertently excessively fortified with vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High serum 1,25D concentrations are usually due to ingestion of calcitriol as treatment for hypoparathyroidism or for the hypocalcemia and secondary hyperparathyroidism of renal failure. Calcitriol-induced hypercalcemia usually lasts only one to two days because of the relatively short biologic half-life of calcitriol. Thus, stopping the calcitriol, increasing salt and fluid intake, or perhaps hydration with intravenous saline may be the only therapy that is needed.",
"   </p>",
"   <p>",
"    Hypercalcemia caused by vitamin D or calcidiol lasts longer. More aggressive therapy such as glucocorticoids and intravenous bisphosphonates may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercalcemia can also be caused by increased endogenous production of 1,25D, as can occur in patients with malignant lymphoma (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    ), chronic granulomatous disorders (especially sarcoidosis) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    ), and less frequently in other illnesses characterized by granuloma formation, such as Wegener's granulomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, a rare cause of hypercalcemia is spontaneous idiopathic excess production of calcitriol in the apparent absence of granulomatous disease. These patients have high serum concentrations of angiotensin converting enzyme and calcitriol, and a presumed increase in calcitriol production by macrophages. The hypercalcemia responds to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    but continuous therapy is required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of hypercalcemia include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy often develop mild hypercalcemia, most likely due to increased secretion of PTH due to an increase in the set point at which calcium suppresses PTH release. The hypercalcemia usually, but not always, subsides when the lithium is stopped. Lithium can also unmask previously unrecognized mild hyperparathyroidism. Conversely, lithium can also raise serum PTH concentrations without raising serum calcium concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link&amp;anchor=H23#H23\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\", section on 'Lithium therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazide diuretics lower urinary calcium excretion, an effect that is useful in the treatment of patients with hypercalciuria and recurrent calcium nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .) This effect rarely causes hypercalcemia in otherwise normal persons but can lead to hypercalcemia in patients with an underlying increase in bone resorption, such as those with hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\", section on 'Thiazide therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a rare complication of pheochromocytoma. It can be due to concurrent hyperparathyroidism (in MEN, type II) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/24\">",
"     24",
"    </a>",
"    ] or to the pheochromocytoma itself [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .) The hypercalcemia in the latter patients appears to be due to tumoral production of PTH-related protein. Serum PTH-related protein concentrations in these patients can be reduced by alpha-adrenergic blockers, suggesting a mediating role for alpha-stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia occurs in occasional patients with Addisonian crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Multiple factors appear to contribute to the hypercalcemia including increased bone resorption, volume contraction and increased proximal tubular calcium reabsorption, hemoconcentration, and perhaps increased binding of calcium to serum proteins. Cortisol administration reverses the hypercalcemia within several days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/28\">",
"     28",
"    </a>",
"    ]. Hypercalcemia has also been reported in patients with secondary adrenal insufficiency due to lymphocytic hypophysitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The increased release of calcium from bone occurs despite appropriate suppression of PTH and calcitriol release and appears to be mediated, at least in part, by thyroid hormone via a process normally inhibited by glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis and acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia has been described during the diuretic phase of acute renal failure, most often in patients with rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Hypercalcemia in this setting is primarily due to the mobilization of calcium that had been deposited in the injured muscle. Correction of hyperphosphatemia (induced by the rise in glomerular filtration rate), mild secondary hyperparathyroidism induced by the renal failure, and an unexplained increase in serum calcitriol concentrations all appear to contribute to the hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512212#H11512212\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar mechanism of mobilization of calcium phosphate as renal failure-induced hyperphosphatemia is corrected plus persistent secondary hyperparathyroidism may account for the transient hypercalcemia that can occur after successful renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Theophylline toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    toxicity has been associated with mild hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/22\">",
"     22",
"    </a>",
"    ]. As in hyperthyroidism, the hypercalcemia usually subsides in response to administration of a beta-adrenergic antagonist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"     \"Theophylline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Familial hypocalciuric hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hypocalciuric hypercalcemia is a rare autosomal dominant disorder characterized by mild hypercalcemia, hypocalciuria (suggesting a contribution from increased renal tubular calcium reabsorption), normal to moderately elevated serum magnesium concentrations, and normal to slightly increased serum PTH concentrations. The majority of these patients has few if any symptoms of hypercalcemia and requires no therapy; subtotal parathyroidectomy does not correct the hypercalcemia.",
"   </p>",
"   <p>",
"    The primary defect in this disorder is a loss-of-function mutation in the calcium-sensing sensor on the parathyroid cells and in the kidneys so that higher than normal serum calcium concentrations are needed to suppress PTH release. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare acquired form of hypocalciuric hypercalcemia due to autoantibodies directed against the calcium-sensing receptor has been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link&amp;anchor=H18#H18\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\", section on 'Acquired disorders of the calcium-sensing receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Metaphyseal chondrodysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare form of dwarfism, Jansen-type metaphyseal chondrodysplasia, is associated with asymptomatic but significant hypercalcemia and hypophosphatemia. The parathyroid glands are normal and serum PTH and PTH-related protein concentrations are normal or low. The primary defect in this condition is a mutation in the PTH-PTH-related protein receptor gene, resulting in continuous activation of the receptor at normal or low levels of PTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Congenital lactase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia and medullary nephrocalcinosis have been described in infants with congenital",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28007/abstract/35\">",
"     35",
"    </a>",
"    ]. The hypercalcemia resolves rapidly after institution of a lactose-free diet but the nephrocalcinosis may persist. The hypercalcemia may be due to an increase in calcium absorption in the ileum in the presence of nonhydrolyzed lactose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a relatively common clinical problem. Among all causes of hypercalcemia, hyperparathyroidism and malignancy are the most common. The many other causes of hypercalcemia occur less frequently but are important to consider in clinical situations when hypercalcemia is not caused by hyperparathyroidism or malignancy (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnostic approach to hypercalcemia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/1\">",
"      Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/2\">",
"      Burman KD, Monchik JM, Earll JM, Wartofsky L. Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 1976; 84:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/3\">",
"      Iqbal AA, Burgess EH, Gallina DL, et al. Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract 2003; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/4\">",
"      Alikhan Z, Singh A. Hyperthyroidism manifested as hypercalcemia. South Med J 1996; 89:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/5\">",
"      Stewart AF, Adler M, Byers CM, et al. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982; 306:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/6\">",
"      Alborzi F, Leibowitz AB. Immobilization hypercalcemia in critical illness following bariatric surgery. Obes Surg 2002; 12:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/7\">",
"      Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999; 80:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/8\">",
"      Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981; 47:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/9\">",
"      Valentin-Opran A, Eilon G, Saez S, Mundy GR. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells. J Clin Invest 1985; 75:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/10\">",
"      Bhalla K, Ennis DM, Ennis ED. Hypercalcemia caused by iatrogenic hypervitaminosis A. J Am Diet Assoc 2005; 105:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/11\">",
"      Fishbane S, Frei GL, Finger M, et al. Hypervitaminosis A in two hemodialysis patients. Am J Kidney Dis 1995; 25:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/12\">",
"      Villablanca JG, Khan AA, Avramis VI, Reynolds CP. Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid. Am J Pediatr Hematol Oncol 1993; 15:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/13\">",
"      Niesvizky R, Siegel DS, Busquets X, et al. Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Br J Haematol 1995; 89:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/14\">",
"      Akiyama H, Nakamura N, Nagasaka S, et al. Hypercalcaemia due to all-trans retinoic acid. Lancet 1992; 339:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/15\">",
"      Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore) 1995; 74:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/16\">",
"      Abreo K, Adlakha A, Kilpatrick S, et al. The milk-alkali syndrome. A reversible form of acute renal failure. Arch Intern Med 1993; 153:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/17\">",
"      Picolos MK, Lavis VR, Orlander PR. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 2005; 63:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/18\">",
"      Jacobus CH, Holick MF, Shao Q, et al. Hypervitaminosis D associated with drinking milk. N Engl J Med 1992; 326:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/19\">",
"      Scanlon KS, Blank S, Sinks T, et al. Subclinical health effects in a population exposed to excess vitamin D in milk. Am J Public Health 1995; 85:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/20\">",
"      Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/21\">",
"      Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol (Oxf) 1995; 43:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/22\">",
"      Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab 2005; 90:6316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/23\">",
"      Evron E, Goland S, von der Walde J, et al. Idiopathic calcitriol-induced hypercalcemia. A new disease entity? Arch Intern Med 1997; 157:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/24\">",
"      Heath DA. Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. Endocrinol Metab Clin North Am 1989; 18:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/25\">",
"      Stewart AF, Hoecker JL, Mallette LE, et al. Hypercalcemia in pheochromocytoma. Evidence for a novel mechanism. Ann Intern Med 1985; 102:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/26\">",
"      Bridgewater JA, Ratcliffe WA, Bundred NJ, Owens CW. Malignant phaeochromocytoma and hypercalcaemia. Postgrad Med J 1993; 69:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/27\">",
"      Mune T, Katakami H, Kato Y, et al. Production and secretion of parathyroid hormone-related protein in pheochromocytoma: participation of an alpha-adrenergic mechanism. J Clin Endocrinol Metab 1993; 76:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/28\">",
"      Muls E, Bouillon R, Boelaert J, et al. Etiology of hypercalcemia in a patient with Addison's disease. Calcif Tissue Int 1982; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/29\">",
"      Montoli A, Colussi G, Minetti L. Hypercalcaemia in Addison's disease: calciotropic hormone profile and bone histology. J Intern Med 1992; 232:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/30\">",
"      Vasikaran SD, Tallis GA, Braund WJ. Secondary hypoadrenalism presenting with hypercalcaemia. Clin Endocrinol (Oxf) 1994; 41:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/31\">",
"      Fujikawa M, Kamihira K, Sato K, et al. Elevated bone resorption markers in a patient with hypercalcemia associated with post-partum thyrotoxicosis and hypoadrenocorticism due to pituitary failure. J Endocrinol Invest 2004; 27:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/32\">",
"      Llach F, Felsenfeld AJ, Haussler MR. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol. N Engl J Med 1981; 305:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/33\">",
"      Akmal M, Bishop JE, Telfer N, et al. Hypocalcemia and hypercalcemia in patients with rhabdomyolysis with and without acute renal failure. J Clin Endocrinol Metab 1986; 63:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/34\">",
"      Schipani E, Langman CB, Parfitt AM, et al. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med 1996; 335:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28007/abstract/35\">",
"      Saarela T, Simil&auml; S, Koivisto M. Hypercalcemia and nephrocalcinosis in patients with congenital lactase deficiency. J Pediatr 1995; 127:920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 839 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28007=[""].join("\n");
var outline_f27_22_28007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BONE RESORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary and tertiary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thyrotoxicosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CALCIUM ABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increased calcium intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Milk alkali syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypervitaminosis D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MISCELLANEOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rhabdomyolysis and acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Theophylline toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Familial hypocalciuric hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Metaphyseal chondrodysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Congenital lactase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/40/29324\" title=\"table 1\">",
"      Causes hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=related_link\">",
"      The milk-alkali syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_22_28008="Cellular NSIP histology";
var content_f27_22_28008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Nonspecific interstitial pneumonia, cellular pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The interstitium is infiltrated by a moderate chronic inflammatory infiltrate; fibrosis is absent. The infiltrate consists of lymphocytes and plasma cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28008=[""].join("\n");
var outline_f27_22_28008=null;
var title_f27_22_28009="Recognition and management of diaphragmatic injury in adults";
var content_f27_22_28009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recognition and management of diaphragmatic injury in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Mallory Williams, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/22/28009/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/22/28009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19492460\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragmatic injury is uncommon, representing less than 1 percent of all traumatic injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The diaphragm is usually injured in association with other thoracic and abdominal organs. Although diaphragmatic injury can be obvious (eg, herniation of abdominal contents on chest radiograph), the injury may be subtle and imaging studies can be nondiagnostic. A high index of suspicion needs to be maintained because delayed diagnosis is associated with an increased risk for herniation and strangulation of abdominal organs, which can be life-threatening. For patients in whom the diagnosis is uncertain, diagnostic laparoscopy, thoracoscopy or open surgical exploration may be needed to establish the diagnosis. When identified, diaphragm injury is repaired with open surgical or minimally invasive techniques, the choice and timing of which depends upon the presence of associated injuries and the overall condition of the patient.",
"   </p>",
"   <p>",
"    This topic will discuss the recognition and surgical management of blunt and penetrating injury to the diaphragm. Injuries to associated thoracic and abdominal organs are discussed in separate topic reviews. The general approach to blunt and penetrating chest and abdominal trauma are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43817542\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE DIAPHRAGM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragm (dia: across, phragm: fence) is the musculotendinous boundary between the negative-pressure thoracic cavity and positive-pressure abdominal cavity. The diaphragm plays a significant role in respiratory mechanics and injury to the diaphragm impairs ventilation and oxygen delivery. The normal mechanics of respiration are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H2#H2\">",
"     \"Diseases of the chest wall\", section on 'Normal structure and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diaphragm is dome-shaped and attaches to the chest and abdominal walls circumferentially (",
"    <a class=\"graphic graphic_figure graphicRef64543 \" href=\"UTD.htm?31/27/32184\">",
"     figure 1",
"    </a>",
"    ). The liver, spleen, transverse colon, stomach, pancreas, adrenal glands, and kidneys contact the undersurface of the diaphragm. Thoracoabdominal structures, including the aorta, inferior vena cava, thoracic duct, esophagus, vagus nerves and phrenic nerves, traverse the diaphragm through three major apertures (ie, aortic, caval, esophageal) (",
"    <a class=\"graphic graphic_figure graphicRef77888 \" href=\"UTD.htm?16/29/16857\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diaphragm is composed of two muscle groups, costal and crural, which are compositionally and functionally distinct. Both groups are innervated by the phrenic nerves (",
"    <a class=\"graphic graphic_figure graphicRef52752 \" href=\"UTD.htm?16/21/16725\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52959 \" href=\"UTD.htm?16/42/17061\">",
"     figure 4",
"    </a>",
"    ). The costal muscle group that forms the diaphragmatic leaflets is thin, and contraction of its fibers flattens the diaphragm and lowers the ribs. The crural muscle groups are thicker but contribute minimally to the displacement of the diaphragm. The median arcuate ligament anterior to the aortic hiatus is formed by the continuation of the medial tendinous margins of the crura.",
"   </p>",
"   <p>",
"    The costal and crural fibers insert into the central tendon (",
"    <a class=\"graphic graphic_figure graphicRef64543 \" href=\"UTD.htm?31/27/32184\">",
"     figure 1",
"    </a>",
"    ). The anterior portion of the tendon attaches to the posterior aspect of the xiphisternal junction. The posterior portion of the central tendon attaches to the first three lumbar vertebral bodies (L1-L3). Lateral insertions of the central tendon occur on the 6",
"    <sup>",
"     th",
"    </sup>",
"    rib anteriorly and the 12",
"    <sup>",
"     th",
"    </sup>",
"    rib posteriorly. &nbsp;",
"   </p>",
"   <p>",
"    The vascular supply of the diaphragm is derived from the phrenic artery below the diaphragm and the pericardiophrenic arteries above the diaphragm (",
"    <a class=\"graphic graphic_figure graphicRef77888 \" href=\"UTD.htm?16/29/16857\">",
"     figure 2",
"    </a>",
"    ). The phrenic nerve originates from the anterior rami of C3, C4 and C5 and traverses the neck and mediastinum before inserting into the diaphragm centrally (",
"    <a class=\"graphic graphic_figure graphicRef52752 \" href=\"UTD.htm?16/21/16725\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52959 \" href=\"UTD.htm?16/42/17061\">",
"     figure 4",
"    </a>",
"    ). The outer rim of the diaphragmatic muscle is innervated laterally from the T7 through T12 (",
"    <a class=\"graphic graphic_figure graphicRef64543 \" href=\"UTD.htm?31/27/32184\">",
"     figure 1",
"    </a>",
"    ). The crural group of muscles receives innervation from the vagus nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98788934\">",
"    <span class=\"h2\">",
"     Diaphragmatic injury severity scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragm injuries are classified according to the American Association for the Surgery of Trauma (AAST) organ injury scale. Increased morbidity and mortality has been correlated with increasing injury grade for some injuries (eg, liver, spleen, kidney), but to date, not for diaphragmatic injuries. The diaphragmatic injury severity scale is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade &nbsp; I: Contusion",
"     </li>",
"     <li>",
"      Grade &nbsp;II: Laceration &le;2 cm",
"     </li>",
"     <li>",
"      Grade III: Laceration 2 to 10 cm",
"     </li>",
"     <li>",
"      Grade IV: Laceration &gt;10 cm; tissue loss &le;25 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Grade &nbsp;V: Laceration and tissue loss &gt;25 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055088\">",
"    <span class=\"h1\">",
"     TRAUMA EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial resuscitation, diagnostic evaluation, and management of the patient with blunt or penetrating injury is based upon protocols from the Advanced Trauma Life Support (ATLS&reg;) program, established by the American College of Surgeons Committee on Trauma. The initial resuscitation and evaluation of the patient with blunt or penetrating abdominal or thoracic trauma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28247?source=see_link\">",
"     \"Initial evaluation and management of chest wall trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of acute trauma, many patients cannot relate their symptoms or medical history due to altered mental status (eg, neurologic injury, intoxication) or because they are intubated and sedated. Every attempt should be made to identify preexisting medical conditions by contacting the patient's primary care physician or family members. The presence of significant medical comorbidities and medical conditions requiring antiplatelet or anticoagulation should be determined, as these may impact management decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38056485\">",
"    <span class=\"h1\">",
"     RECOGNITION OF DIAPHRAGMATIC INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using the National Trauma Data Bank (NTDB), the largest trauma registry in the world, have found an overall incidence of diaphragm injury of 0.63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/2\">",
"     2",
"    </a>",
"    ]. A suspicion for diaphragmatic injury begins with the identification of the injury mechanism, physical examination of the patient and assessment of associated injuries. Certain injury patterns increase the risk for diaphragmatic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38057037\">",
"    <span class=\"h2\">",
"     Injury mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragm can be injured directly, due to an impalement or missile passing through it from the abdominal cavity to the thoracic cavity or vice versa, or indirectly from blunt rupture, which is caused by a sudden increase in intra-abdominal pressure that is sufficient to overcome the strength of the diaphragmatic tissue. Blunt diaphragm rupture usually causes large radial tears of the diaphragm, while penetrating injury leads to smaller rents that approximate the size of the penetrating impalement. As such, penetrating injuries are more likely to be missed. (See",
"    <a class=\"local\" href=\"#H38057599\">",
"     'Delayed presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38056649\">",
"    <span class=\"h3\">",
"     Penetrating injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating mechanisms to the thoracoabdominal region, such as stabs, gunshot, shotgun and impalements, account for about 65 percent of all diaphragmatic injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/2\">",
"     2",
"    </a>",
"    ]. The diaphragm can rise as high as the fourth thoracic (T4) dermatome on the right and the fifth dermatome (T5) (",
"    <a class=\"graphic graphic_figure graphicRef53938 \" href=\"UTD.htm?22/19/22836\">",
"     figure 5",
"    </a>",
"    ) on the left with deep inspiration, and it descends to as low as the eighth thoracic dermatome (T8) with expiration. The lowest level of the lateral diaphragm attachment is the base of the 12",
"    <sup>",
"     th",
"    </sup>",
"    rib. Thus, any impalement or missile that passes through the chest or abdominal wall from T4 through T12 has the potential to injure the diaphragm. Penetrating injury due to stabbing is more common on the left compared with the right, presumably because the majority of assailants are right-handed, assuming a frontal assault.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38056656\">",
"    <span class=\"h3\">",
"     Blunt diaphragmatic rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt mechanisms account for the remaining 35 percent of diaphragmatic injuries and occur in 0.8 to 1.6 percent of patients sustaining blunt trauma. Motor vehicle collisions are responsible for up to 90 percent of blunt diaphragm rupture with the remainder due to falls or crush injury, both of which can sufficiently elevate intra-abdominal pressure to rupture the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the diaphragm contracts, the relaxed dome-shaped diaphragm flattens which increases the volume of the thoracic cavity, decreases the volume of the abdominal cavity and changes intrapleural and intra-abdominal pressure. During normal quiet breathing, intraperitoneal pressure ranges from +2 to +10 cm water (H",
"    <sub>",
"     2",
"    </sub>",
"    0) and intrapleural pressure is from -5 to -10 cm water which results in a pleuroperitoneal gradient of +7 to +20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0 in the supine position. With maximal inspiration, the diaphragm is forced downward and the pleuroperitoneal pressure gradient can rise as high as +100 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0. Changes in the compliance of the abdominal or chest wall alter normal mechanics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H2#H2\">",
"     \"Diseases of the chest wall\", section on 'Normal structure and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The application of blunt force to the abdomen or chest can result in pleuroperitoneal gradients of +150 to 200 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0, which exceeds the strength of the muscle or tendinous tissues, and can rupture or avulse the diaphragm from its attachments. (See",
"    <a class=\"local\" href=\"#H43817542\">",
"     'Anatomy of the diaphragm'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The left diaphragmatic leaflet is two to three times more likely than the right leaflet to be injured with blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Bilateral blunt rupture of the diaphragm occurs in 2 to 6 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/9\">",
"     9",
"    </a>",
"    ]. In one retrospective study of 731 patients with traumatic diaphragm rupture, the left posterolateral region medial to the spleen was the most common site of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/8\">",
"     8",
"    </a>",
"    ]. This is felt to be due to a congenital weakness of this region. Another explanation may be that the liver protects the right diaphragm by attenuating or preventing the transmission of force across the diaphragm. However, a tendency toward more right-sided diaphragmatic injuries is observed as collision speed increases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38057331\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 50 percent of patients with diaphragmatic injury also suffer associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For penetrating trauma, the passage of an impalement or missile through the abdominal or chest walls rarely injures the diaphragm in isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In one study, 75 percent of patients with penetrating diaphragmatic injury had an associated organ injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/6\">",
"     6",
"    </a>",
"    ]. In another study, an average of two organ injuries were present in patients who suffered stab wounds and three organ injuries in those patients sustaining gunshot wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For blunt trauma, the percent of patients with a given injury who also have a traumatic diaphragmatic rupture are: liver (48 percent), hemothorax",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pneumothorax (47 percent), spleen (35 percent), rib fracture (28 percent), bowel (23 percent), kidney (16 percent), pelvic fracture (14 percent), closed head injury (11 percent), thoracic aorta (4 percent), and spinal cord injury (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38057468\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s abdomen and chest should be examined for the presence of contusions or ecchymoses that might suggest that significant blunt forces have been sustained. Although diaphragmatic excursion depends upon variables such as body build, body posture and lung volume, any bullet or stab wound between the level of the T4 and T12 dermatomes (",
"    <a class=\"graphic graphic_figure graphicRef53938 \" href=\"UTD.htm?22/19/22836\">",
"     figure 5",
"    </a>",
"    ) has the potential to cause diaphragmatic injury, particularly if penetrating wounds are found on both sides of the diaphragm. Penetrating wounds in the posterior or flank region of the trunk can also lead to diaphragmatic injury. (See",
"    <a class=\"local\" href=\"#H43817542\">",
"     'Anatomy of the diaphragm'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presence of a rent in the diaphragm can lead to acute herniation of abdominal contents into the chest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87089 \" href=\"UTD.htm?18/30/18912\">",
"     image 1",
"    </a>",
"    ). The finding of diminished breath sounds may indicate collapse of the lung due to herniation. If the stomach has herniated, air injected into the nasogastric tube may be heard in the chest upon auscultation although this finding is non-specific. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=see_link&amp;anchor=H522921978#H522921978\">",
"     \"Nasogastric and nasoenteric tubes\", section on 'Confirmation of placement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38057599\">",
"    <span class=\"h3\">",
"     Delayed presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trauma patient may initially have no symptoms or signs to suggest an injury to the diaphragm or associated injuries may be sufficiently severe that definitive evaluation for diaphragmatic injury is delayed. With time, the diaphragmatic defect due to injury has a tendency to become larger, and herniation of abdominal organs becomes more likely, particularly if left-sided. In one small series of delayed diagnosis of traumatic diaphragm rupture, 3 of 16 patients (19 percent) had their injuries missed at initial laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of these injuries (15 out of 16) were on the left [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/12\">",
"     12",
"    </a>",
"    ]. Small right-sided injuries may remain stable because the liver tamponades the defect preventing bowel herniation.",
"   </p>",
"   <p>",
"    Patients with previous thoracoabdominal trauma who present with abdominal pain and",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    should be evaluated for a possible missed diaphragmatic injury as a cause of gastrointestinal obstruction due to herniation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87312 \" href=\"UTD.htm?26/21/26966\">",
"     image 2",
"    </a>",
"    ). Failure to diagnose and repair the diaphragm can lead to intestinal strangulation and, potentially, death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055634\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of injury and physical exam findings may suggest the need for additional studies beyond the plain chest x-ray that is typically obtained during the primary survey during trauma resuscitation. A diagnosis of diaphragmatic injury is often coincidentally made while using computed tomography (CT) to rule out significant life-threatening injuries (eg, traumatic aortic rupture) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/13\">",
"     13",
"    </a>",
"    ]. Small tears may not be seen even with sophisticated imaging techniques; however, higher resolution multidetector CT scanning appears to hold the most promise. (See",
"    <a class=\"local\" href=\"#H38055658\">",
"     'Computed tomography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055642\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph is the most commonly obtained imaging study used for the evaluation of trauma patients. Diagnosis of diaphragmatic injury on chest radiograph can be as obvious as visualization of the stomach or other abdominal organs in the chest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71982 \" href=\"UTD.htm?8/14/8418\">",
"     image 3",
"    </a>",
"    ), or suggested by subtle signs including elevation of the diaphragm, basilar atelectasis, lack of clarity of the hemidiaphragm, abnormal nasogastric tube positioning (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79270 \" href=\"UTD.htm?17/3/17457\">",
"     image 4",
"    </a>",
"    ), or even hemothorax from bleeding in the abdomen (eg, splenic injury) .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055650\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Focused Assessment with Sonography in Trauma (FAST) examination is an important component of trauma management that is used primarily to detect free intraperitoneal blood following trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Ultrasound'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Ultrasound techniques can also be used to evaluate the diaphragm, but the use of ultrasound to identify traumatic diaphragmatic rupture is not standardized and a negative study cannot be used to exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. To perform the examination, a 5.0 to 7.5 MHz linear array transducer is placed transversely on the abdomen with the transducer directed posteriorly toward the diaphragm. The diaphragm appears as a hyperechoic (ie, white) line superior to the liver. The diaphragm is followed from right to left and its continuity evaluated.",
"   </p>",
"   <p>",
"    Findings on ultrasound consistent with diaphragmatic injury include discontinuity of the diaphragm, herniation of the liver or bowel loops through a diaphragmatic defect, floating diaphragm, and nonvisualization of the diaphragm. Indirect findings include pleural effusion or subphrenic fluid collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055658\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following blunt thoracoabdominal trauma, computed tomography (CT) is often performed as part of the initial trauma evaluation or based upon findings of a chest radiograph. CT is most commonly used in hemodynamically stable patients as a means to rule out solid organ and hollow viscus injuries.",
"   </p>",
"   <p>",
"    CT can detect diaphragm injury and is more useful for assessing the posterior lumbar elements of the diaphragm (crura and arcuate ligaments) compared with the anterior leaflets. Portions of the diaphragm may be obscured due to a similarity in attenuation levels to adjacent structures (eg, liver, spleen). &nbsp;",
"   </p>",
"   <p>",
"    Findings on CT scan suggestive of diaphragm injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuity of the diaphragm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87088 \" href=\"UTD.htm?23/47/24310\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61222 \" href=\"UTD.htm?3/25/3473\">",
"       image 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herniation of the abdominal contents into the chest (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87090 \" href=\"UTD.htm?20/8/20609\">",
"       image 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abnormal positioning of a nasogastric tube",
"     </li>",
"     <li>",
"      Waist-like constriction of bowel",
"     </li>",
"     <li>",
"      Dependence of the viscera meaning that the viscera (liver, stomach) are in direct contact with the posterior ribs",
"     </li>",
"     <li>",
"      Contiguous injury from one side of the diaphragm to the other (ie, left pulmonary laceration and splenic laceration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the available studies, 4 or 16 slice CT scanners have a sensitivity of 82 to 87 percent and specificity of 72 to 99 percent for detecting diaphragmatic injury due to penetrating trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, first and second generation imaging studies were prone to missing centrally located radial tears. Some of the limitations of earlier scanners are being overcome with newer helical and multidetector (up to 256 slice) computed tomography (MDCT) studies, which are able to acquire volumetric data, eliminate motion artifact and can provide excellent three-dimensional reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/19\">",
"     19",
"    </a>",
"    ]. However, because of the rarity of diaphragmatic injury, the sensitivity and specificity for detecting diaphragmatic injury with advanced CT technology has yet to be established. We expect the accuracy to be improved due to better longitudinal and in-plane image resolution.",
"   </p>",
"   <p>",
"    Even with higher resolution scans, injuries can be missed in intubated patients on positive pressure ventilation because the abdominal organs that might have herniated into the chest are pushed back into the abdomen. Sagittal reconstructions may be helpful to define the injury in these patients. Where available, multidetector CT scanning is the primary diagnostic modality for identifying patients who require repair of a diaphragmatic injury. However, many hospitals, including some Level I trauma centers, may not have the benefit of these high-resolution scanners which may alter the management approach. (See",
"    <a class=\"local\" href=\"#H19492586\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055666\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) can be time-consuming to perform, and often places the patient in a hospital location that is remote from ready access and intervention. For this reason, MRI does not play a significant role in the initial evaluation of the injured patient. However, MRI may be applicable in a subset of hemodynamically stable patients who cannot undergo computed tomography (eg, allergic to IV contrast) or in those for whom a suspicion for diaphragmatic injury remains high in spite of other negative diagnostic studies (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87312 \" href=\"UTD.htm?26/21/26966\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43817177\">",
"    <span class=\"h2\">",
"     Diagnostic peritoneal lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic peritoneal lavage (DPL) was commonly used in the past, but has been supplanted by the Focused Assessment with Sonography for Trauma (FAST) examination and other imaging modalities for the diagnosis of diaphragmatic injury. The interpretation of DPL is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Diagnostic peritoneal lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DPL may still play a role in the evaluation of penetrating thoracoabdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/21\">",
"     21",
"    </a>",
"    ]. To improve its sensitivity for diagnosing diaphragmatic injuries in penetrating thoracoabdominal trauma, many clinicians have modified the red blood count (RBC) criteria, accepting lower RBC counts (5000 to",
"    <span class=\"nowrap\">",
"     10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    to decrease the rate of false negative results. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38055673\">",
"    <span class=\"h2\">",
"     Diagnostic dilemmas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies may be falsely positive for diaphragmatic injury; such occurs with eventration of the diaphragm and Chilaiditi&rsquo;s sign.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eventration of the diaphragm is due to thinning and elevation of the diaphragm in such a manner that pneumoperitoneum or herniation of bowel seems to be present above the diaphragm. Eventration of the diaphragm is thought to be due to a congenital defect of the diaphragm or an acquired defect from complete or incomplete paralysis of the diaphragm. Hypoplasia of the lung on the involved side may contribute to the etiology in the congenital variant. The acquired variant usually occurs on the right side. If suspected, previous imaging studies, if available, should be compared with images obtained at the time of trauma admission.",
"     </li>",
"     <li>",
"      Chilaiditi&rsquo;s sign can also lead to a false positive diagnosis of diaphragmatic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/22\">",
"       22",
"      </a>",
"      ]. Chilaiditi&rsquo;s sign is due to a loop of bowel interposed between the liver and the diaphragm. Although the involved bowel is usually transverse colon, it can also be distended small bowel. When associated with abdominal pain, this entity is known as Chilaiditi&rsquo;s syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654387\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF DIAPHRAGMATIC INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall morbidity associated with diaphragmatic injury ranges from 30 to 68 percent and is related to the presence of associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/7,23,24\">",
"     7,23,24",
"    </a>",
"    ]. Patients suffering blunt trauma have higher complication rates (60 percent) compared with those who have penetrating trauma (40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654412\">",
"    <span class=\"h2\">",
"     Herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of abdominal organ herniation due to diaphragmatic injury is unknown since many cases likely go undiagnosed. Herniation of the stomach, spleen, colon, small intestine and omentum occur on the left and, on the right, the liver or colon. Cardiac herniation has also been reported. &nbsp;",
"   </p>",
"   <p>",
"    Patients with prior thoracoabdominal trauma who present with signs and symptoms consistent with gastrointestinal obstruction or ischemia should be evaluated for a possible missed diaphragmatic injury. (See",
"    <a class=\"local\" href=\"#H38057599\">",
"     'Delayed presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654419\">",
"    <span class=\"h2\">",
"     Diaphragm paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragm is the major muscle of respiration, and during quiet breathing, its contraction is responsible for 75 to 80 percent of tidal volume. With unilateral paralysis of the diaphragm, the normal hemidiaphragm descends normally, while the paralyzed hemidiaphragm moves upward. The resultant mediastinal shift reduces lung capacity by as much as 20 to 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Altered function with diaphragmatic paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although phrenic nerve injury associated with trauma is more commonly seen with high cervical spine injuries or penetrating neck trauma, injury to the phrenic nerves can occur as a result of thoracoabdominal trauma and its management such as during emergent thoracotomy or repair of injuries to mediastinal structures. Phrenic nerve injury can also be due to diaphragm tears [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with traumatic diaphragm paralysis who require ventilator support beyond two weeks may be candidates for diaphragmatic plication. &nbsp;",
"   </p>",
"   <p>",
"    Diaphragm plication fixes a paralyzed hemidiaphragm in the flat position, decreasing its paradoxical movement and improving the overall efficiency of mechanical ventilation without impairing the potential for the recovery of diaphragm function (",
"    <a class=\"graphic graphic_figure graphicRef70441 \" href=\"UTD.htm?2/61/3029\">",
"     figure 6",
"    </a>",
"    ). The treatment of diaphragm paralysis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of diaphragmatic paralysis\", section on 'Surgical plication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654426\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragmatic injury is often accompanied by rib fractures and pulmonary contusion. Pulmonary complications are common with atelectasis occurring in 11 to 68 percent of patients, pleural effusion in 10 to 23 percent, and empyema in 2 to 10 percent with diaphragmatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/7,23,24\">",
"     7,23,24",
"    </a>",
"    ]. Diagnosis and management of these complications are discussed in individual topics reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link\">",
"     \"Inpatient management of traumatic rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H654433\">",
"    <span class=\"h2\">",
"     Biliary fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined injury of the liver, diaphragm and lung can lead to biliary-pleural or bronchobiliary fistula formation. Biliary drainage from the thoracostomy tube establishes the diagnosis of biliary-pleural fistula. Bronchobiliary fistula occurs due to penetrating mechanisms that traverse a bronchus and biliary radical. The presenting symptom may be bilioptysis (coughing up bile).",
"   </p>",
"   <p>",
"    The management of these traumatic fistulae is similar to biliary fistulae from other causes. Patients who develop fever, chills, or leukocytosis should undergo computed tomography of the chest and abdomen to identify any pleural fluid collections which should be percutaneously drained and cultured. The presence of bile confirms the presence of a biliary-pleural fistula. A HIDA scan can also be used for the diagnosis. Endoscopic retrograde cholangiopancreatography (ERCP) defines the anatomy of the injury and potentially offers treatment with sphincterotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biliary stent placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19492586\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing exploratory laparotomy for trauma for other reasons should have a thorough inspection of the diaphragm as a part of the trauma laparotomy. (See",
"    <a class=\"local\" href=\"#H98788189\">",
"     'Trauma laparotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All left-sided diaphragm injuries and most right-sided injuries require repair when recognized. Acute injuries are usually repaired using an abdominal approach. The force needed to cause blunt diaphragmatic injury is significant and although diaphragmatic injury can be isolated, it is more likely to be associated with other injuries that may need repair. Similarly, abdominal exploration is generally indicated for penetrating injuries. (See",
"    <a class=\"local\" href=\"#H38057331\">",
"     'Associated injuries'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients with severe associated injuries may require delayed management of the diaphragmatic injury.",
"   </p>",
"   <p>",
"    The timeframe over when an acute injury becomes chronic is subject to debate. Once the repair becomes elective and there is no longer a concern for concomitant injury, the possibility of minimally invasive repair from either an abdominal or thoracic approach increases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Chronic diaphragmatic hernia is typically repaired with a thoracic approach.",
"   </p>",
"   <p>",
"    Hemodynamically stable patients with a negative physical exam and imaging studies can be observed. Small asymptomatic right-sided injuries that are &ldquo;tamponaded&rdquo; by the liver have a low risk for significant long-term sequelae and can also be managed expectantly.",
"   </p>",
"   <p>",
"    If the index of suspicion is high for diaphragmatic injury, but imaging studies have been inconclusive, an alternative approach is to use minimally invasive techniques (laparoscopy, thoracoscopy) to confirm (or rule out) a diaphragmatic injury and potentially repair it with minimally invasive techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/27,29-31\">",
"     27,29-31",
"    </a>",
"    ]. Although there is the theoretical concern for pneumothorax with insufflation of the abdomen in patients with diaphragmatic injury, this has not been described in the literature. We prefer to prepare the chest along with the abdomen in the event that a chest tube is needed.",
"   </p>",
"   <p>",
"    Laparoscopy has a sensitivity of 88 percent and a specificity approaching 100 percent in the diagnosis of diaphragmatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/29\">",
"     29",
"    </a>",
"    ]. In one retrospective review of 119 patients with left-sided penetrating thoracoabdominal trauma, 31 percent of the patients found to have diaphragmatic injury on laparoscopy had no abdominal tenderness and normal chest radiograph was seen in 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/27\">",
"     27",
"    </a>",
"    ]. One-fourth of patients did not have sufficient clinical signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiology examination to diagnose the injury.",
"   </p>",
"   <p>",
"    Thoracoscopy can also be used to diagnose diaphragmatic injury. In a small series of 14 patients, all injuries of the diaphragm were detected with thoracoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When diaphragmatic injury is identified on laparoscopy or thoracoscopy, it may not be amenable to repair with minimally invasive techniques necessitating conversion to open surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H385765483\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86034093\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient (or the patient's next of kin if the patient is intubated or unresponsive) should be informed that although exploration is being performed to manage identified injuries, other intra-abdominal injuries may be discovered that need specific management. (See",
"    <a class=\"local\" href=\"#H38057331\">",
"     'Associated injuries'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Blood products should be available in the event the patient becomes hemodynamically unstable. A trauma transfusion protocol should be in place including packed red blood cells, fresh frozen plasma, and platelets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic antibiotics are administered to prevent surgical site infection. For emergent trauma surgery, antibiotic selection is the same as for elective surgery with administration of a first generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ). If there is concern for or confirmed enteric, or colorectal contamination, anaerobic coverage with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is appropriate (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98788189\">",
"    <span class=\"h2\">",
"     Trauma laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A midline trauma laparotomy incision is used to evaluate the abdomen and retroperitoneum and rule out or repair identified injuries. Control of hemorrhage and gastrointestinal spillage are the first priorities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=see_link&amp;anchor=H11#H11\">",
"     \"Surgical management of splenic injury in the adult trauma patient\", section on 'Exploratory laparotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abdominal surface of the diaphragm should be included as part of a standard abdominal exploration. After ligation and division of the falciform ligament, the right hemidiaphragm is inspected by downward traction on the liver. The liver does not usually need to be mobilized away from its coronary ligamentous attachments. Downward traction on the fundus of the stomach and dome of the spleen allows visualization of the left hemidiaphragm. The central tendon, the esophageal hiatus and the diaphragmatic crura at the aortic hiatus should also be inspected to ensure they remain firmly attached to the lumbar vertebrae and are not torn.",
"   </p>",
"   <p>",
"    When herniation of abdominal organs is present, the organs should be gently reduced from the diaphragmatic defect back into the abdominal cavity. With chronic herniation, there is always a hernia sac with adhesions. Dissection of the hernia sac away from the abdominal contents is first necessary; then the abdominal organs can be reduced without causing injury. Any serosal or capsular tears that occur are identified and repaired.",
"   </p>",
"   <p>",
"    The edges of the diaphragmatic defect are grasped with Allis clamps. The thoracic cavity is inspected through the defect for contamination or ongoing hemorrhage. If contamination exists, copious lavage is performed. Irrigation of the thoracic cavity through a laparotomy approach has been shown to be effective in controlling biliary, gastric or enteric contamination in patients with penetrating trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any devitalized diaphragmatic tissue is debrided. The diaphragm is repaired with permanent suture or absorbable monofilament suture (Size 0, 1) in a running or interrupted fashion. Gentle downward traction of the cardiac surface of the diaphragm away from the heart during the placement of sutures will avoid inadvertent cardiac injury. In rare cases of massive diaphragmatic and chest wall destruction, other surgical options are available (eg, diaphragm transposition) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diaphragm has an excellent blood supply (",
"    <a class=\"graphic graphic_figure graphicRef77888 \" href=\"UTD.htm?16/29/16857\">",
"     figure 2",
"    </a>",
"    ) and breakdown of repairs is generally uncommon. However, infection can contribute to breakdown of the repair. Antibiotics should be given prophylactically prior to surgery and are continued postoperatively only when indicated. (See",
"    <a class=\"local\" href=\"#H86034093\">",
"     'Preparation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98788336\">",
"    <span class=\"h2\">",
"     Use of mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the rare instance that primary repair is not possible due to excess diaphragmatic tissue loss or chronic expansion of the defect (Grade IV or V injury), nonabsorbable prosthetic materials (eg, polytetrafluoroethylene, polyethylene) can be used, provided no colonic contamination is present. When contamination is present, the abdomen is copiously irrigated and an autologous tissue flap (eg, omentum, latissimus dorsi flap), or a bioprosthesis should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98790511\">",
"    <span class=\"h2\">",
"     Managing cardiac herniation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cardiac herniation is usually due to high-speed motor vehicle collision [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/35\">",
"     35",
"    </a>",
"    ]. The heart herniates inferiorly into the peritoneal cavity due to disruption of the central tendon. The diagnosis is established with chest radiograph or FAST examination. Repair of this injury is through a laparotomy incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19492669\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality for diaphragmatic injury depends upon the trauma mechanism and presence of associated injuries. The National Trauma Databank (NTDB) reports an overall mortality of 25 percent for patients with diaphragmatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/2\">",
"     2",
"    </a>",
"    ]. The immediate 24-hour mortality from diaphragmatic injuries is due to associated injuries. Mortality is higher with blunt compared with penetrating injury due to the presence of significant associated thoracic or abdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor physiologic status upon presentation of the patient accompanied by continued hemorrhage is a predictor of death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/8\">",
"     8",
"    </a>",
"    ]. The mortality for delayed presentation of diaphragmatic injury for the patient with incarceration of gastrointestinal contents is about 20 percent, increasing to 40 to 57 percent when bowel strangulation is present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/22/28009/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19492683\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diaphragm is the musculotendinous boundary between the negative-pressure thoracic cavity and positive-pressure abdominal cavity and plays a significant role in normal respiratory function. (See",
"      <a class=\"local\" href=\"#H43817542\">",
"       'Anatomy of the diaphragm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diaphragmatic injury is uncommon, representing less than one percent of all traumatic injuries. The diaphragm is usually injured in association with other thoracic and abdominal organs. A high index of suspicion for this injury is needed because delayed diagnosis is associated with an increased risk for herniation and strangulation of abdominal organs, which can be life-threatening. Penetrating injury leads to smaller rents which are more likely to be missed compared with blunt rupture which typically causes large radial tears. &nbsp;(See",
"      <a class=\"local\" href=\"#H38056485\">",
"       'Recognition of diaphragmatic injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A suspicion for diaphragmatic injury begins with the identification of the injury mechanism, physical examination and assessment of associated injuries. Direct injury to the diaphragm is due to an implement or missile passing through the diaphragm. Indirect injury is caused by a sudden increase in intra-abdominal pressure that is sufficient to overcome the strength of the diaphragmatic tissues resulting in blunt rupture. (See",
"      <a class=\"local\" href=\"#H38057037\">",
"       'Injury mechanism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blunt traumatic injuries that are highly associated (&gt;30 percent) with diaphragmatic injury include hemothorax, liver injury and splenic injury. Any penetrating mechanism found to involve organs on either side of the diaphragm is likely to be associated with a diaphragmatic injury. (See",
"      <a class=\"local\" href=\"#H38057331\">",
"       'Associated injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of injury and physical exam findings may suggest the need for additional studies beyond plain chest radiograph. Computed tomography (CT) is the primary imaging modality used to diagnose diaphragmatic injury. Features consistent with diaphragmatic injury on CT scan include discontinuity of the diaphragm, herniation of abdominal contents into the chest, abnormal positioning of the nasogastric tube, or other subtle findings. Alternative modalities include ultrasound or MRI. Small tears, particularly right-sided penetrating injuries, may not be identified by any imaging modality. (See",
"      <a class=\"local\" href=\"#H38055634\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic or thoracoscopic exploration may be appropriate to obtain a diagnosis (and an opportunity for repair) in the patient for whom a high index of suspicion for diaphragmatic injury persists in spite of negative imaging studies. (See",
"      <a class=\"local\" href=\"#H19492586\">",
"       'Management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All left-sided diaphragmatic injuries and most right-sided injuries should be repaired when recognized. Acute injuries of the diaphragm are repaired from the abdomen, often in conjunction with abdominal exploration to identify and repair other associated injuries. (See",
"      <a class=\"local\" href=\"#H19492586\">",
"       'Management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamically stable patients with a negative physical exam and imaging studies can be observed. Small right-sided diaphragmatic injuries in hemodynamically stable patients can be managed expectantly. Patients who are being observed should be monitored for signs or symptoms that suggest herniation. (See",
"      <a class=\"local\" href=\"#H19492586\">",
"       'Management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diaphragm is repaired primarily unless a large defect is present, in which case prosthetic materials are used provided there is no colonic contamination. (See",
"      <a class=\"local\" href=\"#H385765483\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall mortality associated with diaphragmatic injury is 25 percent primarily due to the presence of life-threatening chest or abdominal injury but can also result from complications of the injury itself. Complications of diaphragmatic injury include gastrointestinal herniation, pulmonary sequelae due to altered respiratory mechanics, diaphragm paralysis, and pleural fistula. Of these complications, gastrointestinal herniation contributes to mortality the most due to bowel ischemia and infarction. (See",
"      <a class=\"local\" href=\"#H19492669\">",
"       'Mortality'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H654387\">",
"       'Complications of diaphragmatic injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Trauma, 6, Feliciano, DV, Mattox, KL, Moore, EF (Eds), McGraw-Hill, 2008..",
"    </li>",
"    <li>",
"     National Trauma Data Base. American College of Surgeons 2000-2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/3\">",
"      Young RL, Page AJ, Cooper NJ, et al. Sensory and motor innervation of the crural diaphragm by the vagus nerves. Gastroenterology 2010; 138:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/4\">",
"      Hedblom, CA. Diaphragmatic hernia: A study of three hundred and seventy eight cases in which operation was performed. JAMA 1925; 85:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/5\">",
"      Rodriguez-Morales G, Rodriguez A, Shatney CH. Acute rupture of the diaphragm in blunt trauma: analysis of 60 patients. J Trauma 1986; 26:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/6\">",
"      Demetriades D, Kakoyiannis S, Parekh D, Hatzitheofilou C. Penetrating injuries of the diaphragm. Br J Surg 1988; 75:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/7\">",
"      Wiencek RG Jr, Wilson RF, Steiger Z. Acute injuries of the diaphragm. An analysis of 165 cases. J Thorac Cardiovasc Surg 1986; 92:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/8\">",
"      Williams M, Carlin AM, Tyburski JG, et al. Predictors of mortality in patients with traumatic diaphragmatic rupture and associated thoracic and/or abdominal injuries. Am Surg 2004; 70:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/9\">",
"      Bergin D, Ennis R, Keogh C, et al. The \"dependent viscera\" sign in CT diagnosis of blunt traumatic diaphragmatic rupture. AJR Am J Roentgenol 2001; 177:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/10\">",
"      May AK, Moore MM. Diagnosis of blunt rupture of the right hemidiaphragm by technetium scan. Am Surg 1999; 65:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/11\">",
"      Shanmuganathan K, Killeen K, Mirvis SE, White CS. Imaging of diaphragmatic injuries. J Thorac Imaging 2000; 15:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/12\">",
"      Feliciano DV, Cruse PA, Mattox KL, et al. Delayed diagnosis of injuries to the diaphragm after penetrating wounds. J Trauma 1988; 28:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/13\">",
"      Bhavnagri SJ, Mohammed TL. When and how to image a suspected broken rib. Cleve Clin J Med 2009; 76:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/14\">",
"      Blaivas M, Brannam L, Hawkins M, et al. Bedside emergency ultrasonographic diagnosis of diaphragmatic rupture in blunt abdominal trauma. Am J Emerg Med 2004; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/15\">",
"      Kim HH, Shin YR, Kim KJ, et al. Blunt traumatic rupture of the diaphragm: sonographic diagnosis. J Ultrasound Med 1997; 16:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/16\">",
"      Gangahar R, Doshi D. FAST scan in the diagnosis of acute diaphragmatic rupture. Am J Emerg Med 2010; 28:387.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/17\">",
"      Stein DM, York GB, Boswell S, et al. Accuracy of computed tomography (CT) scan in the detection of penetrating diaphragm injury. J Trauma 2007; 63:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/18\">",
"      Bodanapally UK, Shanmuganathan K, Mirvis SE, et al. MDCT diagnosis of penetrating diaphragm injury. Eur Radiol 2009; 19:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/19\">",
"      Iochum S, Ludig T, Walter F, et al. Imaging of diaphragmatic injury: a diagnostic challenge? Radiographics 2002; 22 Spec No:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/20\">",
"      Shanmuganathan K, Mirvis SE, White CS, Pomerantz SM. MR imaging evaluation of hemidiaphragms in acute blunt trauma: experience with 16 patients. AJR Am J Roentgenol 1996; 167:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/21\">",
"      Soyka JM, Martin M, Sloan EP, et al. Diagnostic peritoneal lavage: is an isolated WBC count greater than or equal to 500/mm3 predictive of intra-abdominal injury requiring celiotomy in blunt trauma patients? J Trauma 1990; 30:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/22\">",
"      Kamiyoshihara M, Ibe T, Takeyoshi I. Chilaiditi's sign mimicking a traumatic diaphragmatic hernia. Ann Thorac Surg 2009; 87:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/23\">",
"      Payne JH Jr, Yellin AE. Traumatic diaphragmatic hernia. Arch Surg 1982; 117:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/24\">",
"      Chen JC, Wilson SE. Diaphragmatic injuries: recognition and management in sixty-two patients. Am Surg 1991; 57:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/25\">",
"      Meyers BF, McCabe CJ. Traumatic diaphragmatic hernia. Occult marker of serious injury. Ann Surg 1993; 218:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/26\">",
"      Davies SJ. \"C3, 4, 5 Keeps the Diaphragm Alive.\" Is phrenic nerve palsy part of the pathophysiological mechanism in strangulation and hanging? Should diaphragm paralysis be excluded in survived cases?: A review of the literature. Am J Forensic Med Pathol 2010; 31:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/27\">",
"      Murray JA, Demetriades D, Cornwell EE 3rd, et al. Penetrating left thoracoabdominal trauma: the incidence and clinical presentation of diaphragm injuries. J Trauma 1997; 43:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/28\">",
"      Murray JA, Demetriades D, Asensio JA, et al. Occult injuries to the diaphragm: prospective evaluation of laparoscopy in penetrating injuries to the left lower chest. J Am Coll Surg 1998; 187:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/29\">",
"      Friese RS, Coln CE, Gentilello LM. Laparoscopy is sufficient to exclude occult diaphragm injury after penetrating abdominal trauma. J Trauma 2005; 58:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/30\">",
"      Ivatury RR, Simon RJ, Stahl WM. A critical evaluation of laparoscopy in penetrating abdominal trauma. J Trauma 1993; 34:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/31\">",
"      Ochsner MG, Rozycki GS, Lucente F, et al. Prospective evaluation of thoracoscopy for diagnosing diaphragmatic injury in thoracoabdominal trauma: a preliminary report. J Trauma 1993; 34:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/32\">",
"      Zellweger R, Navsaria PH, Hess F, et al. Transdiaphragmatic pleural lavage in penetrating thoracoabdominal trauma. Br J Surg 2004; 91:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/33\">",
"      Bender JS, Lucas CE. Management of close-range shotgun injuries to the chest by diaphragmatic transposition: case reports. J Trauma 1990; 30:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/34\">",
"      Edington HD, Evans S, Sindelar WF. Reconstruction of a functional hemidiaphragm with use of omentum and latissimus dorsi flaps. Surgery 1989; 105:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/35\">",
"      Kamiyoshihara M, Nagashima T, Ibe T, Takeyoshi I. Rupture of the diaphragm and pericardium with cardiac herniation after blunt chest trauma. Gen Thorac Cardiovasc Surg 2010; 58:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/22/28009/abstract/36\">",
"      Sullivan RE. Strangulation and obstruction in diaphragmatic hernia due to direct trauma. Report of two cases and review of the English literature. J Thorac Cardiovasc Surg 1966; 52:725.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15146 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28009=[""].join("\n");
var outline_f27_22_28009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19492683\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19492460\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43817542\">",
"      ANATOMY OF THE DIAPHRAGM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98788934\">",
"      Diaphragmatic injury severity scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38055088\">",
"      TRAUMA EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38056485\">",
"      RECOGNITION OF DIAPHRAGMATIC INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38057037\">",
"      Injury mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38056649\">",
"      - Penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38056656\">",
"      - Blunt diaphragmatic rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38057331\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38057468\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38057599\">",
"      - Delayed presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38055634\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38055642\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38055650\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38055658\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38055666\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43817177\">",
"      Diagnostic peritoneal lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38055673\">",
"      Diagnostic dilemmas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H654387\">",
"      COMPLICATIONS OF DIAPHRAGMATIC INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H654412\">",
"      Herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H654419\">",
"      Diaphragm paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H654426\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H654433\">",
"      Biliary fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19492586\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385765483\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86034093\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98788189\">",
"      Trauma laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98788336\">",
"      Use of mesh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98790511\">",
"      Managing cardiac herniation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19492669\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19492683\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15146|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/30/18912\" title=\"diagnostic image 1\">",
"      Barium enema traumatic diaphragmatic hernia of colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/21/26966\" title=\"diagnostic image 2\">",
"      Chronic traumatic disruption of the left hemidiaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/14/8418\" title=\"diagnostic image 3\">",
"      Plain chest radiograph of diaphragmatic injury with herniation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/3/17457\" title=\"diagnostic image 4\">",
"      Chest radiograph with rupture of the left hemidiaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/47/24310\" title=\"diagnostic image 5\">",
"      Traumatic diaphragmatic hernia on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/25/3473\" title=\"diagnostic image 6\">",
"      Diaphragmatic injury with left hemidiaphragm discontinuity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/8/20609\" title=\"diagnostic image 7\">",
"      Traumatic disruption of the diaphragm on plain film and CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15146|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/27/32184\" title=\"figure 1\">",
"      Anatomy and innervation of the diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/29/16857\" title=\"figure 2\">",
"      Surfaces of the diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/21/16725\" title=\"figure 3\">",
"      Left phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17061\" title=\"figure 4\">",
"      Right phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/19/22836\" title=\"figure 5\">",
"      Thoracic dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/61/3029\" title=\"figure 6\">",
"      Diaphragm plication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=related_link\">",
"      Causes and diagnosis of bilateral diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28247?source=related_link\">",
"      Initial evaluation and management of chest wall trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=related_link\">",
"      Inpatient management of traumatic rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=related_link\">",
"      Surgical management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=related_link\">",
"      Treatment of diaphragmatic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_22_28010="Anticancer agents Potential for interaction with antiretrovirals";
var content_f27_22_28010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticancer agents: Potential for interaction with antiretroviral agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anticancer drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route of elimination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on CYP450/transporters",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect of ARVs on cancer drugs as a substrate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alteration to ARVs due to enzyme or transporter induction or inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Alkylating agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bendamustine",
"        <sup>",
"         [1, 2]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Busulfan",
"        <sup>",
"         [3, 4, 11]",
"        </sup>",
"       </td>",
"       <td>",
"        Glutathione S-transferase, CYP3A4",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carmustine",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlorambucil",
"        <sup>",
"         [6-8, 11]",
"        </sup>",
"       </td>",
"       <td>",
"        ABCC1, ABCC2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclophosphamide",
"        <sup>",
"         [9-11, 16, 167, 168]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4/5",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2B6, CYP2C8, CYP2C9",
"        </p>",
"        <p>",
"         Inhibitor: CYP3A4, UGT*",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dacarbazine",
"        <sup>",
"         [12]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2 , CYP2E1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estramustine",
"        <sup>",
"         [13]",
"        </sup>",
"       </td>",
"       <td>",
"        Alkaline phosphatase",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ifosfamide",
"        <sup>",
"         [9, 11, 14-17]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP3A4/5",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2C8, CYP2C9",
"        </p>",
"        <p>",
"         Inhibitor: CYP3A4",
"        </p>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lomustine",
"        <sup>",
"         [18-20]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2D6",
"       </td>",
"       <td>",
"        Inhibitor: CYP2D6, CYP3A4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mechlorethamine",
"        <sup>",
"         [21]",
"        </sup>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melphalan",
"        <sup>",
"         [8, 22]",
"        </sup>",
"       </td>",
"       <td>",
"        Chemical hydrolysis, ABCC1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Procarbazine",
"        <sup>",
"         [23]",
"        </sup>",
"       </td>",
"       <td>",
"        Auto-oxidation",
"       </td>",
"       <td>",
"        Inhibitor: monoamine oxidase",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptozocin",
"        <sup>",
"         [24]",
"        </sup>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temozolomide",
"        <sup>",
"         [25-27]",
"        </sup>",
"       </td>",
"       <td>",
"        Hydrolysis, ABCB1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thiotepa",
"        <sup>",
"         [28-31]",
"        </sup>",
"       </td>",
"       <td>",
"        Glutathione S-transferase, CYP2B6, CYP3A4/5",
"       </td>",
"       <td>",
"        Inhibitor: CYP2B6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Anthracyclines/anthracenedione",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daunorubicin",
"        <sup>",
"         [8, 32, 33, 37]",
"        </sup>",
"       </td>",
"       <td>",
"        Aldoketoreductase, NADPH-dependent cytochrome reductase, ABCB1, ABCC1, ABCG2",
"       </td>",
"       <td>",
"        Inducer: ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxorubicin",
"        <sup>",
"         [8, 11, 16, 18, 19, 32-35, 37]",
"        </sup>",
"       </td>",
"       <td>",
"        Aldoketoreductase, NADPH-dependent cytochrome reductase, CYP2D6, CYP3A4, ABCB1, ABCC1, ABCC2, ABCG2, SLC22A16",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: ABCB1",
"        </p>",
"        <p>",
"         Inhibitor: CYP2B6, CYP2D6, CYP3A4",
"        </p>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epirubicin",
"        <sup>",
"         [8, 11, 33, 36, 37]",
"        </sup>",
"       </td>",
"       <td>",
"        Aldoketoreductase, NADPH-dependent cytochrome reductase, ABCG2",
"       </td>",
"       <td>",
"        Inducer: ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idarubicin",
"        <sup>",
"         [37, 38]",
"        </sup>",
"       </td>",
"       <td>",
"        Aldoketoreductase, NADPH-dependent cytochrome reductase, ABCB1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitoxantrone",
"        <sup>",
"         [8, 20, 39]",
"        </sup>",
"       </td>",
"       <td>",
"        ABCB1, ABCG2",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2E1",
"        </p>",
"        <p>",
"         Inhibitor: CYP3A4",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Antiandrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abiraterone",
"        <sup>",
"         [173]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, SULT2A1",
"       </td>",
"       <td>",
"        Inhibitor: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP2D6, ABCB1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Antitumor antibiotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleomycin",
"        <sup>",
"         [11, 40]",
"        </sup>",
"       </td>",
"       <td>",
"        Non-enzymatic",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dactinomycin",
"        <sup>",
"         [41]",
"        </sup>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitomycin C",
"        <sup>",
"         [11, 42, 43]",
"        </sup>",
"       </td>",
"       <td>",
"        NADPH-dependent cytochrome reductase, xanthine oxidase, ABCB1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Antimetabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Capecitabine",
"        <sup>",
"         [16, 44, 45, 56]",
"        </sup>",
"       </td>",
"       <td>",
"        Carboxylesterases, Cytidine deaminase, Dihydropyrimidine dehydrogenase, Thymidine phosphorylase",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C9",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cladribine",
"        <sup>",
"         [47]",
"        </sup>",
"       </td>",
"       <td>",
"        Deoxycytidine kinase, 5'-nucleotidase",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clofarabine",
"        <sup>",
"         [46, 49, 50]",
"        </sup>",
"       </td>",
"       <td>",
"        Deoxycytidine kinase, 5'-nucleotidase, ABCG2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytarabine",
"        <sup>",
"         [11, 51-53]",
"        </sup>",
"       </td>",
"       <td>",
"        Cytidine deaminase, Deoxycytidine kinase, 5'-nucleotidase",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fludarabine",
"        <sup>",
"         [48, 54]",
"        </sup>",
"       </td>",
"       <td>",
"        Deoxycytidine kinase, 5'-nucleotidase",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5-Fluorouracil",
"        <sup>",
"         [11, 16, 45, 52, 55, 56]",
"        </sup>",
"       </td>",
"       <td>",
"        Dihydropyrimidine dehydrogenase, ABCC4, ABCG2, SLC22A7",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C9",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gemcitabine",
"        <sup>",
"         [16. 57, 58]",
"        </sup>",
"       </td>",
"       <td>",
"        Cytidine deaminase, Cytidylate kinase Deoxycytidylate deaminase, Deoxycytidine kinase, SLC28A1, SLC28A3, SLC29A1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxyurea",
"        <sup>",
"         [59]",
"        </sup>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-Mercaptopurine",
"        <sup>",
"         [11, 16, 60-63]",
"        </sup>",
"       </td>",
"       <td>",
"        Thiopurine methyltransferase, ABCC4, SLC28A2, SLC28A3, SLC29A1, SLC29A2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"        <sup>",
"         [8, 11, 16, 64-69]",
"        </sup>",
"       </td>",
"       <td>",
"        ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCG2, SLC19A1, SLC22A6, SLC22A8, SLC46A1, SLCO1A2, SLCO1B1, SLCO1B3",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nelarabine",
"        <sup>",
"         [70]",
"        </sup>",
"       </td>",
"       <td>",
"        Adenosine deaminase",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pemetrexed",
"        <sup>",
"         [71, 72]",
"        </sup>",
"       </td>",
"       <td>",
"        Non-enzymatic, SLC22A8",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pentostatin",
"        <sup>",
"         [73]",
"        </sup>",
"       </td>",
"       <td>",
"        Non-enzymatic",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-Thioguanine",
"        <sup>",
"         [16, 61, 62, 64]",
"        </sup>",
"       </td>",
"       <td>",
"        Thiopurine methyltransferase, ABCC4",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Antimicrotubular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cabazitaxel",
"        <sup>",
"         [74]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C8, CYP3A4/5, ABCB1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Docetaxel",
"        <sup>",
"         [8, 11, 16, 75-79]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1B1, CYP3A4/5, ABCB1, ABCC1, ABCC2, ABCG2, SLCO1B3",
"       </td>",
"       <td>",
"        Inhibitor: CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eribulin",
"        <sup>",
"         [80, 81]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, SLCO1B3",
"       </td>",
"       <td>",
"        Inhibitor: CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ixabepilone",
"        <sup>",
"         [82]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paclitaxel",
"        <sup>",
"         [8, 11, 16, 75, 77,&nbsp;79, 83, 84]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1B1, CYP2C8, CYP3A4, ABCB1, ABCC1, ABCC2, ABCG2, SLCO1B3",
"       </td>",
"       <td>",
"        Inducer: CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Aromatase inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anastrozole",
"        <sup>",
"         [85, 86]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C8, CYP2C9, CYP3A4/5, UGT1A4",
"       </td>",
"       <td>",
"        Inhibitor: CYP1A2, CYP2C8, CYP2C9, CYP3A4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exemestane",
"        <sup>",
"         [87, 88]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A1/2, CYP3A4, CYP4A11, Aldoketoreductase",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Letrozole",
"        <sup>",
"         [89, 90]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2A6, CYP3A4",
"       </td>",
"       <td>",
"        Inhibitor: CYP2A6, CYP2C19",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Camptothecins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Irinotecan",
"        <sup>",
"         [16, 91-94]",
"        </sup>",
"       </td>",
"       <td>",
"        Carboxylesterase, CYP2B6, CYP3A4/5, UGT1A1, UGT1A9, ABCB1, ABCC1, ABCC2, ABCG2, SLCO1B1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Topotecan",
"        <sup>",
"         [8, 95, 96]",
"        </sup>",
"       </td>",
"       <td>",
"        Non-enzymatic, CYP3A4, UGT*, ABCB1, ABCC4, ABCG2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        DNA methylation inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azacitidine",
"        <sup>",
"         [174, 175]",
"        </sup>",
"       </td>",
"       <td>",
"        Hydrolysis",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Epipodophyllotoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etoposide",
"        <sup>",
"         [8, 11, 16, 19, 97-101]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, CYP2E1, CYP3A4/5, UGT1A1, ABCB1, ABCC1, ABCC3",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C9, CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Teniposide",
"        <sup>",
"         [8, 11, 19, 99, 102]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C9, CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Estrogen receptor antagonist; selective estrogen receptor modulator (SERM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fulvestrant",
"        <sup>",
"         [103]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tamoxifen",
"        <sup>",
"         [16, 104-112]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A1/2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, SULT*, UGT*",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP3A4",
"        </p>",
"        <p>",
"         Inhibitor: CYP2B, CYP2C8, CYP2C9, CYP3A4, ABCB1",
"        </p>",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Hedgehog inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vismodegib",
"        <sup>",
"         [178-181]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C9, CYP3A4/5, ABCB1",
"       </td>",
"       <td>",
"        Inhibitors: CYP2C8, CYP2C9, CYP2C19, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Histone deacetylase inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Romidepsin",
"        <sup>",
"         [113-115]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A1, CYP2B6, CYP2C19, CYP3A4/5, ABCB1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vorinostat",
"        <sup>",
"         [117, 118]",
"        </sup>",
"       </td>",
"       <td>",
"        Hydrolysis, UGT*1A8, UGT1A9, UGT1A10, UGT2B17",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arsenic trioxide",
"        <sup>",
"         [116]",
"        </sup>",
"       </td>",
"       <td>",
"        Methylation",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asparaginase",
"        <sup>",
"         [120]",
"        </sup>",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitotane",
"        <sup>",
"         [176]",
"        </sup>",
"       </td>",
"       <td>",
"        Not determined",
"       </td>",
"       <td>",
"        Inducer: CYP3A4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tretinoin",
"        <sup>",
"         [119,121-122,177]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A1, CYP2C8, CYP2C9, CYP3A4/7",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2E1",
"        </p>",
"        <p>",
"         Inhibitor: CYP1A1, CYP2C9, CYP2C19",
"        </p>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        mTOR inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Everolimus",
"        <sup>",
"         [123, 124]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C8, CYP3A4/5, ABCB1",
"       </td>",
"       <td>",
"        Inhibitor: CYP2D6, CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temsirolimus",
"        <sup>",
"         [125-128]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        Inhibitor: CP2D6, CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Platinums",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carboplatin",
"        <sup>",
"         [11,129]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal, ATP7A, ATP7B, SLC31A1, SLC31A2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cisplatin",
"        <sup>",
"         [11,16,129-131]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal, ABCC1, ABCC2, ATP7A, ATP7B, SLC22A1, SLC22A2, SLC31A1, SLC31A2, SLC47A1",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxaliplatin",
"        <sup>",
"         [16, 129,131]",
"        </sup>",
"       </td>",
"       <td>",
"        Renal, SLC22A1, SLC22A2, SLC47A1, SLC47A2",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Proteasome inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bortezomib",
"        <sup>",
"         [132, 133]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4",
"       </td>",
"       <td>",
"        Inhibitor: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Kinase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Axitinib",
"        <sup>",
"         [182, 186]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, CYP2C19, CYP3A4/5, UGT1A1, ABCB1, SLCO1B1",
"       </td>",
"       <td>",
"        Inhibitor: CYP1A2, CYP2C8, ABCB1, SLCO1B1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crizotinib",
"        <sup>",
"         [134]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4/5, ABCB1",
"       </td>",
"       <td>",
"        Inhibitor: CYP3A4, ABCB1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dasatinib",
"        <sup>",
"         [135-137]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, FMO3, UGT*, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: CYP3A4, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erlotinib",
"        <sup>",
"         [16, 138-142]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A1/2, CYP3A4/5, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C8, UGT1A1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gefitinib",
"        <sup>",
"         [16,139,140,143-145]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A1, CYP2D6, CYP3A4/5, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C19, CYP2D6, UGT1A1, UGT1A7, UGT1A9, UGT2B7, ABCG2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imatinib",
"        <sup>",
"         [16,136,146-148]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C9, CYP2D6, CYP3A4, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lapatinib",
"        <sup>",
"         [149]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP2C8, CYP2C19, CYP3A4/5, ABCB1",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C8, CYP3A4, ABCB1, ABCG2, SLCO1B1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nilotinib",
"        <sup>",
"         [136, 150, 151]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP2B6, CYP2C8, CYP2C9",
"        </p>",
"        <p>",
"         Inhibitor: CYP2C8, CYP2C9, CYP2D6, CYP3A4, UGT1A1, ABCB1, ABCG2",
"        </p>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pazopanib",
"        <sup>",
"         [152, 153]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, CYP2C8, CYP3A4, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: CYP2C8, CYP2D6, CYP3A4, UGT1A1, SLCO1B1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sorafenib",
"        <sup>",
"         [154-156]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, UGT1A9, ABCG2",
"       </td>",
"       <td>",
"        Inhibitor: CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A9, ABCB1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sunitinib",
"        <sup>",
"         [157-160]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        Inhibitor: ABCB1, ABCG2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vandetanib",
"        <sup>",
"         [161-163]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, FMO1, FMO3, UGT*",
"       </td>",
"       <td>",
"        Inhibitor: ABCB1, ABCGG2, SLC22A2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vemurafenib",
"        <sup>",
"         [164, 165]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, ABCG2",
"       </td>",
"       <td>",
"        <p>",
"         Inducer: CYP3A4",
"        </p>",
"        <p>",
"         Inhibitor: CYP1A2, CYP2D6, ABCB1",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vinca alkaloids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vinblastine",
"        <sup>",
"         [8, 11, 18, 19, 166]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4, ABCB1, ABCC2",
"       </td>",
"       <td>",
"        <p>",
"         Inhibitor: CYP2D6, CYP3A4",
"        </p>",
"        <p>",
"         Inducer: ABCB1",
"        </p>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vincristine",
"        <sup>",
"         [8, 11, 16, 169-170]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4/5, ABCB1, ABCC1, ABCC2, ABCC3, ABCC10",
"       </td>",
"       <td>",
"        Inhibitor: CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vinorelbine",
"        <sup>",
"         [18, 171, 172]",
"        </sup>",
"       </td>",
"       <td>",
"        CYP3A4",
"       </td>",
"       <td>",
"        Inhibitor: CYP2D6, CYP3A4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    DDI potential code and clinical relevance:",
"    <br/>",
"    1) Interaction unlikely or known minor interaction not requiring modification to therapy.",
"    <br/>",
"    2) Possible interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity.",
"    <br/>",
"    3) Potential for significant interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity. Consider therapy modification if unable to monitor closely.",
"    <br/>",
"    4) Potential for clinically significant interaction based on pharmacology of the drug or known interaction. Need for dose adjustment or consideration of therapy modification.",
"    <br/>",
"    5) Major clinically significant interaction or potential critical interaction. Co-administration is contraindicated.",
"    <div class=\"footnotes\">",
"     <p>",
"      ABC: ATP-binding cassette sub-family/member; ALDH: alcohol dehydrogenase; ATP: copper- and platinum drug-efflux transporters;CYP: cytochrome P450; FMO: flavin-containing monooxygenase; SLC: sodium-coupled nucleoside transport family/member; SLCO: solute carrier organic anion transporter family/member; SULT: sulfotransferase;UGT: uridine 5'-diphospho-glucuronosyltransferase.",
"      <br>",
"       <br>",
"        * Isozyme not specified.",
"       </br>",
"      </br>",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      1. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59:759.",
"      <br>",
"       2. Cephalon Inc. Treanda (bendamustine HCl) for injection package insert: prescribing information. Frazer, PA 2010.",
"       <br>",
"        3. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56:3678.",
"        <br>",
"         4. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36:525.",
"         <br>",
"          5. Bedford Laboratories. BiCNU (carmustine for injection) package insert: prescribing information. Bedford, Ohio 1998.&nbsp;&nbsp;",
"          <br>",
"           6. Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 2004; 308:260.",
"           <br>",
"            7. GlaxoSmithKline. LEUKERAN (chlorambucil) tablets package insert. Research Triangle Park, NC 2006.",
"            <br>",
"             8. Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6:71.",
"             <br>",
"              9. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629.",
"              <br>",
"               10. Lindley C, Hamilton G, McCune JS, et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 2002; 30:814.",
"               <br>",
"                11. Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39:517.",
"                <br>",
"                 12. Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999; 5:2192.",
"                 <br>",
"                  13. Tritsch GL, Shukla SK, Mittelman A, Murphy GP. Estracyt (NSC 89199) as a substrate for phosphatases in human serum. Invest Urol 1974; 12:38.",
"                  <br>",
"                   14. Granvil CP, Madan A, Sharkawi M, et al. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999; 27:533.",
"                   <br>",
"                    15. Walker D, Flinois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994; 47:1157.",
"                    <br>",
"                     16. McDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011; 5(6); 795-806.",
"                     <br>",
"                      17. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Ifosfamide Pathway, Pharmacokinetics. Available at:",
"                      <a href=\"file://www.pharmgkb.org/pathway/PA2037\">",
"                       file://www.pharmgkb.org/pathway/PA2037",
"                      </a>",
"                      . Accessed 06/19/12.",
"                      <br>",
"                       18. Le Guellec C, Lacarelle B, Catalin J, Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol 1993; 32:491.",
"                       <br>",
"                        19. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53:5121.",
"                        <br>",
"                         20. Zhou XJ, Zhou-Pan XR, Gauthier T, et al. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 1993; 45:853.",
"                         <br>",
"                          21. Lundbeck Inc., Trituration of Mustargen (mechlorethamine HCl for injection) Rx only: prescribing information. Deerfield, IL 2009.",
"                          <br>",
"                           22. Celgene. Alkeran (melphalan) Tablets Prescribing Information. Warren, NJ 2004.",
"                           <br>",
"                            23. Sigma-Tau Pharmaceuticals Inc. MATULANE brand of procarbazine hydrochloride capsules prescribing information. Gaithersburg, MD 2004.",
"                            <br>",
"                             24. Teva Parenteral Medicines, Inc. Zanosar (streptozocin sterile powder) package insert. Irvine, CA 2007.",
"                             <br>",
"                              25. Merck &amp; Co. Inc. TEMODAR (temozolomide) Prescribing Information. Whitehouse Station, NJ 2011.",
"                              <br>",
"                               26. Tsang LL, Quarterman, CP Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27:342.",
"                               <br>",
"                                27. Schaich M, Kestel L, Pfirrmann M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009 20(1): 175-81.",
"                                <br>",
"                                 28. Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002; 49:461.",
"                                 <br>",
"                                  29. Dirven HA, Dictus EL, Broeders, NL, et al. The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res 1995; 55:1701.",
"                                  <br>",
"                                   30. Turpeinen M, Nieminen R, Juntunen T, et al. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626.",
"                                   <br>",
"                                    31. Ekhart C, Doodeman VD, Rodenhuis S, et al. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol. 2009 67(1):50-60.",
"                                    <br>",
"                                     32. Loveless H, Arena E, Felsted RL, Bachur NR. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978; 38:593.",
"                                     <br>",
"                                      33. Le Bot MA, Glaise D, Kernaleguen D, et al. Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells. Pharmacol Res 1991; 24:243.",
"                                      <br>",
"                                       34. Mercier C, Decleves X, Masseguin C, et al. P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes. J Neurochem 2003; 87:820.",
"                                       <br>",
"                                        35. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Doxorubicin Pathway, Pharmacokinetics. Available at:",
"                                        <a href=\"file://www.pharmgkb.org/pathway/PA165292177\">",
"                                         file://www.pharmgkb.org/pathway/PA165292177",
"                                        </a>",
"                                        . Accessed 06/19/12.",
"                                        <br>",
"                                         36. Pfizer. Ellence (epirubicin hydrochloride injection) U.S. physician prescribing information. New York, NY 2007.",
"                                         <br>",
"                                          37. Hargrave RM, Davey MW, Davey RA, Kidman AD. Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs 1995; 6:432.",
"                                          <br>",
"                                           38. Gillies HC, Herriott D, Liang R, et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23:303.",
"                                           <br>",
"                                            39. Hospira. MitoXANTRONE injection, USP (concentrate) prescribing information. Lake Forest, IL 2007.",
"                                            <br>",
"                                             40. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19:3.",
"                                             <br>",
"                                              41. Tattersall MH, Sodergren JE, Dengupta SK, et al. Pharmacokinetics of actinoymcin D in patients with malignant melanoma. Clin Pharmacol Ther 1975; 17:701.",
"                                              <br>",
"                                               42. Pan SS, Andrews PA, Glover CJ, Bachur NR. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 1984; 259:959.",
"                                               <br>",
"                                                43. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993; 62:385-427.",
"                                                <br>",
"                                                 44. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40:85.",
"                                                 <br>",
"                                                  45. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Fluoropyrimidine Pathway, Pharmacokinetics. Available at:",
"                                                  <a href=\"file://www.pharmgkb.org/pathway/PA150653776\">",
"                                                   file://www.pharmgkb.org/pathway/PA150653776",
"                                                  </a>",
"                                                  . Accessed 06/19/12.",
"                                                  <br>",
"                                                   46. Genzyme Corporation. Clolar&reg; (clofarabine) injection for intravenous use prescribing information. Cambridge, MA 2010.",
"                                                   <br>",
"                                                    47. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81:597.",
"                                                    <br>",
"                                                     48. Genzyme Corporation. Fludara&reg; (fludarabine phosphate) injection for intravenous use prescribing information. Cambridge, MA 2007.",
"                                                     <br>",
"                                                      49. Nagai S, Takenaka K, Nachagari D, et al. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 2011; 71:1781.",
"                                                      <br>",
"                                                       50. Bonate PL, Arthaud L, Cantrell WR, Jr., et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006; 5:855.",
"                                                       <br>",
"                                                        51. Bedford Laboratories. CYTARABINE injection, powder, lyophilized, for solution: prescribing information. Bedford, Ohio 2008.",
"                                                        <br>",
"                                                         52. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47:131.",
"                                                         <br>",
"                                                          53. Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol. 1989 7(5):622-8.",
"                                                          <br>",
"                                                           54. Brockman RW, Cheng YC, Schabel FM, Jr., Montgomery JA. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 1980; 40:3610.",
"                                                           <br>",
"                                                            55. Shiotani T, Weber G. Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem 1981; 256:219.",
"                                                            <br>",
"                                                             56. Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol 2006; 98:197.",
"                                                             <br>",
"                                                              57. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41:77.",
"                                                              <br>",
"                                                               58. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Gemcitabine Pathway, Pharmacodynamics. Available at:",
"                                                               <a href=\"file://www.pharmgkb.org/pathway/PA2036\">",
"                                                                file://www.pharmgkb.org/pathway/PA2036",
"                                                               </a>",
"                                                               . Accessed 06/19/12.",
"                                                               <br>",
"                                                                59. Bristol-Myers Squibb Company. DROXIA (hydroxyurea capsules, USP) prescribing information. Princeton, NJ 2011.",
"                                                                <br>",
"                                                                 60. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651.",
"                                                                 <br>",
"                                                                  61. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276:33747.",
"                                                                  <br>",
"                                                                   62. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64:753.",
"                                                                   <br>",
"                                                                    63. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. Available at:",
"                                                                    <a href=\"file://www.pharmgkb.org/pathway/PA2040\">",
"                                                                     file://www.pharmgkb.org/pathway/PA2040",
"                                                                    </a>",
"                                                                    #. Accessed 06/19/12.",
"                                                                    <br>",
"                                                                     64. Ifergan I, Shafran A, Jansen G, et al. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 2004; 279:25527.",
"                                                                     <br>",
"                                                                      65. Vlaming ML, van Esch A, Pala Z, et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 2009; 8:3350.",
"                                                                      <br>",
"                                                                       66. Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120:1689.",
"                                                                       <br>",
"                                                                        67. Mikkelsen TS, Thorn CF, Yang JJ, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011 21(10):679-86.",
"                                                                        <br>",
"                                                                         68. Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 9;101(10):3569-74.",
"                                                                         <br>",
"                                                                          69. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Methotrexate Pathway, Pharmacokinetics. Available at:",
"                                                                          <a href=\"file://www.pharmgkb.org/pathway/PA165816349\">",
"                                                                           file://www.pharmgkb.org/pathway/PA165816349",
"                                                                          </a>",
"                                                                          . Accessed 06/19/12.",
"                                                                          <br>",
"                                                                           70. GlaxoSmithKline. ARRANON (nelarabine) injection prescribing information. Research Triangle Park, NC 2009.",
"                                                                           <br>",
"                                                                            71. Sorensen, JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011; 7:919.",
"                                                                            <br>",
"                                                                             72. Lilly USA, LLC. ALIMTA (pemetrexed for injection) lyophilized powder, for solution for intravenous use prescribing information. Indianapolis, IN 2012.",
"                                                                             <br>",
"                                                                              73. Bedford Laboratories. PENTOSTATIN for injection package insert: prescribing information. Bedford, OH 2006.",
"                                                                              <br>",
"                                                                               74. Sanofi Aventis LLC, USA. JEVTANA&reg; (cabazitaxel) injection prescribing information. Bridgewater, NJ 2010.",
"                                                                               <br>",
"                                                                                75. Nallani SC, Goodwin B, Buckley AR, et al. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004; 54:219.",
"                                                                                <br>",
"                                                                                 76. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56:1296.",
"                                                                                 <br>",
"                                                                                  77. Smith NF, Acharya MR, Desai N, et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4:815.",
"                                                                                  <br>",
"                                                                                   78. Koolen SL, Oostendorp RL, Beijnen JH, et al. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010; 69:465.",
"                                                                                   <br>",
"                                                                                    79. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Taxane Pathway, Pharmacokinetics. Available at:",
"                                                                                    <a href=\"file://www.pharmgkb.org/pathway/PA154426155\">",
"                                                                                     file://www.pharmgkb.org/pathway/PA154426155",
"                                                                                    </a>",
"                                                                                    . Accessed 06/19/12.",
"                                                                                    <br>",
"                                                                                     80. Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin-A review of preclinical and clinical studies. Crit Rev Oncol Hematol 2011.",
"                                                                                     <br>",
"                                                                                      81. Zhang ZY, King BM, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 62(4):707-16.",
"                                                                                      <br>",
"                                                                                       82. Bristol-Myers Squibb Company. IXEMPRA&reg; Kit (ixabepilone) for injection prescribing information. Princeton, NJ 2010.",
"                                                                                       <br>",
"                                                                                        83. Desai PB, Duan JZ, Zhu YW, Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998; 23:417.",
"                                                                                        <br>",
"                                                                                         84. Cianfrocca M, Lee S, Von Roenn J, et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol 2011.",
"                                                                                         <br>",
"                                                                                          85. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 1997; 25:598.",
"                                                                                          <br>",
"                                                                                           86. Kamdem LK, Liu Y, Stearns V, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010; 70:854.",
"                                                                                           <br>",
"                                                                                            87. Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011; 39:98.",
"                                                                                            <br>",
"                                                                                             88. Pfizer. AROMASIN&reg; (exemestane) tablets, oral prescribing information. New York, NY 2011.",
"                                                                                             <br>",
"                                                                                              89. Murai K, Yamazaki H, Nakagawa K, et al. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009; 39:795.",
"                                                                                              <br>",
"                                                                                               90. Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 2009; 64:867.",
"                                                                                               <br>",
"                                                                                                91. Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 2010; 5:209.",
"                                                                                                <br>",
"                                                                                                 92. Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008; 83:601.",
"                                                                                                 <br>",
"                                                                                                  93. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6:2012.",
"                                                                                                  <br>",
"                                                                                                   94. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Irinotecan Pathway, Pharmacokinetics. Available at:",
"                                                                                                   <a href=\"file://www.pharmgkb.org/pathway/PA2001\">",
"                                                                                                    file://www.pharmgkb.org/pathway/PA2001",
"                                                                                                   </a>",
"                                                                                                   . Accessed 06/19/12.",
"                                                                                                   <br>",
"                                                                                                    95. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24:7612.",
"                                                                                                    <br>",
"                                                                                                     96. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998; 4:783.",
"                                                                                                     <br>",
"                                                                                                      97. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998; 286:1294.",
"                                                                                                      <br>",
"                                                                                                       98. Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 2010; 16:130.",
"                                                                                                       <br>",
"                                                                                                        99. Relling MV, Nemec J, Schuetz EG, et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45:352.",
"                                                                                                        <br>",
"                                                                                                         100. Yang J, Bogni A, Schuetz EG, et al. Etoposide pathway. Pharmacogenet Genomics. 2009 19(7):552-3.",
"                                                                                                         <br>",
"                                                                                                          101. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Etoposide Pathway, Pharmacokinetics/Pharmacodynamics. Available at:",
"                                                                                                          <a href=\"file://www.pharmgkb.org/pathway/PA2025\">",
"                                                                                                           file://www.pharmgkb.org/pathway/PA2025",
"                                                                                                          </a>",
"                                                                                                          . Accessed 06/19/12.",
"                                                                                                          <br>",
"                                                                                                           102. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252:442.",
"                                                                                                           <br>",
"                                                                                                            103. Astra-Zeneca. FASLODEX&reg; (fulvestrant) injection prescribing information. Wilmington, DE 2011.",
"                                                                                                            <br>",
"                                                                                                             104. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53:171.",
"                                                                                                             <br>",
"                                                                                                              105. Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30:869.",
"                                                                                                              <br>",
"                                                                                                               106. Coller JK, Krebsfaenger N, Klein K, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54:157.",
"                                                                                                               <br>",
"                                                                                                                107. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002; 30:608.",
"                                                                                                                <br>",
"                                                                                                                 108. Zhao XJ, Jones DR, Wang YH, et al. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32:863.",
"                                                                                                                 <br>",
"                                                                                                                  109. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 45(1):68-78.",
"                                                                                                                  <br>",
"                                                                                                                   110. Boruban MC, Yasar U, Babaoglu MO, Sencan O, et al. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 18(4):421-4.",
"                                                                                                                   <br>",
"                                                                                                                    111. Sridar C, Kent UM, Notley LM, Gillam EM, et al. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 301(3):945-52.",
"                                                                                                                    <br>",
"                                                                                                                     112. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Tamoxifen Pathway, Pharmacokinetics. Available at:",
"                                                                                                                     <a href=\"file://www.pharmgkb.org/pathway/PA145011119\">",
"                                                                                                                      file://www.pharmgkb.org/pathway/PA145011119",
"                                                                                                                     </a>",
"                                                                                                                     . Accessed 06/19/12.",
"                                                                                                                     <br>",
"                                                                                                                      113. Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005; 28:124.",
"                                                                                                                      <br>",
"                                                                                                                       114. Celgene Corporation. ISTODAX&reg; (romidepsin) for injection Prescribing Information. Summit, NJ 2011.",
"                                                                                                                       <br>",
"                                                                                                                        115. Iwamoto FM, Lamborn KR, Kuhn JG, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 13(5):509-16.",
"                                                                                                                        <br>",
"                                                                                                                         116. Cephalon Inc. TRISENOX&reg; (arsenic trioxide) injection prescribing information. Frazer, PA 2010.",
"                                                                                                                         <br>",
"                                                                                                                          117. Merck &amp; Co., ZOLINZA&reg; (vorinostat) capsules prescribing information. Whitehouse Station, NJ 2009.",
"                                                                                                                          <br>",
"                                                                                                                           118. Balliet RM, Chen G, Gallagher CJ, et al. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res. 2009 1;69(7):2981-9.",
"                                                                                                                           <br>",
"                                                                                                                            119. McSorley LC, Daly AK. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 2000; 60:517.",
"                                                                                                                            <br>",
"                                                                                                                             120. Lundbeck Inc., ELSPAR&reg; (asparaginase) for injection, intravenous or intramuscular prescribing information. Deerfield, IL 2010.",
"                                                                                                                             <br>",
"                                                                                                                              121. Yamazaki H, Shimada T. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 1999; 29:231.",
"                                                                                                                              <br>",
"                                                                                                                               122. Adedoyin A, Stiff DD, Smith DC, et al. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 1998; 41:133.",
"                                                                                                                               <br>",
"                                                                                                                                123. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43:83.",
"                                                                                                                                <br>",
"                                                                                                                                 124. Novartis Pharmaceuticals Corporation. AFINITOR (everolimus) tablets for oral administration prescribing information. East Hanover, NJ 2011.",
"                                                                                                                                 <br>",
"                                                                                                                                  125. Pfizer. TORISEL Kit (temsirolimus) injection prescribing information. Philadelphia, PA 2011.",
"                                                                                                                                  <br>",
"                                                                                                                                   126. Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009; 64:263.",
"                                                                                                                                   <br>",
"                                                                                                                                    127. Boni JP, Leister C, Burns J, Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008; 98:1797.",
"                                                                                                                                    <br>",
"                                                                                                                                     128. Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr. 2012 15;59(5):447-54.",
"                                                                                                                                     <br>",
"                                                                                                                                      129. Burger H, Loos WJ, Eechoute K, et al. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 2011.",
"                                                                                                                                      <br>",
"                                                                                                                                       130. Sprowl JA, Gregorc V, Lazzari C, et al. Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy. Clin Pharmacol Ther. 2012 25. doi: 10.1038/clpt.2011.330. [Epub ahead of print].",
"                                                                                                                                       <br>",
"                                                                                                                                        131. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Platinum Pathway, Pharmacokinetics/Pharmacodynamics. Available at:",
"                                                                                                                                        <a href=\"file://www.pharmgkb.org/pathway/PA150642262\">",
"                                                                                                                                         file://www.pharmgkb.org/pathway/PA150642262",
"                                                                                                                                        </a>",
"                                                                                                                                        . Accessed 06/19/12.",
"                                                                                                                                        <br>",
"                                                                                                                                         132. Venkatakrishnan K, Rader M, Ramanathan RK, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009; 31 Pt 2:2444.",
"                                                                                                                                         <br>",
"                                                                                                                                          133. Millennium Pharmaceuticals, Inc. VELCADE&reg; (bortezomib) for injection prescribing information. Cambridge, MA 2010.",
"                                                                                                                                          <br>",
"                                                                                                                                           134. Pfizer. XALKORI&reg; (crizotinib) capsules, oral prescribing information. New York, NY 2011.",
"                                                                                                                                           <br>",
"                                                                                                                                            135. Bristol-Myers Squibb Company. SPRYCEL&reg; (dasatinib) tablet prescribing information. Princeton, NJ 2010.",
"                                                                                                                                            <br>",
"                                                                                                                                             136. Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010; 38:1371.",
"                                                                                                                                             <br>",
"                                                                                                                                              137. Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008; 36:1828.",
"                                                                                                                                              <br>",
"                                                                                                                                               138. Marchetti S, de Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7:2280.",
"                                                                                                                                               <br>",
"                                                                                                                                                139. Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13:3731.",
"                                                                                                                                                <br>",
"                                                                                                                                                 140. Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007; 6:432.",
"                                                                                                                                                 <br>",
"                                                                                                                                                  141. Liu Y, Ramarez J, House L, Ratain MJ. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 38(1):32-9.",
"                                                                                                                                                  <br>",
"                                                                                                                                                   142. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Erlotinib Pathway, Pharmacokinetics. Available at:",
"                                                                                                                                                   <a href=\"file://www.pharmgkb.org/pathway/PA154426903\">",
"                                                                                                                                                    file://www.pharmgkb.org/pathway/PA154426903",
"                                                                                                                                                   </a>",
"                                                                                                                                                   . Accessed 06/19/12.",
"                                                                                                                                                   <br>",
"                                                                                                                                                    143. Astra-Zeneca. Iressa (gefitinib tablets) Prescribing Information. Wilmington, DE 2005.",
"                                                                                                                                                    <br>",
"                                                                                                                                                     144. Nakamura Y, Oka M, Soda H, et al. Gefitinib (\"Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65:1541.",
"                                                                                                                                                     <br>",
"                                                                                                                                                      145. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Gefitinib Pathway, Pharmacokinetics. Available at:",
"                                                                                                                                                      <a href=\"file://www.pharmgkb.org/pathway/PA152325160\">",
"                                                                                                                                                       file://www.pharmgkb.org/pathway/PA152325160",
"                                                                                                                                                      </a>",
"                                                                                                                                                      . Accessed 06/19/12.",
"                                                                                                                                                      <br>",
"                                                                                                                                                       146. Novartis Pharmaceuticals Corporation. GLEEVEC (imatinib mesylate) tablets for oral use prescribing information. East Hanover, NJ 2011.",
"                                                                                                                                                       <br>",
"                                                                                                                                                        147. van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007; 13:7394.",
"                                                                                                                                                        <br>",
"                                                                                                                                                         148. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Imatinib Pathway, Pharmacokinetics/Pharmacodynamics. Available at:",
"                                                                                                                                                         <a href=\"file://www.pharmgkb.org/pathway/PA164713427\">",
"                                                                                                                                                          file://www.pharmgkb.org/pathway/PA164713427",
"                                                                                                                                                         </a>",
"                                                                                                                                                         . Accessed 06/19/12.",
"                                                                                                                                                         <br>",
"                                                                                                                                                          149. GlaxoSmithKline. TYKERB (lapatinib) tablets prescribing information. Research Triangle Park, NC 2011.",
"                                                                                                                                                          <br>",
"                                                                                                                                                           150. Novartis Pharmaceuticals Corporation. Tasigna&reg; (nilotinib) capsules prescribing information. East Hanover, NJ 2011.",
"                                                                                                                                                           <br>",
"                                                                                                                                                            151. Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011; 51:75.",
"                                                                                                                                                            <br>",
"                                                                                                                                                             152. Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 2010; 88:652.",
"                                                                                                                                                             <br>",
"                                                                                                                                                              153. GlaxoSmithKline. VOTRIENT (pazopanib) tablets prescribing information Research Triangle Park, NC 2010.",
"                                                                                                                                                              <br>",
"                                                                                                                                                               154. Bayer HealthCare Pharmaceuticals, Inc. NEXAVAR(sorafenib) tablets, oral prescribing information. Wayne, NJ 2011.",
"                                                                                                                                                               <br>",
"                                                                                                                                                                155. Flaherty KT, Lathia C, Frye RF, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011.",
"                                                                                                                                                                <br>",
"                                                                                                                                                                 156. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther. 2011 336(1):223-33.",
"                                                                                                                                                                 <br>",
"                                                                                                                                                                  157. Pfizer. SUTENT&reg; (sunitinib malate) capsules, oral prescribing information. New York, NY 20-11.",
"                                                                                                                                                                  <br>",
"                                                                                                                                                                   158. Tang SC, Lagas JS, Lankheet NA, Poller B, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer. 2012 1;130(1):223-33.",
"                                                                                                                                                                   <br>",
"                                                                                                                                                                    159. Deeken JF, Rudek MA, Aboulafia DM, et al. AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors. J Clin Oncol 2011; 29:abstr 2591.",
"                                                                                                                                                                    <br>",
"                                                                                                                                                                     160. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009; 37:359.",
"                                                                                                                                                                     <br>",
"                                                                                                                                                                      161. Astra-Zeneca. CAPRELSA&reg; (vandetanib) tablets prescribing information. Wilmington, DE 2011.",
"                                                                                                                                                                      <br>",
"                                                                                                                                                                       162. Martin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D 2011; 11:37.",
"                                                                                                                                                                       <br>",
"                                                                                                                                                                        163. Zheng LS, Wang F, Li YH, et al. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172.",
"                                                                                                                                                                        <br>",
"                                                                                                                                                                         164. Genentech USA, Inc. ZELBORAF&trade; (vemurafenib) tablet, oral prescribing information. South San Francisco, CA 2011.",
"                                                                                                                                                                         <br>",
"                                                                                                                                                                          165. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012 342(1):33-40.",
"                                                                                                                                                                          <br>",
"                                                                                                                                                                           166. Smith NF, Mani S, Schuetz EG, et al. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother 2010; 44:1709.",
"                                                                                                                                                                           <br>",
"                                                                                                                                                                            167. Rajaonarison JF, Lacarelle B, Catalin J, et al. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. Drug Metab Dispos 1993; 21:823.",
"                                                                                                                                                                            <br>",
"                                                                                                                                                                             168. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Cyclophosphamide Pathway, Pharmacokinetics. Available at:",
"                                                                                                                                                                             <a href=\"file://www.pharmgkb.org/pathway/PA2034\">",
"                                                                                                                                                                              file://www.pharmgkb.org/pathway/PA2034",
"                                                                                                                                                                             </a>",
"                                                                                                                                                                             . Accessed 06/19/12.",
"                                                                                                                                                                             <br>",
"                                                                                                                                                                              169. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006; 34:1317.",
"                                                                                                                                                                              <br>",
"                                                                                                                                                                               170. Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Vinka Alkaloid Pathway, Pharmacokinetics. Available at:",
"                                                                                                                                                                               <a href=\"file://www.pharmgkb.org/pathway/PA150981002\">",
"                                                                                                                                                                                file://www.pharmgkb.org/pathway/PA150981002",
"                                                                                                                                                                               </a>",
"                                                                                                                                                                               . Accessed 06/19/12.",
"                                                                                                                                                                               <br>",
"                                                                                                                                                                                171. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000; 28:1121.",
"                                                                                                                                                                                <br>",
"                                                                                                                                                                                 172. Beulz-Rich D, Grud P, Puozzo C, et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 19(5):545-53.",
"                                                                                                                                                                                 <br>",
"                                                                                                                                                                                  173. Janssen Biotech, Inc. ZYTIGA&reg; (abiraterone acetate) tablets for oral administration prescribing information. Horsham, PA 2012.",
"                                                                                                                                                                                  <br>",
"                                                                                                                                                                                   174. Celgene Corporation. VIDAZA (azacitidine for injection) for SC or IV use prescribing information. Summit, NJ 2012.",
"                                                                                                                                                                                   <br>",
"                                                                                                                                                                                    175. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005 10;23(17):3906-11.",
"                                                                                                                                                                                    <br>",
"                                                                                                                                                                                     176. van Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effort on CYP3A4 activity. Eur J Endocrinol 2011; 164:621.",
"                                                                                                                                                                                     <br>",
"                                                                                                                                                                                      177. Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450a involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58:1341.",
"                                                                                                                                                                                      <br>",
"                                                                                                                                                                                       178. Genentech USA, Inc. ERIVEDGE&trade; (vismodegib) capsule for oral use prescribing information. South San Francisco, CA 2012.",
"                                                                                                                                                                                       <br>",
"                                                                                                                                                                                        179. Wong H, Chen JZ, Chou B, et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica. 2009 39(11):850-61.",
"                                                                                                                                                                                        <br>",
"                                                                                                                                                                                         180. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia. 2009 11(1):96-101.",
"                                                                                                                                                                                         <br>",
"                                                                                                                                                                                          181. Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos. 2011 39(8):1460-7.",
"                                                                                                                                                                                          <br>",
"                                                                                                                                                                                           182. Pfizer, INLYTA&reg; (axitinib) tablets for oral administration prescribing information. New York, NY 2012.",
"                                                                                                                                                                                           <br>",
"                                                                                                                                                                                            183. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 20;23(24):5474-83.",
"                                                                                                                                                                                            <br>",
"                                                                                                                                                                                             184. Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol. 2010 65(3):563-70.",
"                                                                                                                                                                                             <br>",
"                                                                                                                                                                                              185. Pithavala YK, Tong W, Mount J, et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs. 2012 30(1):273-81. 186. Brennan M, Williams JA, Chen Y, et al. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 68(5):645-55.",
"                                                                                                                                                                                              <p>",
"                                                                                                                                                                                               Modified from: Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12:905.",
"                                                                                                                                                                                              </p>",
"                                                                                                                                                                                             </br>",
"                                                                                                                                                                                            </br>",
"                                                                                                                                                                                           </br>",
"                                                                                                                                                                                          </br>",
"                                                                                                                                                                                         </br>",
"                                                                                                                                                                                        </br>",
"                                                                                                                                                                                       </br>",
"                                                                                                                                                                                      </br>",
"                                                                                                                                                                                     </br>",
"                                                                                                                                                                                    </br>",
"                                                                                                                                                                                   </br>",
"                                                                                                                                                                                  </br>",
"                                                                                                                                                                                 </br>",
"                                                                                                                                                                                </br>",
"                                                                                                                                                                               </br>",
"                                                                                                                                                                              </br>",
"                                                                                                                                                                             </br>",
"                                                                                                                                                                            </br>",
"                                                                                                                                                                           </br>",
"                                                                                                                                                                          </br>",
"                                                                                                                                                                         </br>",
"                                                                                                                                                                        </br>",
"                                                                                                                                                                       </br>",
"                                                                                                                                                                      </br>",
"                                                                                                                                                                     </br>",
"                                                                                                                                                                    </br>",
"                                                                                                                                                                   </br>",
"                                                                                                                                                                  </br>",
"                                                                                                                                                                 </br>",
"                                                                                                                                                                </br>",
"                                                                                                                                                               </br>",
"                                                                                                                                                              </br>",
"                                                                                                                                                             </br>",
"                                                                                                                                                            </br>",
"                                                                                                                                                           </br>",
"                                                                                                                                                          </br>",
"                                                                                                                                                         </br>",
"                                                                                                                                                        </br>",
"                                                                                                                                                       </br>",
"                                                                                                                                                      </br>",
"                                                                                                                                                     </br>",
"                                                                                                                                                    </br>",
"                                                                                                                                                   </br>",
"                                                                                                                                                  </br>",
"                                                                                                                                                 </br>",
"                                                                                                                                                </br>",
"                                                                                                                                               </br>",
"                                                                                                                                              </br>",
"                                                                                                                                             </br>",
"                                                                                                                                            </br>",
"                                                                                                                                           </br>",
"                                                                                                                                          </br>",
"                                                                                                                                         </br>",
"                                                                                                                                        </br>",
"                                                                                                                                       </br>",
"                                                                                                                                      </br>",
"                                                                                                                                     </br>",
"                                                                                                                                    </br>",
"                                                                                                                                   </br>",
"                                                                                                                                  </br>",
"                                                                                                                                 </br>",
"                                                                                                                                </br>",
"                                                                                                                               </br>",
"                                                                                                                              </br>",
"                                                                                                                             </br>",
"                                                                                                                            </br>",
"                                                                                                                           </br>",
"                                                                                                                          </br>",
"                                                                                                                         </br>",
"                                                                                                                        </br>",
"                                                                                                                       </br>",
"                                                                                                                      </br>",
"                                                                                                                     </br>",
"                                                                                                                    </br>",
"                                                                                                                   </br>",
"                                                                                                                  </br>",
"                                                                                                                 </br>",
"                                                                                                                </br>",
"                                                                                                               </br>",
"                                                                                                              </br>",
"                                                                                                             </br>",
"                                                                                                            </br>",
"                                                                                                           </br>",
"                                                                                                          </br>",
"                                                                                                         </br>",
"                                                                                                        </br>",
"                                                                                                       </br>",
"                                                                                                      </br>",
"                                                                                                     </br>",
"                                                                                                    </br>",
"                                                                                                   </br>",
"                                                                                                  </br>",
"                                                                                                 </br>",
"                                                                                                </br>",
"                                                                                               </br>",
"                                                                                              </br>",
"                                                                                             </br>",
"                                                                                            </br>",
"                                                                                           </br>",
"                                                                                          </br>",
"                                                                                         </br>",
"                                                                                        </br>",
"                                                                                       </br>",
"                                                                                      </br>",
"                                                                                     </br>",
"                                                                                    </br>",
"                                                                                   </br>",
"                                                                                  </br>",
"                                                                                 </br>",
"                                                                                </br>",
"                                                                               </br>",
"                                                                              </br>",
"                                                                             </br>",
"                                                                            </br>",
"                                                                           </br>",
"                                                                          </br>",
"                                                                         </br>",
"                                                                        </br>",
"                                                                       </br>",
"                                                                      </br>",
"                                                                     </br>",
"                                                                    </br>",
"                                                                   </br>",
"                                                                  </br>",
"                                                                 </br>",
"                                                                </br>",
"                                                               </br>",
"                                                              </br>",
"                                                             </br>",
"                                                            </br>",
"                                                           </br>",
"                                                          </br>",
"                                                         </br>",
"                                                        </br>",
"                                                       </br>",
"                                                      </br>",
"                                                     </br>",
"                                                    </br>",
"                                                   </br>",
"                                                  </br>",
"                                                 </br>",
"                                                </br>",
"                                               </br>",
"                                              </br>",
"                                             </br>",
"                                            </br>",
"                                           </br>",
"                                          </br>",
"                                         </br>",
"                                        </br>",
"                                       </br>",
"                                      </br>",
"                                     </br>",
"                                    </br>",
"                                   </br>",
"                                  </br>",
"                                 </br>",
"                                </br>",
"                               </br>",
"                              </br>",
"                             </br>",
"                            </br>",
"                           </br>",
"                          </br>",
"                         </br>",
"                        </br>",
"                       </br>",
"                      </br>",
"                     </br>",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28010=[""].join("\n");
var outline_f27_22_28010=null;
var title_f27_22_28011="Major causes of hypernatremia";
var content_f27_22_28011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypernatremia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unreplaced water loss (which requires an impairment in either thirst or access to water)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insensible and sweat losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central or nephrogenic diabetes insipidus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Osmotic diuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucose in uncontrolled diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Urea in high-protein tube feedings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mannitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypothalamic lesions impairing thirst or osmoreceptor function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary hypodipsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reset osmostat in mineralocorticoid excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Water loss into cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe exercise or seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sodium overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intake or administration of hypertonic sodium solutions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28011=[""].join("\n");
var outline_f27_22_28011=null;
var title_f27_22_28012="Pediatric range TFTs";
var content_f27_22_28012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal ranges for thyroid function tests in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Free T4",
"        <br/>",
"        (ng/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        T4",
"        <br/>",
"        (microg/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Free T3",
"        <br/>",
"        (pg/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        T3",
"        <br/>",
"        (ng/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        TSH",
"        <br/>",
"        (microIU/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        TBG",
"        <br/>",
"        (mg/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cord blood",
"       </td>",
"       <td>",
"        0.9-2.2",
"       </td>",
"       <td>",
"        7.4-13.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        15-75",
"       </td>",
"       <td>",
"        1.0-17.4",
"       </td>",
"       <td>",
"        2.5-5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-4 days",
"       </td>",
"       <td>",
"        2.2-5.3",
"       </td>",
"       <td>",
"        14.0-28.4",
"       </td>",
"       <td>",
"        180-760",
"       </td>",
"       <td>",
"        100-740",
"       </td>",
"       <td>",
"        1.0-39.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-20 weeks",
"       </td>",
"       <td>",
"        0.9-2.3",
"       </td>",
"       <td>",
"        7.2-15.7",
"       </td>",
"       <td>",
"        185-770",
"       </td>",
"       <td>",
"        105-245",
"       </td>",
"       <td>",
"        1.7-9.1",
"       </td>",
"       <td>",
"        2.1-6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-24 months",
"       </td>",
"       <td>",
"        0.8-1.8",
"       </td>",
"       <td>",
"        7.2-15.7",
"       </td>",
"       <td>",
"        215-770",
"       </td>",
"       <td>",
"        105-269",
"       </td>",
"       <td>",
"        0.8-8.2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-7 years",
"       </td>",
"       <td>",
"        1.0-2.1",
"       </td>",
"       <td>",
"        6.0-14.2",
"       </td>",
"       <td>",
"        215-700",
"       </td>",
"       <td>",
"        94-241",
"       </td>",
"       <td>",
"        0.7-5.7",
"       </td>",
"       <td>",
"        2.0-5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-20 years",
"       </td>",
"       <td>",
"        0.8-1.9",
"       </td>",
"       <td>",
"        4.7-12.4",
"       </td>",
"       <td>",
"        230-650",
"       </td>",
"       <td>",
"        80-210",
"       </td>",
"       <td>",
"        0.7-5.7",
"       </td>",
"       <td>",
"        1.8-4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21-45 years",
"       </td>",
"       <td>",
"        0.9-2.5",
"       </td>",
"       <td>",
"        5.3-10.5",
"       </td>",
"       <td>",
"        210-440",
"       </td>",
"       <td>",
"        70-204",
"       </td>",
"       <td>",
"        0.4-4.2",
"       </td>",
"       <td>",
"        1.8-4.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nelson J, Pediatr 1993; 123:899; Elmlinger, Clin Chem Lab Med 2001; 39:973; and Esoterix (Endocrine Sciences).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28012=[""].join("\n");
var outline_f27_22_28012=null;
var title_f27_22_28013="Med guide antidepressants";
var content_f27_22_28013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2007 Revised Medication Guide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Medication Guide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Read the Medication Guide that comes with you or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines.",
"       <strong>",
"        Talk to your, or your family member's, healthcare provider about:",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; All risks and benefits of treatment with antidepressant medicines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; All treatment choices for depression or other serious mental illness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults when the medicine is first started.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is first started or when the dose is changed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       4. Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Thoughts about suicide or dying",
"      </td>",
"      <td>",
"       &bull; Trouble sleeping (insomnia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Attempts to commit suicide",
"      </td>",
"      <td>",
"       &bull; New or worse irritability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; New or worse depression",
"      </td>",
"      <td>",
"       &bull; Acting aggressive, being angry, or violent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; New or worse anxiety",
"      </td>",
"      <td>",
"       &bull; Acting on dangerous impulses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Feeling very agitated or restless",
"      </td>",
"      <td>",
"       &bull; An extreme increase in activity and talking (mania)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Panic attacks",
"      </td>",
"      <td>",
"       &bull; Other unusual changes in behavior or mood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       5. What else do I need to know about antidepressant medicines?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Never stop an antidepressant medicine without first talking to a healthcare provider.",
"       </strong>",
"       Stopping an antidepressant medicine suddenly can cause other symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Antidepressants are medicines used to treat depression and other illnesses.",
"       </strong>",
"       It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Antidepressant medicines have other side effects.",
"       </strong>",
"       Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Antidepressant medicines can interact with other medicines.",
"       </strong>",
"       Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Not all antidepressant medicines prescribed for children are FDA approved for use in children.",
"       </strong>",
"       Talk to your child's healthcare provider for more information.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This Medication Guide has been approved by the US Food and Drug Administration for all antidepressants.",
"    <br>",
"     Revised 2007.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: US Food and Drug Administration, Center for Drug Evaluation and Research. Medication Guide for Antidepressant Drugs. Available at: www.fda.gov/Cder/drug/antidepressants (Accessed on August 1, 2008).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28013=[""].join("\n");
var outline_f27_22_28013=null;
var title_f27_22_28014="Vent responses to hypercapnia";
var content_f27_22_28014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Ventilatory responses to hypercapnia in patients with mild and severe hypothyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ventilatory responses are shown as the relationships between alveolar carbon dioxide (PACO2) and minute ventilation (VE, standard temperature and pressure dry [STPD]).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zwillich AA, Pierson DJ, Hofeldt FD. Ventilatory control in myxedema and hypothyroidism.&nbsp;N Engl J Med 1975; 292:662.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28014=[""].join("\n");
var outline_f27_22_28014=null;
var title_f27_22_28015="Aphakic spectacles";
var content_f27_22_28015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphakic spectacles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 181px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aphakic spectacles have optical features or artifacts that cause peripheral distortion and cause images to \"jump\" into the field of view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_22_28015=[""].join("\n");
var outline_f27_22_28015=null;
